PharmaTalkRadio: Recent Episodes
Pharma Talk Radio
PharmaTalkRadio is an internet radio podcast platform organized and supported by the Conference Forum to give easy and free access to industry professionals, patient advocacy and students in medicine development. PharmaTalkRadio features industry insiders on the latest strategies, business models, and new innovations to advance clinical research with emphasis on clinical trials, patient- centricity, drug delivery, Immuno-oncology, digital, mobile and other technologies as well as leadership topics and emerging biotech challenges. Also featured on PharmaTalkRadio are podcasts covering a wide range of topics from Conference Forum events.
To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.
Summary:The 2024 CRAACO: Clinical Research as a Care Option conference is a unique opportunity for pharma, healthcare and patients to come together and address how we can integrate healthcare and clinical research to improve patient access to clinical trials.In this short podcast, Valerie Bowling, Executive Director of the Conference Forum, outlines the key themes and sessions for the 9th annual meeting.
To learn more about the Chief Medical Officer Summit 360° and its associated editorials, podcasts and webcasts, please visit CMO360.org
To learn more about the Chief Medical Officer Summit 360° and its associated editorials, podcasts and webcasts, please visit CMO360.org
To learn more about the Chief Medical Officer Summit 360° and its associated editorials, podcasts and webcasts, please visit CMO360.org
To learn more about the Chief Medical Officer Summit 360° and its associated editorials, podcasts and webcasts, please visit CMO360.org
Valerie Bowling, Executive Director of the Conference Forum, discusses what attendees can expect at the 8th annual Patients as Partners EU conference, including keynotes, key topics, and the wide breadth of pharma companies present. For more information about the upcoming event, full agenda and speakers, visit https://patientsaspartnerseu.com/
As new drugs in development have poorer solubility and bioavailability, there is a need for novel solubility enhancing polymers to improve drug loading and improve patient adherence.In this podcast, Nick DiFranco explains some of the shortcomings of traditional solubility enhancers as well as key considerations for novel technologies. Nick also presents an overview of Lubrizol’s Apinovex™ polymers for oral solubility enhancement and Apisolex™ polymers for injectable solubility enhancement. For more information about Lubrizol Life Science, visit Lubrizol.com. For more information about the PODD Conference, please visit PODDConference.com.
Summary:In this podcast, Terri Conneran tells the story of how her cancer diagnosis and a search for relevant biomarkers turned into KRAS Kickers, a cancer research advocate community. For more information on PharmaTalk Radio podcasts, visit theconferenceforum.org.
About the episode: It's estimated that only 20% of health outcomes are due to clinical care, with the remaining 80% as a result of social determinants of health. Medicine development leaders must understand the broader context of patient lives in order to create therapies with real-world efficacy. In this podcast, Noël Theodosiou tells us how she's working with life science companies, to understand and contextualize the real world that patients live in to create therapeutics that fit in the environment to deliver actual impact. Noël argues that taking an approach that combines biology, psychology and sociology provides companies with decision-making capabilities that connects good business practices with life science's social contracts with patients. About the Speaker: Noël Theodosiou is principal, founder and CEO of Luminous, which empowers organizations in the life sciences with insights, strategies, and capabilities that lead to better outcomes for patients, business, and society. Using proven methods such as behavioral science, culture and discourse analysis, and cutting-edge methodologies such as biosemiotics, we identify and address the myriad factors that influence health outcomes. www.luminouseffect.com. For more information on PharmaTalkRadio podcasts, visit theconferenceforum.org.
To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.
To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.
To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.
To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.
To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.
To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.
To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.
To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.
Learn more about the DPHARM: Disruptive Innovations to Modernize Clinical Research conference, visit DPHARMconference.com.
To learn more about the DPHARM: Disruptive Innovations to Modernize Clinical Research conference, visit DPHARMconference.com.
Learn more about Patients as Partners in Clinical Research at patientsaspartnersconference.com.
For more information on Patients as Partners in Clinical Research, visit patientsaspartnersconference.com.
In this Episode:As clinical trials become more complex, sampling schemes keep pace. That makes proper sample and inventory management so crucial. Slope's Hope Meely and Kyle Baker shed light on the intricacies and the complexities related to clinical inventory management and sample management. Listeners can learn more about clinical inventory involved for biospecimens, the challenges experienced in executing clinical trials and how these issues can be resolved. Speakers: Hope Meely, Chief Clinical Officer, SlopeHope Meely is the Chief Clinical Officer at Slope, the industry-leading provider of a clinical trial execution platform for highly complex, sample-intensive clinical trials. Hope has spent the entirety of her 25-year clinical research career supporting several sponsors and CROs in leading clinical operations teams in the execution of their clinical trial programs. Most recently, she spent 3 years in a growing biotech leading operations for a robust early phase oncology pipeline. Kyle Baker, Content Marketing Manager, SlopeKyle Baker is a former project manager in the central lab space. In his most recent role before joining Slope, Kyle spent nearly 2 years supporting sample management and inventory management for various trial sponsors. By leveraging his clinical trial background and his passion for storytelling to create content for Slope, Kyle marries his understanding of site- and sponsor-specific challenges with his belief that the industry needs a more comprehensive solution for clinical trial execution. For more information about disruptive innovations to modernize clinical trials, click here.
About the Episode:
For those of us who work in clinical trials, we know all too well that the majority of sites don't hit recruitment targets, resulting in costly delays and burnout from sites and patients.
Tegan Mead and Julie Mansson, both at Javara, describe how they are applying data and technology to identify the right fit and make sure that sites are set up for success, advising sponsors on making trials less burdensome for patients, and keeping physicians in the loop on trials for their patients, to make clinical trials more successful in more places, for the benefit of patients.
About the Speakers:
Tegan Mead, Executive Director of Operational Excellence, Javara
Tegan Mead began her career in clinical research in 2014, working as a Clinical Operations Manager at PMG Research. She has served in various roles across the site enterprise, including operational leadership, feasibility management and operational excellence, with most of her career centered on clinical operations execution, development, and growth.
Julie Mansson, Associate Director, Project Strategy, Javara
Julie Mansson has over 24 years of clinical research experience primarily focused on trial implementation, study startup, and site operational development. For the last two and a half years she has served in several roles on Javara’s Project Strategy team, supporting cross-functional teams on trial feasibility and project optimization.
For more information about clinical research as a care option, click here.
Innovating Patient Recruitment: A Conversation with BBK Worldwide Founders Joan F. Bachenheimer and Bonnie A. Brescia
The Conference Forum moderates a webcast featuring Joan F. Bachenheimer and Bonnie A. Brescia, the founders of BBK Worldwide, who walk us through the evolution of patient recruitment and engagement, the connection to the women’s and consumer healthcare movement, the need for changes in communication and the rise of the patient voice.
They also address the impact of scientific advances on patient recruitment and the importance of preparing to meet the evolving changes. The timing of the webcast coincides with the company’s 40-year anniversary.
Guests:
Joan F. Bachenheimer, Founder, Chief Executive Officer, BBK Worldwide
Bonnie A. Brescia, Founder, Chief Development Officer, BBK Worldwide
Moderated by:
Valerie Bowling, Executive Director, Conference Forum
For more information on BBK Worldwide, visit www.bbkworldwide.com
For more information on the Conference Forum, visit www.theconferenceforum.org
Directors, Valerie Bowling and Kate Woda, discuss what to expect at the upcoming 10th annual Mobile Tech in Clinical Trials conference taking place on September 19, 2023 in Boston, MA.
Director, Valerie Bowling, reviews what to expect at the upcoming Clinical Research as a Care Option (CRAACO) conference taking place on May 22-23 at the Sheraton Imperial Hotel in Raleigh-Durham, NC.
In this podcast, you will hear a panel discussion moderated by Paul Jansen from the 2022 PODD Conference regarding the biggest challenges as well as future solutions to vaccine administration and distribution.Panelists include:Jeffrey T Blue, MerckDerek O’Hagan, PhD, GSKTo learn more about the PODD Conference, please visit PODDConference.com.
In this podcast, you will hear a panel discussion moderated by Mark DeStefano, Teva, from the 2022 PODD Conference regarding balancing the level of connected activity with user needs, determining how broadly or specifically to use connectivity and slowly implementing connectivity to provide good user acceptance.Panelists include:Kevin Deane, Phillips-Medisize, a Molex CompanyDavid Harrison, UCBLilly StairsBrad Womble, JabilAndrei Yosef, Eitan MedicalTo learn more about the PODD Conference, please visit PODDConference.com.
Why is enhancing the interferon pathway an attractive approach for treating cancer?What are the novel therapeutic approaches being investigated to harness the innate immune system to enhance the interferon pathway to treat cancer?What are the translational approaches being applied to better study therapeutics that activate the interferon pathway against hematologic and solid tumors and identify the patients who may respond better to these therapeutics?Christine Ward, PhD, Head, oncology Precision and Translational Medicine, Takeda PharmaceuticalsLearn more about the IO360° Summit at www.io360summit.com
In this talk, first recorded at the 2022 IO360° Summit, Dr Rachel Haurwitz, CEO, Caribou Biosciences, addresses the big picture view of where the cell therapy field is going and how innovative CRISPR-based editing will help with the treatment of hematologic and solid tumors. Key topics include:Approach that requires highly specific and efficient multiplex genome editingWhat are some of the potential stumbling blocks?What are the tools for solving those challenges?Tackling solid tumors as the next frontier for cell therapiesRachel Haurwitz, PhD, President & CEO, Caribou BiosciencesLearn more about the IO360° Summit at www.io360summit.com
Moderated by:Axel Hoos, MD, PhD, CEO, Scorpion TherapeuticsPanelists:Jonathan Fassberg, Vice Chairman of Healthcare Investment Banking, OppenheimerIrina Margine, PhD, Principal, Biotech Private Equity, Wellington ManagementAsthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst, Truist SecuritiesGraig Suvannavejh, PhD, Managing Director, Equity Research Biopharmaceuticals & Biotechnology, Mizuho Securities USALearn more about the IO360° Summit at www.io360summit.com
This panel, first recorded at the 2022 IO360° Summit addressed:What are the risks and implications of investing in cell/gene therapy companies who have no clinical data from programs available?Venture company perspectives on what they are investing in and why? • What science needs to be seen in order to invest in either a startup or IPO?What are investors/pharma partners looking for and how does that inform what people should be doing?How do we think about partnerships between organizations?Moderated by:Michael Polansky, CEO, Parker GroupPanelists:Mark Bonyhadi, PhD, Senior Advisor, Qiming Venture PartnersElaine Cheung, SVP, Corporate Strategy & Business Development, Lyell ImmunopharmaArjun Goyal, MD, MPhil, MBA, Co-founder and Managing Director, Vida VenturesLearn more about the IO360° Summit at www.io360summit.com
In this session, first recorded at the 2022 IO360° Summit, Dr Semenza will talk about how his work is impacting cancer immunotherapy. Dr Semenza’s groundbreaking discovery of hypoxia-inducible factors paves the way for the development of drugs that could kill cancer cells by cutting off the oxygen supply tumors need to grow and improve the response to immunotherapies. Key areas addressed include:Regions of intratumoral hypoxia are a common feature of advanced cancersHypoxia-inducible factors increase the expression of multiple proteins that mediate immune evasionHIF inhibitors stimulate anti-tumor immunity and improve the response to immune checkpoint blockadeGregg Semenza, MD, PhD, Director, Vascular Program, Institute for Cell Engineering and Professor of Genetic Medicine, Johns Hopkins University School of MedicineLearn more about the IO360° Summit at www.io360summit.com
Neoadjuvant (pre-surgical) immune checkpoint blockade may prevent cancer relapse and progression.This treatment approach is now FDA-approved for resectable triple-negative breast cancer, and hundreds of clinical trials in other cancers are ongoing.Surgical resection specimens collected after several weeks of neoadjuvant ICB offer vast opportunities for predictive biomarker discovery and understanding ICB response/resistance.Suzanne Topalian, MD, Associate Director / Professor of Surgery, Bloomberg~Kimmel Institute for Cancer Immunotherapy / Johns Hopkins UniversityLearn more about the IO360° Summit at www.io360summit.com
Nouhad Husseini, MBA, SVP, Business Development and Corporate Strategy, Regeneron PharmaceuticalswithAllan Shaw, CFO / Founder & Senior Managing Director, Portage Biotech / Shaw Strategic Capital, LLCLearn more about the IO360 Summit at www.io360summit.com
What is the impact of targeted radiotherapy on the immune system?What are the implications for combination IO?Current approaches and future directionModerated by:Michael Groaning, PhD, Global Medical Affairs Lead, Genitourinary, AmgenPanelists:Charles Glaus, PhD, Sr Director, Radiomics & Radiology Biomarkers, Bayer US-PharmaceuticalsJeff Legos, PhD, MBA, EVP, Global Head of Oncology & Hematology Development , NovartisMatthew Silva, PhD, CEO , InvicroOhad Ilovich, PhD, Senior Director, Translational Sciences, Curie TherapeuticsLearn more about the IO360° Summit at www.io360summit.com
This panel, first recorded at the 2021 Immuno-Oncology 360° Summit, will bring together chinese biotechs to share how they are partnering with additional IO companies to advance cancer treatments for patients. This will include partnering strategies and decision making. To learn more about the IO360° Summit visit, www.io360summit.com
In this session, GSK shares how they delivered on patient and caregiver engagements, especially with communities experiencing the highest COVID burden. They gained insights on study designs, educational pieces and captured patient experiences to enhance HCP/public COVID awareness. GSK will discuss:Value of COVID engagementsNovel approaches and mechanisms for finding patients who don’t belong to an organized patient communityOvercoming challengesHow this initiative could be modeled to help find future patients when the pathway is not clearPatient Perspectives-In their own wordsSusan Burriss, Patient Engagement Lead, GSKLearn more about the Patients as Partners in Clinical Research conference at www.patientsaspartners.org
In this session, Janssen shares how they are collaboratively working with patients and sites to advance DCTs and willshare engagement methodologies, what they have learned from the perspective of participants and sites, and the directionthis has taken them in DCTs.Alyson Gregg, Director Patient Insights, GMA Commercial Operations, JanssenMorgan Wooten, Investigator & Patient Engagement Program Team Leader, JanssenLearn more about the Patients as Partners in Clinical Research conference at www.patientsaspartners.org
Merck’s iLab53 (a modular 39-foot mobile unit) was used to bring clinical research into community settings as an effort to increase clinical trial awareness and engagement.More specifically:How the iLab53 was created and implementedHow Merck is continuing to work to help build trust within communities, and provide increased access to clinical researchChallenges, learnings and successes to dateHow this initiative can be scaled and adaptedSusan Manoff, MD, MPH, Executive Director, Office of the Chief Patient Officer, MerckKai Bode, Director, Digital Innovation and Patient Strategy, Global Digital Analytics & Technologies Team, MerckLearn more about the Patients as Partners in Clinical Research conference at www.patientsaspartners.org
In this session, Sanofi shares how they created and implemented an end-to-end fully integrated patient informed R&Dorganization that works directly with patients as advisors in 100% of development staged programs from discovery andsupporting research pipeline prioritization to registration. Key topics include:Aligning with the patient community’s most pressing needsGaining insights that established clinical programs and studies and reshaped clinical trial designs and logisticsPrioritizing early diversity & inclusion planningGenerating patient relevant data that supports improved patient experienceVictoria DiBiaso, MPH, BScN, Global Head, Patient Informed Development & Health Value Translation, Sanofi R&DLearn more about the Patients as Partners in Clinical Research conference at www.patientsaspartners.org
Legal barriers exist for many good reasons, but can block our pathway in making the changes needed to help patients in the current climate. The panel addresses:Protocols that require approval from legal and complianceR&D and compliance, breaking down the silos and working jointly for patient needsHow to bring the patient voice to legal and compliance initiatives that impact patients?What are the next steps? What initiatives could legal/compliance be a part of with patient engagement to gain an understanding of the impact and urgency of their approvals?Led by:Marilyn Metcalf, PhD, Senior Director, Patient-Focused Development, Global Medical, GSKPanelists:Roslyn Schneider MD, VP, Scientific, Medical and Patient Affairs, Theravance Biopharma USParthena Psyllos, Senior Corporate Counsel, Clinical Development Legal, PfizerSue Gregory, Former Managing Counsel/Executive Director, GSKCandace Lerman, Patient Advocate and AttorneyKate Harr-Sponsler, Associate General Counsel – Global Commercial, Spark TherapeuticsLearn more about the Patients as Partners in Clinical Research conference at www.patientsaspartners.org
In this session recorded at DPHARM 2022, Memorial Sloan Kettering Cancer Center shares about their Connected Care protocol.Digital monitoring of patients has the potential to better the delivery of cancer care through improved patient-provider communication, enhanced symptom and toxicity assessment and management, and optimized engagement across the cancer continuum. Remote monitoring is especially crucial when patients are at high risk for experiencing symptoms or toxicities from treatment. During these episodes, patients and clinicians benefit from routine assessments of electronic patient-reported outcomes (ePROs) to identify symptoms early and prevent adverse outcomes. The Connected Care protocol provides remote monitoring to medical oncology patients for 10-days post hospital discharge as this is a high-risk period for patients due to a lingering symptom burden and a need for enhanced patient-clinician communication as symptom management shifts from the inpatient to outpatient team. Specifically, Dr. Daly will discuss:The feasibility and acceptability of remote monitoring in the post discharge setting for patients with cancerPatient perspectives for remote monitoring post hospital dischargeePRO versus device and challenges with implementationThoughts on the right data to collect and at what intervalsSpeaker:Robert Daly, MD, MBA, Assistant Attending Medical Oncologist, Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
In this session recorded at DPHARM 2022, panelists from Pfizer discuss:Understanding the key steps Pfizer is taking to make remote clinical trials a reality for patientsExploring the cross functional team approach to scaling remote clinical trials across all therapeutic areasExamining the impact of adopting the light speed mindsetReviewing the key learnings and what the voice of the patient data reveals to dateSpeakers:Tim Joy, Executive Director, Head of Strategic Solutions, PfizerDaniela Graham, Clinician, Pfizer
This session was recorded at DPHARM 2022.As the life sciences industry’s focus on digital transformation advances at a rapid pace, the opportunity to understand how well your organization stacks up to the rest of the industry around digital maturity in clinical operations can be highly valuable. This session examines a new benchmarking effort to help pharmaceutical companies rank their digital capabilities in clinical operations, codify specific terms that are used readily and leverage insights to drive strategic priorities. Specifically, this session will:Discuss the study purpose, methodology and areas being ranked for digital readinessExamine the value for companies participatingConsider how the study with greater industry participation could evolve into an innovation index and generate industry digital maturity metricsModerated by: Craig Lipset, MBA, Founder, Clinical Innovation PartnersSpeakers:Hassan Kadhim, Director, Head of Clinical Trial Business Capabilities, Global Development Operations, BMSTim Joy Executive Director, Head of Strategic Solutions, PfizerAman Thukral, Head of Digital Operations and Clinical Systems, AbbVieBrandon Maggio, Director, Digital & Process Optimization, GSK
This is a session recorded from DPHARM 2022.As the competition to recruit patients for clinical trials increases and sites are burdened by staffing shortages, technology shifts and more, how can innovative trial designs reduce patient, site and investigator burden?Designing for patient centricity – reducing the burden for patients, sites and investigatorsAddressing organizational implementation challengesEngaging in collaborative partnerships and innovation to operationalize and deliver innovative trials designsSpeakers:Victoria L. Chiou, MD, Head of Clinical Excellence and Innovation, AstraZenecaSheryl Jacobs, VP, Global Development Operations, AmgenCamilla Richmond, MD, MA, Medical Director, Translational Medicine, TakedaDaniel Millar, MBA, Senior Director, Strategic Business Transformation, Janssen Research & Development, LLC
In this session recorded at DPHARM 2022, moderated by Pfizer's Amy Cramer, the panelists discuss patient data.Often the elephant in the room that hinders the advancement of innovation in clinical trials for the benefit of patients in the lack of structured, clean patient data. R&D executives know the ability to garner greater data value from all data sources [clinical trials, EHRs, claims data, etc] is critical to supporting the future of drug development. The continued conundrum is that data is too often unstructured, incompatible, incomplete and unreliable and leads to an output of a research-intensive, operational bottlenecks.We have a unique group of panelists who will prioritize the critical issues first, provide potential solutions and address what to do about pending issues to be resolved.Speakers:Amy Cramer, Global Product Development Strategic Partnerships, PfizerXiaoying Wu, MD, MS, VP, Data Science Data Platform & Privacy, The Janssen Pharmaceutical Companies of Johnson & JohnsonPaul Bleicher, MD, PhD, Executive Partner, Arden EquityLekan Wang, Head, Machine Learning Services, Parexel
In this session recorded at DPHARM 2022, Pfizer's Judy Sewards is joined by Patient Advocate Barry Nelson.Judy Sewards was one of the top 30 leaders who played a critical role in the success of Pfizer’s Covid-19 vaccine clinical trial program. In her role, she led patient and site communications and engagement. She was responsible for Pfizer’s relationships with the over 150 trial sites who conducted the Covid-19 vaccine clinical trials. She also helped create awareness about the clinical trials and worked with community, and government partners to elevate the importance of participation in the trial by diverse communities and organized services to make clinical trial participation more convenient and sustainable for patients. In this fireside keynote chat, Judy will discuss leadership lessons needed to drive innovation and specifically, how to better support patients and sites.Speakers:Judy Sewards, VP, Head of Clinical Trial Experience, PfizerBarry Nelson, Patient Advocate
About The EpisodeWhen developing and bringing a therapeutic for a rare disease to market, sponsors should think with the end in mind and plan for payer requirements early in protocol design. The economic and clinical value evidence required by payers for market access differs from the clinical efficacy and safety evidence demanded by regulators. Securing approval but lacking market access results in unrealized revenue and, most importantly, patients left untreated. But how do we price and how do we gain access on the promise of long-term value when we don’t have the long-term data?Join Sangeeta Budhia, VP and Global Head, Pricing and Market Access, and Wyatt Gotbetter, Worldwide Head, Access Consulting, of Parexel, to discuss early market access planning, including inclusive data collection, payer models and the impact of new regulations and innovative trial design on data collection and ongoing evidence provision.About the Speakers: Sangeeta Budhia is VP and Global Head, Pricing and Market Access, at Parexel. Her role is to ensure that global strategies including pivotal clinical trials, long-term data collection studies, real world evidence generation plans and HEOR strategies are prepared for the reimbursement challenges that each product will face. Wyatt Gotbetter is SVP & WW Head of Access Consulting, leading all facets of Parexel's Access Consulting business with a focus on helping customers position products for market success. With more than 25 years of industry experience, he brings unique insights to guide Parexel's strategy as we invest in this segment of the business to further our patients-first focus.Sangeeta and Wyatt can be contacted at Sangeeta.Budhia@parexel.com & Wyatt.Gotbetter@parexel.com.
About The EpisodeWith pharma’s focus on the extension of drug release windows, new technologies are needed that can lengthen that duration. Today, Zach Fletcher of Trelleborg Healthcare & Medical provides an insight into how the emerging field of long-acting implantables & polymeric drug delivery can address that need.He will be addressing: current applications of implantables and likely future applications, top concerns from pharma and assessing your portfolio for lifecycle applications, manufacturing and scalability challenges, likely conversations around reimbursement from payers.About the Speaker: Zach Fletcher, Business Development Manager - Implantable Drug Delivery & Combo Products at Trelleborg Healthcare & MedicalZach Fletcher is the Business Development Manager - Implantable Drug Delivery & Combo Products at Trelleborg Healthcare & Medical. In this role, he identifies, establishes and develops relationships with device organizations and pharmaceutical companies to deliver unique solutions and therapies to patients. Trelleborg is a world leader in engineered polymer solutions that seal, damp and protect critical applications in demanding environments. For more information on drug delivery news and partnership opportunities, click here.
Kate Woda, IO360° Conference Director, gives a 6 minute overview on what you can expect at the 9th annual IO360° Summit taking place February 7-10 in Brooklyn, NY.Keynotes Include:Dr Carolyn Bertozzi, Stanford University on Bioorthogonal and Click Chemistries Impact on Advancing Cancer ImmunotherapyDr Marcela Maus, Massachusetts General Hospital on Mechanisms Driving CAR T CellsDr Isabelle Rivière, Memorial Sloan Kettering Cancer Center on Cell Therapy Manufacturing Progress Report and Novel Manufacturing ParadigmsDr Axel Hoos, Scorpion Therapeutics on Transformational Medicines & The Next Wave of IODr Andrew Baum, Citi on What’s Next on the IO Radar? Top 10 RecommendationsDr Arjun Goyal, Vida Ventures on Investor Perspective on the State of the Current Market and Impact on the IO Cell Therapy FieldOswald Peterson, Stage IV Lung Cancer Survivor who will share his extraordinary story from diagnosis through to immunotherapy treatments that saved his lifePlenary Topics:Biomarkers / Assay DevelopmentDiscovery / PreclinicalImaging AdvancementsClinical OperationsBusiness DevelopmentsTranslational ScienceCell TherapyRNA TherapeuticsClinical DevelopmentsLearn more about the upcoming IO360° Summit at www.io360summit.com
About the Episode
In this podcast, you will hear a panel discussion moderated by Dr Sheela Kolluri, Teva Pharmaceuticals, from the 2022 Chief Medical Officer Summit 360° regarding what CMOs need to know about statistics, strategies for clinical development, strengths and weaknesses of complex trial designs and how to maximize the use of your statisticians.
Panelists include: Marcia Levenstein, ScD, MBE, VivliNatasha Mühlemann, MD, MBA, CytelJeffrey Bornstein, MD, Eledon Pharmaceuticals To learn more about the upcoming 2023 CMO Summit 360°, please visit: www.theconferenceforum.org
About The Episode
As technology advances in clinical research manage operational workflows, others arise as research sites juggle non-integrated technology systems deployed by sponsors and CROs, slowing operations and duplicating work. In this podcast, Stuart Cotter, VP of Product Strategy and Innovation at Advarra, will explain the work being done to allow sites to bring their own tech to research studies when they are working with sponsors and CROs.
This episode addresses: sponsor concerns around site technology being fit-for-purpose; the pain points sites currently face on a daily basis; and Advarra’s Site-Sponsor Consortium that brings together stakeholders to brainstorm and problem-solve this issue.
About the Speaker:
Stuart Cotter, VP, Product Strategy and Innovation, Advarra
Stuart Cotter is the Vice President of Product Strategy and Innovation at Advarra. In this role, he collaborates with current customers and the research community to understand their challenges and translates those challenges into solution-based enhancements to our product offerings. Cotter also leads the Advarra Site-Sponsor Consortium, helping to seamlessly connect site and sponsor technology by addressing key data and process inefficiencies across the clinical research ecosystem. Prior to joining Advarra's strategic team, Cotter worked as a Product Manager for Advarra eRegulatory Management System, and as Product Support Specialist on Allegro CTMS, where he worked alongside dozens of small- to mid-sized research sites to help them overcome their operational hurdles.
For more information on disruptive innovations in clinical research, click here.
About The Episode
As patient-centricity influences every part of the clinical trial process, sponsors may be surprised at how they impact eCOA strategy.
On this episode, THREAD Research's Chris Watson and Rebecca Tomalty share their expertise and experience, strategizing and developing patient-centric eCOAs to avoid surprise costs and delays. Listeners will learn: when to start thinking about eCOA implementation, the unexpected hurdles that can pop up, the ways that patient-centricity has impacted future eCOA planning, and the questions to be asking of your eCOA partners.
About the Speakers:
Chris Watson, Director, Consulting, THREAD
Chris has over 27 years of experience in product and service development within regulated industries across multiple markets. The last 13+ years have focused on Clinical technologies, including tools and platforms to engage, educate and retain participants (and their families) in clinical studies. Chris is a recognised subject matter expert in eCOA and patient engagement, with a proven ability in the technical domain.
Rebecca Tomalty, Director of eCOA and Translations, THREAD
Rebecca has 20 years of industry experience, primarily in Operations. After several years of experience as a Project Manager, she moved to Clinical Outcome Assessment management in the form of scale management (eCOA Licensing and copyright management and Translations) and, most recently, eCOA design and oversight. As Director of eCOA and Translation Services, she has operational oversight for these two key areas of engagement.
For more information on disruptive innovations in clinical research, click here.
About This Episode:
DataArt's engineering capabilities with xCures' oncology expertise created a Natural Language Processing tool. This collaboration tackles the difficult task of ingesting a patient's health records, parsing free-text cancer notes, in order to help patients navigate their options for oncology treatments.
This Conversation Specifically Addresses: The unique challenges facing xCuresHow DataArt and xCures began their collaborationThe ongoing conversations required to create something novel and get the finished product to the end user: the patient Plus how this technology could positively impact clinical trial matching
About the Speakers:
Jamie McCulloch is Vice President of Client Solutions at DataArt. DataArt is a global software engineering firm with over 25 years of experience, teams of highly-trained engineers around the world, deep industry sector knowledge, and ongoing technology research, to help clients create custom software that improves their operations and opens new markets.
Mark Shapiro, Chief Operating Officer of xCures, is a management consultant and drug development expert with over 20 years of experience leading growth, innovation, and business transformation in clinical research and development. xCures is an AI-supported platform predicting top treatment options for cancer patients and creating RWE suitable for FDA submissions.
Lia Parsenadze is a Data Scientist at DataArt, with professional interests revolving around AI/ML/DL, particularly in medical applications.
For more information about cancer research, click here.
About This Episode:
What is in the future for biosimilars?
In this episode, Pierre Bourdage, Chief Operating Officer at Sandoz, lays out the promise and potential of biosimilars, and the important role they play in healthcare system sustainability. We also hear about the new initiative Act4Biosimilars which addresses the challenges of biosimilar approvability, accessibility, acceptability and affordability, with the goal of increasing the global adoption of biosimilars by at least 30% in 30+ countries by 2030.
Key Takeaways: How biosimilars can fuel competition, innovation and generate savingsThe lasting impact on access for patientsHow Act4Biosimilars works to support biosimilar adoption and access About the Speaker:
Pierre Bourdage is the Chief Operating Officer of Sandoz, a division of Novartis, driving high quality off-patent medicine accessibility and affordability for millions of patients. He is a member of the Sandoz Executive Committee. His previous roles at Sandoz include Global Head, Biopharmaceuticals Business Unit and Global Head, Sandoz Biopharmaceuticals Strategy and Portfolio.
For more information about innovations in clinical research, click here.
DPHARM Directors, Valerie Bowling and Tracey Kimball, provide a brief overview of what to expect at the 12th annual DPHARM: Disruptive Innovations to Modernize Clinical Research conference.
Get 10% off with code TEML.
In this 9 minute webinar, CRAACO® Conference Producer, Andrew Goldstein is joined by Executive Director, Valerie Bowling where they give a summary on what you can expect at the CRAACO: Clinical Research as a Care Option conference.
Embedding clinical research in the care setting can lead to higher rates of clinical trial participation inside of a health system, better health outcomes, lower cost of care and more satisfied patients. CRAACO is a unique opportunity for pharma, healthcare and patients to come together and address how we can build a more integrated research ready platform to improve patient access to clinical trials.
The conference takes place September 12, 2022 at the Westin Copley Place in Boston, MA. For more information please visit www.craacoevent.com
In this podcast, Valerie Bowling, Director of the PODD: Partnership Opportunities in Drug Delivery conference gives a 5 minute overview on what you can expect at the 12th annual PODD taking place October 24-25 at the Westin Copley Place in Boston.
Learn more about the upcoming conference at poddconference.com
Summary:
us for an important discussion about the necessity to adjust and adopt media and research strategies to ensure clinical trial recruitment of diverse populations. PharmaTalkRadio’s Valerie Bowling speaks with BBK Worldwide industry experts Justin Jones and Gaby Grekin who will share specific strategies and approaches to apply at the research and media planning stage to achieve more balanced clinical trial representation.
More specifically, our guests discuss: FDA expectationsStrategic media approaches to create a more diverse and inclusive clinical trial environmentWhat to do before initiating an enrollment or engagement campaignKey considerations for planning and executing an effective outreach campaign that engages and motivates diverse audiencesWhat to prioritize? This podcast will especially benefit study sponsors, site staff, PIs, CROs/CRAs, designers and planners of clinical studies, as well industry professionals who support these groups to aid in study recruitment and strategy.
Guests:
Justin Jones, Sr Director Media and Content, BBK Worldwide
Gaby Grekin, Sr Director of Global Strategy, BBK Worldwide
Moderator:
Valerie Bowling, Executive Director, PharmaTalkRadio
For more information about patient involvement, engagement and centricity, click here.
About the Episode:
The number of biotech companies out there makes the struggle to find good talent and good outsourcing partners more difficult and more expensive. As a biotech CMO, working with a CRO more worried about delivering their margins than delivering on what you need leads to an insourcing problem of being inappropriately staffed and an outsourcing problem of not being serviced. In this podcast, Joe Arcangelo, Co-founder & Managing Partner, InSeption Group, and Dr Steven Zelenkofske, CMO, SwanBio Therapeutics discuss how the biotech and CRO industries have evolved and how you can identify the best partner for your needs.
Key Takeaways: How to assess and select outsourcing partnersFocusing on the individuals assigned to your company as opposed to the entire CRODetermining when to outsource and what model to useIntegrating CROs while remaining nimble and flexible as a biotech
About This Episode:
Dr Derk Arts, Founder and CEO of Castor, lays out what he views as the next phase of data presentation to regulatory agencies, moving away from the standard SDTM (study data tabulation model) into something that more accurately represents the diverse streams of data that are being generated. Potential impacts include: drug approvals based on quality of life, a step forward into precision medicine, and overall increase in patient centricity.
Key Takeaways: How companies can prepare for a more data-friendly futureWorking groups at the FDA and their involvement in data submission What this direction means for precision medicine, remote monitoring and other innovations in clinical research
About the Speaker:
Derk Arts, MD, PhD, has over fifteen years of experience in medicine, research and technology. He founded Castor to solve the biggest issues in clinical research: a lack of inclusivity, patient focus and impact of data. Castor enables sponsors worldwide to run patient-centric trials on a unified platform that helps them maximize the impact of research data on patient lives.
Dr Derk Arts believes the key to achieving lasting change in the industry is through scalability and standardization. Technology to run better trials and maximize the impact of data should be available to all researchers.
Over the past 12 months, Castor provided pro-bono support to over 300 COVID-19 trials, and provided the entire infrastructure for the World Health Organizations’ Solidarity Trials.
For more information about innovation in clinical research, click here.
COVID-19 changed the clinical research landscape by proving the use and efficacy of DCTs, patient-centricity and adaptive designs. Dr Ubavka DeNoble, Executive Vice President of Biotech Operations and Senior Medical Officer of Parexel Biotech shares advice on how CMOs can think about leadership, change management and investing in new technologies such as artificial intelligence, improved data collection and system interoperability to improve patient recruitment and retention and drug development efficacy.
Key Takeaways: How to lead with an eye on industry changes and flexibilityThe importance of rewarding innovation rather than standardizing a single approachObservations of successful change management throughout the COVID-19 pandemic
About This Episode:
What is the future of drug delivery for patients, and how do we get there?
In this episode, Dr Shawn Davis, who leads the Drug Delivery team of the Biopharmaceuticals Development organization at AstraZeneca, lays out a bold vision discussing how the future of drug delivery is patients interacting less with their disease, and what steps we can take to make that future a reality.
Key Takeaways: How companies can de-risk drug delivery innovationsHow the current moment in drug delivery is shaping our long-term visionBalancing the competitive landscape, portfolio and patient needs
About the Speaker:
Shawn Davis, PhD is an Executive Director at AstraZeneca and leads the Drug Delivery team of the Biopharmaceuticals Development organization. The team improves patients’ lives by ensuring AZ’s therapies are as safe, effective, and convenient as possible using technologies that target the delivery of medicines to the site of action and optimizing their effective half-life.
This requires the evaluation, development, and commercialization of drug delivery technologies across a wide range of modalities in the biopharmaceutical space. Areas of program delivery include: intracellular delivery of nucleic acids, controlled release of antibodies for less frequent dosing, novel routes of administration for therapeutic benefit, and co-delivery of multiple therapeutic molecules. Dr Davis also serves as the CMC leader for early stage assets in the portfolio.
For more information about drug delivery, click here.
About This Episode:
Current efforts to source and disseminate patient insights in clinical trial planning are expensive and time-consuming.
In this episode, Fabio Gratton, CEO and Co-Founder of InVibe, which was recently acquired by THREAD Research, discusses how patient voice listening technology is enhancing and disrupting clinical research by making it easier to collect and use patient responses. The result could be more patient-centric trials informed by the actual patient voice.
Key Takeaways: How current listening technology can accurately capture and convey patient responses, emotion and perspectiveThe difference from current methods of sourcing patient feedbackNext steps in the journey of making trials more patient-centric
About the Speaker:
Fabio Gratton, Co-Founder and CEO of inVibe, part of THREAD Research, is a digital health entrepreneur. For over two decades he has adapted his early experience as a Hollywood scriptwriter with innate acumen in science and data to redefine how healthcare companies tell patient stories through technology. Of his many Fortune 5000 ventures, inVibe has transformed market research by enabling
brands to supplement their efforts with flexible, scalable, and impactful voice-driven insights.
For more information about innovation in clinical research, click here. For more information about mobile technologies in clinical trials, click here.
About the Episode:
Creating options for patients with decentralized clinical trials can provide tremendous benefits for certain patients and indications. In this podcast, Labcorp’s Linda Ross, Associate Director of Commercial Strategy, Decentralized Clinical Trials, brings an on-the-ground perspective to the benefit of incorporating decentralized strategies into your clinical trial approach.
Having worked on multiple sides of clinical research, Ms Ross is using her experience running clinical trials via flexible approaches to discuss how, after COVID, the industry can and should continue broader applications of flexible, decentralized clinical trials.
Key Takeaways: How to convey the value of consistent DCT planning to sponsorsUnderstanding current attitudes and burdens around decentralizationThe next steps in wider adoption of flexible approaches
About the Speaker:
Linda Ross has over 20 years’ experience in the pharmaceutical industry and commenced work with Labcorp in Nov 2008 where she is currently employed as an Ass. Dir. Commercial Strategy, Decentralized Clinical Trials. Linda has worked in a variety of leadership positions across different therapeutic areas that have involved multiple countries in Asia Pacific as well as Americas and Canada. She has developed extensive experience in developing decentralized clinical trials strategies on projects from pre-award, during set up, as well as leading new initiatives for ongoing studies which have been faced with challenging circumstances.
For more information about disruptive innovation in clinical research, click here.
Dr Viney joined the CMO Summit 360° in October 2021 to share her incredible journey in drug discovery and development, founding and leading Pandion Therapeutics and joining the advisory boards of multiple biotech companies.
Learn more about the 10th annual CMO Summit 360° taking place April 4-5, 2022 here.
In this podcast, hear a keynote session from the 2021 Chief Medical Officer Summit 360˚ with Dr Ron Cohen on his journey founding and building Acorda Therapeutics and leading the company as an MD CEO for 26 years. Dr Cohen also shares advice on how CMOs can best collaborate with their CEOs and add value to their companies.
Learn more about the 10th annual Chief Medical Officer Summit taking place April 4-5, 2022 here.
Conference Producer, Andrew Goldstein, walks through what you can expect to learn and who you'll hear from at the upcoming Chief Medical Officer Summit 360º taking place April 4-5, 2022 in Boston, MA, including: Clinical development and operationsRelationships within the C-suite and team buildingThe role of the CMO in biotech financingExternal communicationsProfessional development For more information, click here.
About the Episode:
In this podcast, we discuss the topic of clinical sites shifting to using the own technologies in sponsored trials and how it can advance (and maintain the pace of) clinical research. Our guest, Bryan Spielman, Chief Growth Officer at Advarra lays out the current burden being faced by performing sponsor trials. Mr Spielman also talks about the work Advarra has led in bringing together sites, CROs and sponsors to brainstorm new solutions, and the path forward to encourage wider conversation, acceptance and adoption.
Key Takeaways: Identifying current burdens faced by sitesUnderstanding current attitudes towards site-owned technologySteps forward to benefit both sides of clinical research
About the Speaker:
Bryan Spielman, MBA, is Chief Growth Officer at Advarra and is responsible for driving Advarra’s corporate strategy, mergers and acquisitions, strategic partnerships, and corporate marketing. Spielman brings over 25 years of business development and corporate strategy experience from leading technology companies including those with a focus on life sciences.
For more information about innovation in clinical research, click here.
About the Episode:
Daniel Chen, MD, PhD, Immuno-Oncology 360º 2022 Strategic Advisor, Physician Scientist, Cancer Immunotherapy and Board of Directors, Society for Immunotherapy of Cancer (SITC) and co-author of the Cancer Immunity Cycle, discusses five talks he is excited for, and why, at the upcoming Immuno-Oncology360 conference.
The 2022 summit will be held March 16th through the 18th, 2022 at the New York Marriott Brooklyn Bridge. For more information, and the full agenda, visit www.io360summit.com.
5 Top Topics To Watch from Dan Chen: ctDNA Guiding Adjuvant ImmunotherapyClinical Data on PSMA BiTeNovel Approaches to Expand the Therapeutic Index of T cell EngagersSynthetic BiologyIO360° Debate: NK-Cars vs T cell- CARs
This 7 minute podcast summarizes what you can expect at the 8th annual Immuno-Oncology 360° conference. IO360˚convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.
Keynotes include: Dr Gregg Semenza, Johns Hopkins University School of MedicineDr Rachel Haurwitz, Caribou BiosciencesDr Christine Brown, City of HopeDr Suzanne Topalian, Johns Hopkins UniversityDr Andrew Baum, Citi Key topic areas include: Discovery/Preclinical ScienceCell & Gene TherapyTranslational ScienceBispecificsClinical DevelopmentsNeoadjuvant/Adjuvant DataEmerging BiomarkersCytokinesClinical OperationsIO CombinationsImaging AdvancementsBusiness Developments The conference takes place February 16-18, 2022 at the New York Marriott Brooklyn Bridge, New York City, NY. For more information please visit www.io360summit.com or contact us at service@tcfllc.org
Conference Producer, Mark Scherzer, talks through what to expect at the upcoming Patients as Partners EU virtual conference taking place 24-25 January 2022.
The 6th annual conference will bring together pharma, biotech, CROs and technologists to figure out how to advance patient involvement in medicines development. Experts from Novartis, Pfizer, Merck, EMD Serono, Janssen, Johnson & Johnson, GSK, Ipsen, UCB, Takeda, AbbVie, Noema Pharma, Gilead Sciences, and Pierre Fabre will gather with patient advocacy to address: Outcome measures that matter most to patients Patient Experience Data for regulatory submissionsCompliance barriers to advance patient involvementIncreasing diversity in clinical researchPatient involvement in Turkey and Eastern EuropeImpacting clinical research through carer InputPatient involvement in the design and execution of platform trialsPatient access to research through digital innovation
About the Episode:
How can artificial intelligence maintain the pace of clinical trials from the COVID-19 pandemic to bring therapeutics to patients faster? Suresh Katta, CEO and founder of Saama Technologies, sits down to discuss exactly how artificial intelligence can be utilized to design better trials from the start, reduce costs and benefit patients and pharma in the long run.
Key Takeaways: How to create broader adoption and change management of new technologiesCreating the best protocol design from the start, without pricey and time-consuming amendmentsHow AI can reduce costs, as well as timelines
About the Speaker:
Suresh Katta founded Saama Technologies in 1997, well before the collective global corporate conscience was aware of the extraordinary opportunities – and significant challenges – inherent in big data. He is a frequent contributor to industry publications and a featured speaker at industry conferences. He earned his M.S. in Computer Engineering at the University of Southwest Louisiana, and his B.S. in Electronics Engineering at the University of Bangalore.
For more information:
About disruptive innovations in clinical research, click here.
For more information about PharmaTalk Radio, visit theconferenceforum.org.
About the Episode:
How can therapeutics like biologics and small molecule drugs evolve in their delivery? Finn Doyle, SVP and General Manager of ENHANZE® at Halozyme, sits down to discuss exactly how these innovative therapeutics can be delivered subcutaneously where they have previously only been administered via IV, the impacts of doing so, and the keys to successful drug delivery collaborations.
Key Takeaways: How switching to a SC delivery model impacts patients, healthcare providers and drug development companies Keys to successful partnerships and collaborations How Halozyme's ENHANZE® technology enables the shift from IV to SC
About the Speaker:
Finn Doyle joined Halozyme in May of 2021 as the Senior Vice President and General Manager of ENHANZE®. She is responsible for overseeing Halozyme’s ENHANZE® drug delivery technology, including responsibility for the annual operating plan and long-term growth strategy for the franchise. Ms Doyle will oversee the alliance management, ENHANZE® business development, regulatory and safety, and project management functions within Halozyme. Ms Doyle received a B.S. in Biochemistry from Trinity College in Dublin (Dublin University) and a degree in International Business and Marketing Ireland and did postgraduate research at MIT/Harvard.
For more information:
About drug delivery and partnerships, click here.
For more information about PharmaTalk Radio, visit theconferenceforum.org.
About the Episode:
What does the future of eyecare look like? How does a global company stay innovative? Listen to this podcast to hear Dr Xiao-Yu Song, Johnson & Johnson Vision, providing the latest information on J&J Vision's new products, and her approach to innovation.
Key Takeaways: How to encourage innovation in a large, global company What the current and future eyecare needs are How Johnson & Johnson Vision is expanding and innovating their products, including a first-in-class drug delivery contact lens
About the Speaker:
Xiao-Yu Song is the Global Head of Research & Development for Johnson & Johnson's eye health business. She has overall R&D responsibility for new product development and life cycle management support as well as portfolio management and innovation governance across all platforms in Johnson & Johnson Vision. Xiao-Yu earned her Ph.D. in Biology from the University of North Carolina at Chapel Hill, her M.S. in Biochemistry and Medical Degree at China Medical University, and completed postdoctoral training in autoimmunity and immunology at the U.S. National Institutes of Health.
For more information:
About disruptive innovation in clinical research, click here.
About drug delivery and partnerships, click here.
For more information about PharmaTalk Radio, visit theconferenceforum.org.
About the Episode:
As the COVID-19 pandemic encourages the widespread adoption of decentralized clinical trial models, there are opportunities to optimize existing processes to make clinical research easier for sites and sponsors to conduct, and for patients to participate. Jonathan Andrus, Clinical Ink, discusses his advice as a flexible data collection expert, thoughts on wider adoption of DCTs and where he thinks the future is headed.
Key Takeaways: The role of regulatory guidance, how-to's and industry examplesShifting from a "surviving" to "thriving" mentality in regards to DCTsNext steps for the industry
About the Speaker:
Jonathan Andrus is Chief Strategy Officer of Clinical Ink. He is responsible for driving the corporate strategic vision, communicating the plan with all those involved, executing the business initiatives, and sustaining implementation efforts. This includes driving important internal initiatives, identifying potential targets for acquisition, and other partnership opportunities to help drive the business forward.
About Mobile in Clinical Trials:
Mobile in Clinical Trials is the meeting place for digital R&D operations leaders who are seeking solutions to apply mobile-digital tools into clinical research. Each year, we bring forward the latest experience-based case studies while presenting fresh ideas to advance fit for purpose, adoption and scale of remote digital solutions. For more information, click here.
For more information about PharmaTalk Radio, visit theconferenceforum.org.
While the idea that trust between sponsors and development partners is integral to success is well known, actually building that relationship requires real effort and empathy from both groups. Today, Dr Skip Sands, Senior Vice President and Senior Medical Officer of Parexel Biotech, discusses practical examples of how to build and maintain that relationship of trust and navigate challenges that arise based on his experience on both sides of the sponsor and CRO partnership.
Key takeaways: How to choose the right development partnerBuilding the relationship infrastructure from the bid process through clinical developmentCommunicating and managing expectations between sponsors and CROs
Guest: Earl “Skip” Sands, MD, MBA, Senior Medical Officer, Parexel Biotech
Prior to joining Parexel Biotech as Senior Medical Officer in 2019, Dr Sands served as the Chief Medical Officer for Selecta Biosciences (2015-2019), Targacept (2014-2015) and Plasma Surgical (2013-2014). From 2011 to 2013, he was a consultant to biotechnology, pharmaceutical, and health care companies, leading protocol development and execution for Phase 1-4 studies in areas including women’s and men’s health, oncology, neuroscience and gastroenterology. From 2003 to 2011, Dr Sands was with Solvay Pharmaceuticals/Abbott Laboratories (following its acquisition of Solvay) in a series of roles of increasing responsibility culminating as Executive Vice President, Market Access and Senior Vice President of Research and Development. Earlier in his career, he worked with Procter & Gamble Pharmaceuticals,
founded a medical education company, and was a managing partner in a medical practice. He earned his Medical Doctor Degree from Hahnemann University School of Medicine in Philadelphia, PA, and has completed courses in the Executive MBA program at Emory University in Atlanta, GA.
In this podcast, Conference Producer, Andrew Goldstein, reviews what to expect at the 9th annual Chief Medical Officer Summit 360°. The conference will take place October 14-15, 2021 in Boston, MA also with virtual attendance options.
Learn more about the conference taking place October 14-15, 2021 at theconferenceforum.org
In this podcast, first presented at the PODD: Partnership Opportunities in Drug Delivery 2020 conference, you will hear Dr Barbara Lueckel, Roche Pharma Partnering provide her annual review on the drug delivery industry including notable highlights and partnerships that occurred over the past ten years.
To learn more about the 2021 PODD: Partnership Opportunities in Drug Delivery conference please visit www.poddconference.com
In this podcast, Conference producer, Mark Scherzer, reviews what to expect at the 8th annual Mobile in Clinical Trials conference. The conference will take place September 27, 2021 in Boston, MA also with virtual attendance options. Learn more here.
In this podcast, Valerie Bowling, Director of the PODD Drug Delivery conference gives a run down summarizing what is being featured at the 11th annual event.
Learn more about the conference taking place October 28-29, 2021 at poddconference.com
Disruptions in the microbiome are increasingly being linked to an associated risk for serious illnesses, opening up vast potential to create a new category of innovative microbiome-based live biotherapeutics to help people live better lives and advance current standards of care.
Today, Dr James Tursi, Chief Scientific Officer of Ferring Pharmaceuticals, discusses study results of Ferring’s Phase III Trial for their microbiome-based live therapeutic (RBX2660), used in the treatment of recurrent C Difficile, and how to harness the potential of the the fast-emerging world of microbiome-based therapeutics.
Key takeaways: Why now is the right time to tackle the microbiomeResults and impact of Ferring's RBX2660 treatmentNext steps for the industry
About the speaker:
Dr James Tursi is Chief Scientific Officer, Ferring Pharmaceuticals, responsible for US Clinical Development, Pharmaceutical Development, Medical Affairs, Pharmacovigilance, Project Planning and Regulatory Affairs. Prior to joining Ferring, as EVP, R&D, Chief Medical Officer for Antares Pharmaceuticals, he created patent extension and portfolio opportunities, was the medical-clinical-PV lead for commercial and business development activities and designed the medical/clinical commercial strategies. Before joining Antares, James held positions of increasing responsibility at Aralez Pharmaceuticals, Auxilium Pharmaceuticals, GlaxoSmithKline, and Procter & Gamble Pharmaceuticals. His therapeutic expertise includes reproductive health, urology, endocrinology (including pediatric), gastroenterology, cardiology, vascular surgery, oncology and neurology.
For more information about PharmaTalk Radio, visit theconferenceforum.org.
DPHARM Executive Director, Valerie Bowling gives a 10 minute run down on what you can expect from DPHARM 2021.
Learn more about the conference taking place Septmeber 28-29, 2021 at DPHARMconference.com.
This PharmaTalk Radio episode features Dr Shawn Carbonell, CEO and co-founder of Brazen Bio.
In this conversation, Dr Carbonell describes how the Brazen Incubator, a turn-key biotech startup incubator, hopes to help fledgling entrepreneurs, the common hurdles that prevent startups from getting off the ground, and recruiting underrepresented founders.
Dr Carbonell started the incubator, based in Los Angeles, with cofounder Dr Brent Witgen.
About Dr Carbonell and Brazen:
In 2009, Dr Carbonell quit neurosurgery residency to found the clinical stage biotech startup, OncoSynergy, Inc, a UCSF spinout. Brazen Bio, which launched in May 2021, is solving the problem Dr Carbonell had over a decade ago when founding his company. Launching a biotech startup requires laboratory access, specialized equipment and other resources. The Brazen Incubator provides the basic infrastructure to founders, including 24/7 laboratory access, resources and housing.
For more information about our PharmaTalk podcasts, you can visit theconferenceforum.org.
For more information about our Chief Medical Officer 360˚ summit, click here; and for more information about our Immuno-Oncology 360˚ conference, click here.
In this conversation between two decentralized clinical trial experts, John Reites, CEO of THREAD, and Andy Iverson, Clinical Outcomes Solutions lead at Medtronic, are discussing decentralized clinical trials: where they don’t work yet and how that might change, the considerations for disease indication and trial type, what technology to use, and what an adoption journey could look like.
Key Takeaways:
When DCTs don’t work (yet)
Technology, operations and knowledge perspectives
What a phased approach looks like
Identifying the key stakeholders
Speakers:
Andy Iverson is the Clinical Outcomes Solutions lead on the Evidence Optimization Center of Expertise team at Medtronic. In this role he functions as a subject matter expert and project team leader for initiatives related to artificial intelligence, decentralized clinical trials, and interoperability. His career includes 10+ years working with provider and payer systems and data. Andy serves as the Co-Chair of HL7s Biomedical Research and Regulation workgroup and is on the Operations Committee of the HL7 Vulcan FHIR Accelerator. He received a BA in Healthcare Management at Concordia College and an MS in Data Science at Northwestern.
John Reites is CEO of THREAD. Executive intrapreneur turned digital health entrepreneur, his career includes 18 years leading global drug development, clinical trials, decentralized studies and clinical research innovation. As CEO of THREAD, he’s led the company’s efforts to change the way clinical research is conducted, focused on decentralized approaches and enabling the use of their platform to conduct modern research studies while supporting partnerships with their customers.
Learn lessons from a healthcare communications and clinical trial recruitment expert about addressing health disparities in racial and ethnic minorities, utilizing technology to precisely raise awareness, and bridging the digital divide, and how to: Leverage technology to raise awareness and engage post-trialChange practices to address mistrust amongst typically underserved populationsUse technology to recruit more diversely and representatively in the pandemic
Speaker:
Becky Johnson, PhD, Director, Global Diversity & Inclusion in Clinical Trials, IQVIA: Becky has 20 years of experience in the biopharmaceutical industry and is a subject matter expert in healthcare communications and clinical trial recruitment with a focus on diversity, equity and inclusion. Becky leverages her expertise to inform the strategic direction and initiatives to support pharmaceutical company sponsors with their efforts to achieve more racially and ethnically diverse trial populations. Becky has a Master’s in Public Health and a PhD in Health Sciences. Her doctoral dissertation research focused on facilitating access to clinical trials for racially and ethnically diverse patients.
For more information on PharmaTalk podcasts, click here.
For more discussions and updates on innovations in clinical trial operations and the use of devices in research, visit theconferenceforum.org to learn about the Patients as Partners in Clinical Research conference.
In this podcast, Roger Boutin, VP of Communications at SCORR Marketing discusses the results of an audience survey from the 2020 CRAACO: Clinical Research as a Care Option Conference. The poll focused on the areas of: Patient Input and EngagementDealing with COVID and Patient OutreachDiversity and Collaboration Around Clinical TrialsAccelerating the CRAACO Movement
In this conversation, you'll learn lessons of how to implement sensors for the most impact in your clinical trials. Join three sensor experts as they discuss: What phases of clinical trials are more suited for sensor useHow to select and integrate the deviceHow to ensure compliance Speaking: Keith Wenzel, Senior Director, Parexel’s Scientific Data Organization: Keith's areas of subject matter expertise include electronic clinical outcomes assessment, patient sensors and a broad range of eClinical technology used within clinical drug trials.Julia Lakeland, Solutions Architect and Program Director, Parexel: Julia is responsible for selection and implementation of real-world scientific data sources and wearables for clinical trial use. Her background is in product management, operational delivery and support of phase III/IV clinical trials. Thomas Wells, CEO, Precision Digital Health: Thomas is currently focused on bringing innovative big data solutions to market to support real-world evidence research and clinical trial research that scale to meet the shear volume and diversity of data sources with evolution of digital health and precision medicine.
For more information on PharmaTalk podcasts, click here.
For more discussions and updates on innovations in clinical trial operations and the use of devices in research, visit theconferenceforum.org to learn about the upcoming DPHARM: Disruptive Innovations conference, held September 28-29, 2021, and the Mobile in Clinical Trials event, held September 27, 2021.
Patients as Partners Europe conference producer, Mark Scherzer, provides an overview of the upcoming virtual conference agenda to take place 25-26 January 2021. Hear about the sessions, keynotes, interactive opportunities, and what you will walk away with, including: A range of examples of patient engagement ideas in the early stages of research to advance clinical outcomesAn understanding of how to design hybrid trials around patient preferences to drive better enrollment and retentionHow to increase diversity in clinical trialsHow to manage the issues that arise when implementing new approachesHow to influence organizational change to support patient engagement and clinical research awareness strategiesExpand your professional network by connecting with peers who can provide a wide range of insightsLearn directly from patient advocates who bring a broad spectrum of ideas to the conversations Learn more about the conference here.
In this podcast, you will hear a panel discussion moderated by Dr Annette Schmid, Takeda Pharmaceuticals from the 2020 IO360° Summit regarding innovations and novel approaches in IO imaging and assessing responses.
Panelists inclue: Gregory Goldmacher, MD, PhD, MBA, MerckS. Peter Eggleton, MD, FFPM, Merck KGaARon Korn, MD, PhD, Imaging EndpointsMatthew Silva, PhD, Invicro To learn more about the upcoming 2021 IO360° Summit please visit www.io360summit.com
Loss of the HLA locus impairs presentation of tumor antigens and is frequently found in advanced cancers. This talk presented by Dr Lee Albacker, Foundation Medicine and first recorded at the 2020 IO360° Summit, will describe the landscape of HLA loss and other response biomarkers in a dataset of 90,000 solid tumor samples and highlight the effect of HLA loss on checkpoint inhibitor response.
To learn more about the upcoming IO360° 2021 Summit please visit www.io360summit.com
In this podcast first recorded at the 2020 IO360° Summit, Dr Aiman Shalabi, GSK, moderated a cell and gene therapy debate on intrinsic editing vs systemic combination
Participants included: Mark O’Hara, MD, University of PennsylvaniaSaul Priceman, PhD, City of Hope To learn more about the upcoming IO360° 2021 Summit please visit www.io360summit.com
In this podcast, first recorded at the IO360° 2020 Summit, Dr Millie Schultz, Seattle Genetics, discusses operational dynamics of implementing and managing basket trials. Discussion points include: What are the operational complexities of basket trials? How do they differ from standard IO trials?How do you identify the right institutions who can handle basket trials? What goes into that decision making?How do you set up your protocol in an open ended way so that you can add a cohort or make adjustments based on signals you received?How do you set up your database to be able to manage all the different tumor types and different types of case port forms. To learn more about the upcoming IO360° 2021 Summit please visit www.io360summit.com
How two companies collaborated on a master trial to drastically improve site startup speed, reduce delays and optimize CRA productivity.
In this podcast, Rick Arlow, Complion, and Dr Len Rosenberg, Leukemia and Lymphoma Society, discuss their collaboration on a LLS master trial, and how adopting Complion’s a purpose-built design optimized site functions and reduces startup time.
Some specific discussion points included: The challenges sites face today with arduous manual tasksHow to pick the right point solution technology for your studyWhat the impacts of their collaboration have been on study progressHow this all benefits patients
For more information about optimizing clinical research for the patient benefit and for improving care, visit the Clinical Research as a Care Option webpage. The 2021 Clinical Research as a Care Option event will be held April 26-28, virtually.
In this podcast, first recorded at the 2021 IO360° Summit, Dr Peter Marks, Center for Biologics Evaluation and Research (CBER), FDA, moderated a panel on the evolution of regulatory policy for cell/gene therapy.
Discussion points include: What are the greatest challenges to the expeditious development of cell and gene therapies at this time?How does the existing regulatory framework mesh with the current state of development of cell and gene therapy products?What adaptations or adjustments to the regulatory framework that might further advance manufacturing or clinical development of these products?Are there scientific developments coming that will require further adaptation or adjustment to the regulatory framework? Panelists include:
Jeff Allen, PhD, Friends of Cancer Research
Anne Chew, PhD, University of Pennsylvania
Alberto Santagostino, Lonza Pharma & Biotech
To learn more about the upcoming 2021 IO360° conference, please visit www.io360summit.com
In this podcast first recorded at the 2020 IO360° Summit, Michael Paglia, ElevateBio, moderated a cell & gene therapy debate on centralized vs decentralized manufacturing.
Participants included:
Boro Dropulić, PhD, Lentigen
Patrick Hanley, PhD, Children’s National Medical Center/George Washington University
To learn more about the upcoming 2021 IO360° Summit, please visit www.io360summit.com
In this podcast, you will hear a panel discussion moderated by Dr Priti Hegde, Foundation Medicine, from the 2020 IO360° Summit regarding next generation bispecifics in solid tumors. Discussion questions include: What is happening in hematology bispecific programs compared to solid tumor bispecific programs?What do bispecifics look like in solid tumors and what is driving efficacy?What’s hindering efficacy in solid tumors compared to hematology?How can we improve on it?What should we be doing on the next generation bispecifics? Panelists:
Julie Bailis, PhD, Amgen
Dimitris Skokos, PhD, Regeneron Pharmaceuticals
David Schaer, PhD, Pfizer
Pablo Umaña, PhD, Roche
To learn more about the 2021 IO360° Summit, please visit www.io360summit.com
In this podcast, you will hear a fireside discussion from the 2020 IO360° Summit featuring cancer survivor and advocate, Ariella Chivil who walked the audience through her immunotherapy trial pathway alongside patient advocate, Cindy Geoghegan, who moderated the chat.
To learn more about the 2021 IO360° Summit, please visit www.IO360Summit.com
In this podcast first recorded at the 2020 IO360° Summit, Asthika Goonewardene, SunTrust Robinson Humphrey, moderated a cancer immunotherapy debate on insitu vaccinations vs systemic neo-epitope vaccinations.
Participants included:
Charles Drake, MD, PhD, Columbia University Medical Center
Karin Jooss, PhD, Gritstone Oncology
To learn more about the upcoming 2021 IO360° Summit, please visit www.io360summit.com
The frenzy of deals around IO programs and companies has led to what could be referred to as “BD outpacing science.” That might be said too of the combination trials that have displayed varied results, with a few showing clear benefit, some being outright failures and some promising but not definitive signs of efficacy. These results, while not exactly slowing the IO gold rush, have somewhat tempered enthusiasm and perhaps led to a certain maturing in dealmaking, as seen by the shifting to more back loaded terms. Which is all by way of framing the context of the macroenvironment, which now begs the question of where will the next big shift come from in immunotherapy.
This podcast, recorded at the 2020 IO360° Summit, will tie together discussion on scientific, translational and business development considerations into the latest thinking on strategizing development in IO that will impact collaborations and investment decision making.
Discussion points: Will it be innovative cell therapies, vaccines against neoantigens, or the next wave of oncolytic viruses?Will it be known targets with better approaches to modulating them like TGF-beta, A2AR/CD73, even CTLA-4?Will it be novel targets and pathways targeting transcription or hitting new TNF superfamily members, or new approaches to modulate the TME “bad actors” like MDSCs, CAFs, TAMs, TANs and Tregs? Moderated by:
Jeffrey Bockman, PhD, Cello Health BioConsulting
Panelists:
Jennifer Buell, PhD, Agenus Bio
Charles Drake, MD, PhD, Columbia University Medical Center
Asthika Goonewardene, MBA, SunTrust Robinson Humphrey
Michael King Jr, Fortress Biotech
Emmett Schmidt, MD, PhD, Merck Research Labs
To learn more about the upcoming 2021 IO360° Summit, please visit www.io360summit.com
In this PharmaTalk episode, get guidance from patient innovation and technology experts about the proper ways of harnessing technology in order to deploy Decentralized Clinical Trials and improve patient care.
Specifically, in this episode Rosamund Round and Julia Lakeland, both of Parexel, discuss: How sensors can be utilizedThe patient impact of COVID-19 and clinical trialsEfforts to support patient safety and trial continuityProtocol around assessments for data collection with sensors
Interview Guests:
Julia Lakeland, Solutions Architect and Program Director at Parexel, is responsible for selection and implementation of real-world scientific data sources and wearables for clinical trial use. Her background is in product management, operational delivery and support of phase III/IV clinical trials.
Rosamund Round, VP, Patient Innovation Center, spends her time devoted to simplifying the patient journey in clinical trials. Focused on the reduction of geographical, financial and practical barriers to study participation, Rosamund is excited by the industry shift towards a truly patient centric approach. Ms Round will be speaking at the upcoming Patient as Partners Europe conference,
In this PharmaTalk episode, learn what can be done to enhance site audit readiness and monitoring.
Rick Arlow, CEO of Complion, recently spoke with DPHARM quarterly newsletter writer, Danny McCarthy, to discuss: Why he believes that the traditional model for site monitoring doesn't serve the industry anymoreHow a purpose-built approach could free up valuable CRA time and reduce costly delays and amendmentsWhat these new processes could mean for research moving forward, answering the question, "How do we make site monitoring better, not just digital?" About Rick Arlow:
Rick Arlow is the CEO and founder of Complion, an eRegulatory and Document Management provider. Mr Arlow began his career in clinical research while participating in a NIH-funded MD/PhD medical scientist training program, and was shocked at how cumbersome operations and regulatory compliance were for the research sites and how much time was wasted on manual tasks and paper binders. Drawing on his engineering background, and inspired by his work in clinical research, Rick Arlow built the first version of the Complion software platform.
Mr Arlow spoke at the DPHARM: Disruptive Innovations in Clinical Trials conference on September 22-23rd, virtually, about bridging sites and sponsors with innovations in site regulatory.
In this podcast, conference producer, Andrew Goldstein, provides a brief overview of what to expect at the 8th annual Chief Medical Officer Summit 360º. The 2020 program will attract the largest gathering of physicians in biotech on October 26-27, 2020. Although the program is primarily designed for CMOs of emerging biotech companies, large pharma CMOs and other R&D decision-makers also attend to exchange best practices in drug development and business management.
Learn more about the 2020 Summit here.
In this PharmaTalk podcast, Benjamine Liu, DPhil, CEO of TrialSpark, discusses the impacts of COVID-19 on the future of clinical research and the innovation being created as a result. Ben recently spoke at DPHARM: Disruptive Innovations to Advance Clinical Trials, moderating an R&D leadership fireside chat with Drs Mark Fishman and Michel Mina.
In this podcast, he recently spoke with DPHARM writer Danny McCarthy about: Embracing powerful technology into trials, particularly for the benefit of at-home monitoringDiversity in clinical researchThe growing and potential impact of artificial intelligence on clinical research Ben will be demonstrating the value of OpenAI's GPT-3 natural language processing model and artificial intelligence at an upcoming webinar, October 22 at 1pm EST. For more information and to register to attend, go to theconferenceforum.org.
Guest:
Benjamine Liu, DPhil, is the co-founder and CEO of TrialSpark, a technology company that is reimagining drug development. TrialSpark partners with doctors to create FDA compliant trial sites within their existing practices (like Airbnb), unlocking the 99% of patients and doctors not involved in trials today and democratizing access to research treatments. TrialSpark runs trials out of these sites using a roaming cohort of research coordinators (like Instacart), optimized by software, data, and machine-learning.
In this PharmaTalk episode, John Potthoff, PhD, CEO of Elligo Health Research explains the benefits of decentralized clinical trials. He recently spoke with CRAACO quarterly news writer, Danny McCarthy to discuss why he believes that decentralized clinical trials can be more patient-friendly, how it epitomizes clinical research as a care option and how the model helps to access patients who have no other way of participating in trials.
Dr Potthoff will be speaking at the CRAACO: Clinical Research as a Care Option conference on November 4-6th virtually.
About John Potthoff, PhD:
John Potthoff, PhD, is the CEO and co-founder of Elligo Health Research, which aims to accelerate the development of new pharmaceutical, biotechnology, medical device, and diagnostic products using their novel clinical technology.
In this PharmaTalk podcast, MaryAnne Rizk, PhD, of IQVIA, leads a multi-perspective panel discussion on monitoring in the digital age as data becomes the new currency.
Together they discuss how AI and ML are empowering sponsors and sites to predict risk before it happens, how modernization is expanding remote monitoring capabilities and the waterfall impact of that on analytical roles, and how this technology can be leveraged to benefit patient engagement and data standards.
Dr Rizk went into deeper detail on this subject at the 2020 DPHARM: Disruptive Innovations conference.
Moderator: MaryAnne Rizk, Ph.D. - SVP Digital R&D, IQVIA Guests: Michael Mittleman – Patient Advocate Ray Reilly – VP, Clinical Operations, TG TherapeuticsRajneesh Patil – Head, Process, Technology & Analytics, IQVIA For more information about PharmaTalk podcasts, visit theconferenceforum.org. A special thanks to the team at IQVIA for their support in presenting this podcast.
In this PharmaTalk episode, Thomas Klein, founder and CEO of Be the Partner, discusses how to implement new retention and engagement methods to stop patients from "vanishing" in the clinical trial process. Mr Klein sat down with PharmaTalk's Danny McCarthy to discuss potential solutions, including transparency of data, increasing communication before, during and after trials, and truly making patients "partners" in the research.
Mr Klein presented at the 2020 Patients as Partners virtual conference.
Guest:
Thomas Klein is the CEO and founder of Be the Partner, a technology company that is focused on how patients can use their health data to improve outcomes for themselves and others around the world.
For more information go to or contact www.bethepartner.com.
Kate Woda, IO Combinations 360° Conference Director, gives a 7 minute overview on what you can expect at the 5th annual IO Combinations 360° conference taking place October 1-2 virtually.
2020 Key Topics: Discovery / Preclinical ScienceBispecificsTranslational Science & BiomarkersNext Generation Cell TherapyClinical DevelopmentsOperationalizing CombinationsBusiness AspectsEmerging Technologies Keynotes Include: Ronald Germain, MD, PhD, National Institutes of HealthSteve Hamilton, Melanoma Cancer SurvivorEdward Tenthoff, Piper Sandler & Co. 2020 Strategic Leadership: Dan Chen, MD, PhD, IGM BiosciencesAxel Hoos, MD, PhD, GSKAlexandra Snyder, MD, Merck Research LabsOmid Hamid, MD, The Angeles Clinic and Research InstituteRaluca Verona, PhD, Janssen R&DJames Gulley, MD, PhD, National Cancer Institute, NIHTheresa LaVallee, PhD, Parker Institute for Cancer ImmunotherapyRoy Baynes, MD, PhD, Merck Research LabsMichael Kalos, PhD, ArsenalBio Learn more about the upcoming IO Combinations 360° virtual conference at www.iocombinations360.com
In this PharmaTalk podcast, Kelly McKee of Medidata leads a multi-perspective panel discussion on the challenges and opportunities of adopting a decentralized model for clinical trials and ensuring clinical trial continuity with live video visits.
Together they discuss lessons learned from the rapid adoption of technologies to allow for more decentralized trials, how incorporating multiple perspectives highlights areas of growth when utilizing a decentralized approach, and the possibility of hybrid trials becoming the new normal for the near future.
Host: Kelly McKee is the Senior Director of Patient Recruitment and Registries at Medidata Guests: Anne Marie Mercurio is a patient and research advocate and caregiver. Rosamund Round is Vice President of PAREXEL’s Patient Innovation Center. Jeff Kingsley, DO, is the founder and CEO of IACT Health. For more information about PharmaTalk podcasts, visit theconferenceforum.org. A special thanks to the team at Medidata for their support in presenting this podcast.
Chair of the Partnership Opportunities in Drug Delivery (PODD) event, Dr Barbara Lueckel, Global Head of Research Technologies Partnering at Roche, presents an annual year-in-review of the drug delivery landscape from 2018. Dr Lueckel’s opening remarks are a highlight of PODD every year, and we’re excited to have her return as program chair for the 2020 event, taking place virtually October 8-9, 2020.
About Dr Lueckel:
Barbara is the Global Head of Research Technologies Partnering and a member of the Roche Pharma Partnering leadership team since May 2019. In her role she is working closely with the two research and early development organizations at Genentech and Roche (gRED and pRED) to identify transformative science developed by biotechs around the globe and help set up partnerships with such biotechs to enable novel discovery programs with the goal to increase the number of medicines impacting patients’ lives.
Prior to Roche, Barbara worked at Novartis for ten years both on formulation development of poorly soluble molecules as well as on evaluations of reformulation opportunities as potential line extensions based on external drug delivery technologies. She is trained as a pharmacist with a PhD from the University of Basel.
This podcast dives into the history of creating a gene therapeutic for Duchenne Muscular Dystrophy. Dr Richard Jude Samulski has been studying gene therapy and the use of the AAV vector for decades. Recently, preliminary results from Pfizer were published on a small gene therapy trial for Duchenne Muscular Dystrophy with promising results, and Pfizer is scheduling a larger trial for later this year.
That gene therapy originated from Dr Samulski work and from AskBio, and uses an adeno-associated virus to carry a healthy copy of the dystrophin gene; the virus was injected into boys with DMD, broke into their muscle cells, and replaced their non-working gene.
Dr Samulski sat down with PharmaTalk's Danny McCarthy to discuss the process of creating an AAV vector to carry the gene therapeutic, the mechanisms of the therapy in DMD and what the future of the gene therapy landscape might look like.
Guest:
R. Jude Samulski, PhD, is President, Chief Scientific Officer and Co-Founder of Asklepios BioPharmaceutical and Professor of Pharmacology in the UNC School of Medicine. Dr Samulski has worked with AAV for 40 years, and for 25 years, he was director of the University of North Carolina Gene Therapy Center.
Asklepios Bio's Chief Medical Officer, Martin Childers, DO, PhD, will be speaking at the Chief Medical Officer 360˚ summit, October 26-27, 2020, virtually.
This podcast tells the story of how a community-based COVID-19 research study was formed from a partnership between Oracle Health Sciences, Javara Research and Wake Forest Baptist Health, with the end goal of using regional infection patterns to understand the virus and develop strategies to contain it.
Kathy Vandebelt of Oracle sat down to talk about the partnership enhanced Oracle's Therapeutic Learning System, which was set up to track how physicians were treating individuals infected with the virus and making the information available for others to learn from, for a real-world surveillance study. The collaboration resulted in the addition of a new component for the platform, the Patient Monitoring System, which aided in collecting daily information across a large population of participants and offering them the potential to participate in regular testing. That technology is being used for multiple studies on local, regional, national and now global levels.
In the conversation, Ms Vandebelt also discusses the unexpected collaborations that emerged across the research spectrum as a result of the pandemic, how the Oracle team adapted their technology to keep pace with an evolving on-the-ground situation, and how clinical operations might benefit from adopting more decentralized measures, ultimately giving patients more choices.
Guest:
Kathy Vandebelt is Global Head of Clinical Innovation for Oracle Health Sciences, where she uses the power of technology to introduce new experiences and expectations to make the clinical research ecosystem better for patients, healthcare providers, sponsors and regulators.
For more information about Oracle's COVID-19 response, visit Oracle.com. For more information about PharmaTalk Radio podcasts, go to theconferenceforum.org.
PharmaTalk Radio’s Kate Woda welcomes guest, Erin Newburn, Director and Field Applications Scientist at Personalis on the topic of IO Biomarker Discovery and Personalized Cancer Therapy and how Personalis is enabling this.
Guest Bio:
Erin Newburn, PhD joined Personalis as a Field Applications Scientist in 2013 with over 12 years of research experience in the areas of molecular biology, genetics, and biotechnology. As the Director of the Field Applications Scientist team, Dr Newburn’s group has the responsibility of providing both pre- and post-sale scientific and technical support for the Personalis ImmunoID NeXT Cancer Portfolio.
Dr Newburn completed her postdoctoral training at the National Institute of Mental Health (NIMH) investigating candidate susceptibility genes for major psychiatric illnesses. Dr Newburn received her PhD from the Ohio State University in Integrated Biomedical Science as a Presidential Fellow.
Information about Personalis, visit www.Personalis.com
Information about upcoming conferences and podcasts on medicine development, visit theconferenceforum.org.
As the country goes through the phases of reopening, what does that mean for the patient and site experience in clinical trials? PharmaTalkRadio’s Valerie Bowling discusses the future of clinical trials with Dr Ray Dorsey, Matt Kibby and Craig Lipset. Together they address lessons learned from the rapid adoption of technologies to allow for more decentralized trials and their impact on study participation design moving forward, what sponsors can do to set themselves up for success, and the possibility of hybrid trials becoming the new normal for the near future.
Guests:
Ray Dorsey, MD, is the David M. Levy Professor of Neurology and Director of the Center for Health & Technology at the University of Rochester.
Matt Kibby is President, Principal of BBK Worldwide
Craig Lipset is the founder of Clinical Innovation Partners and the former Head of Clinical Innovation and Venture Partner at Pfizer
You can find all three of our guests speaking at either the upcoming Mobile in Clinical Trials conference or the 10th annual DPHARM conference virtually over September 21st-23rd. For more information about these conferences and other podcasts, visit theconferenceforum.org.
For more information about BBK, visit BBKworldwide.com
Dr Dorsey's book on Ending Parkinson's Disease can be found on Amazon.
You can keep up with Craig Lipset at twitter.com/craiglipset
A special thanks to the team at BBK for their support in presenting this podcast.
In this podcast, Mark Scherzer, producer of Mobile in Clinical Trials gives an overview of what to expect at the 2020 virtual conference. The 7th annual meeting is co-chaired by Bayer's Michelle Shogren and Healthmode's Dan Karlin and reports on the latest progress in applying mobile-digital tools and patient-facing technologies for flexibility while connecting and empowering patients. It will feature collaborative, experience-based case studies to help R&D move faster to provide more choices for patients and investigators while obtaining better outcomes in drug development.
In this podcast, first recorded at the 2019 DPharm: Disruptive Innovations conference, Takeda's Dr Andrew Plump and Dr Jessica Scott discuss how they have developed KPIs that support innovation for patient-engagement.
Dr Plump leads Takeda's global R&D organization, where he provides strategic direction and oversights. He specializes in bringing and unwavering focus on patients and a deep commitment to innovation and positive change in the healthcare industry.
Speakers:
Andrew Plump, MD, PhD, President, Research & Development, Takeda Pharmaceuticals
Jessica Scott, MD, JD, Head of R&D Patient Engagement, Takeda Pharmaceuticals
The 10th annual DPharm: Disruptive Innovations event is scheduled to take place on September 22-23, 2020. Learn more here.
In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Starbucks' Robert Mercer sits down with Eli Lilly's Joe Kim to discuss the end-user experience in mobile technology. This out-of-industry example covers how they approach innovation and in particular how they designed their mobile experience with the customer in mind. More specifically: Barriers and executive buy-inRolling out the mobile experienceBalancing the scale of new solutions across stores around the globe with the need to maintain existing operations and deliveryHow Starbucks engages with the customers to learn and develop innovative new solutions Speakers:
Robert Mercer, Design Director, Global Digital products, Starbucks
Joseph Kim, MBA, Sr. Advisor, Clinical Operations and Digital Registry, Digital Health Office, Translational Technology & Innovation, Eli Lilly & Co.
The 10th annual DPharm: Disruptive Innovations event is scheduled to take place on September 22-23, 2020. Learn more here.
In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Healthgrades' founder Kerry Hicks sits down with Craig Lipset for a keynote discussion on transparency and the future of patient expectations.
"Everyone likes progress and no one likes change." - Kerry Hicks
Kerry Hicks is the founder of Healthgrades, which puts the power of transparency into millions of patients' hands on provider visit experiences. The discussion begins with his vision for Healthgrades, what it was like to build it, early fears, and unintended consequences. Also covering: the intersection of patient experiences, technology, and clinical research as well as Kerry's insights on why you must consider transparency with everything you build moving forward.
Speakers:
Kerry Hicks, MBA, Founder, Healthgrades
Craig Lipset, MBA, former Head of Clinical Innvation, Pfizer
The 10th annual DPharm: Disruptive Innovation is scheduled to take place on September 22-23, 2020. Learn more here.
One of the goals of the Human Genome Project was to improve therapeutic options for those born with serious inherited diseases. Today gene therapy is beginning to realize this promise, with the ever-increasing level of clinical investigation in the space, and the first products coming to licensing in the last few years.
In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, Dr Katherine High, Spark Therapeutics, reviews the current state of gene therapy, including the development of therapies for diseases that were previously untreatable, and, for diseases where therapeutics already existed, the development of therapies that greatly lessen the burden of treatment for the patient and the family. Hurdles in clinical development of gene therapy will be discussed. Examples will be drawn from already approved products and from investigational agents in late stage development.
To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org
Subcutaneous (SC) delivery has become the norm for treating diseases such as Rheumatoid arthritis and multiple sclerosis, and there remains great potential to offer home- or even self-administered SC delivery for several other biotherapeutics. Given that there are a number of products already on the market, they can be examined to understand what improvements and changes can be made to increase product development opportunities and also enhance the patient experience.
In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, you will hear from clinicians (pharmacist and physician) and industry to gain insight into needs and preferences of future SC biotherapeutic formulations and devices. For example, panelists will address the issue of reducing costs and dose complexity, improving adherence, and also provide input on changes they would like to see in future SC biotherapeutic products.
Moderated by: Dr Beate Bittner, Roche
Panelists include: Dr Mary Nauffal, Brigham and Women's HospitalDr Manuel Sanchez-Felix, Novartis Institutes for BioMedical ResearchDr Anand Subramony, AstraZenecaDr David Ting, MGH Cancer Center/Harvard Medical School To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org
This podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference explores the value of drug delivery technologies both to patients and pharma with a focus on the future direction of the field. This will include a review of the state of the art for traditional modalities such as small molecules and biologics and then expand the conversation to the challenges for less common modalities such as peptides and nucleic acids. The panel members will discuss the potential scientific barriers for these future delivery technologies and the industry's willingness to invest to address these barriers.
Moderated by: Dr Shawn Davis, AstraZeneca
Panelists include: Dr Advait Badkar, PfizerAndré LaFreniere, BattelleMaria Teresa Peracchia, SanofiDr Julia Rashba-Step, PhosphorexTheresa Scheuble, Johnson & Johnson To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org
Merck has a long history of being open to utilizing a wide range of delivery technologies for both enabling and life cycle management. In this leadership keynote, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, Dr Allen Templeton, VP, Pharmaceutical Sciences, discusses how Merck's strategy of utilizing DDS has evolved and the role of enabling drug delivery technologies play in the Merck R&D pipeline. What emerging DDS technologies and modalities does Merck view as the most promising, and why.
To learn more about the upcoming 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit, www.theconferenceforum.org
In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, John Merhige, Credence MedSystems, Inc and Mathias Romacker, formly with Pfizer discuss the journey of an emerging medical device company from a blank piece of paper toward commercialization.
Topics include: The early days: starting the company and inventing with implementation in mindThe importance of listening to the customer and incorporating feedback early - and why that can be difficultStaying in the long game - the mindset, endurance and approach to ensure you are ready when opportunity appearsCollaborating within the supply chain - why it's challenging and the right approach To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org
Effective drug delivery collaborations combine a wide range of experiences and viewpoints with common goals to achieve successful clinical and regulatory outcomes. But the path to developing this eventual relationship is not without challenges, as partnerships that are not clearly defined upfront or effectively managed downstream can quickly derail the best of intentions. In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, BMS and Halozyme panelists will shed light on key considerations, challenges and lessons learned during the pre-deal courting process as well as their ongoing successful alliance.
Moderated by: Jennifer Guzman, Halozyme Therapeutics
Panelists include: Michael Cucolo, BMSBrian Davideit, BMSRenee Tannenbaum, Halozyme TherapeuticsTom Witt, Halozyme Therapeutics To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org
How are industry leaders looking to bridge the gap from pilot systems to scaled solutions in the market? In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, a panel of Connected Health leaders in the industry provide their views on how they are developing value propositions that resonate with internal and external stakeholders. Defining business and operational models that benefit patients and support evolving healthcare payment structures, while delivering strong returns to the business is central to this discussion.
Moderated by: Kevin Deane, Phillips-Medisize Company
Panelists include: Dhairya Mehta, TakedaPaul Upham, Roche/GenentechPaul Schultz, BrightInsightAmir Zur, Teva Pharmaceuticals To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org
Given the increase in focus on digital health and connected device development to improve "patient centricity" and the user experience, there is a large amount of clarity and evidence needed on how to truly ladder in these efforts to achieve the uiltimate outcome for patients. The answer lies in leveraging the power of contextualized, extrinsic data that while readily available given the acceleration of technologies and tools available today, are not readily apparent to connected therapeutic ecosystems as a whole - patients, clinicians, and developers of products and solutions.
This podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, Dr Chris Kovalchick, Eli Lilly and Company, discusses examples from both inside and outside the drug delivery industry to demonstrate how interrogating the massive amount of environmental and background information readily available can be used to activate the seismic shift needed to move us all towars the ultimate goal for all of our customers - improved wellness and awareness.
To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org
In the fourth episode of our series highlighting rare diseases, Conference Forum reporter Danny McCarthy sits down with Neena Nizar, EdD, Founder and Executive Director of the Jansen's Foundation, to discuss Jansen's Metaphyseal Chondrodysplasia.
Jansen type metaphyseal chondrodysplasia is an extremely rare progressive disorder in which portions of the bones of the arms and legs develop abnormally with unusual cartilage formations and subsequent abnormal bone formation.
The Jansen's Foundation goal is to speed up and fund the process of finding a cure and treatment for the rare disease. For more information:
https://www.thejansensfoundation.org/
For more information about our podcasts and the upcoming Patients as Partners event:
www.theconferenceforum.org
In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Cellarity's Milind Kamkolkar presents on the collective struggle to evolve a drug development organization's data and analytics culture and capabilities. Including: The theory of going digital in drug developmentIdentifying hype from realityWhat is the program we are trying to solve?Take a big, complex organization and evolving it to be digitally modernWhat is the intended use of the data?Priorities, structure, culture and next steps Speaker: Milind Kamkolkar, Chief Data Officer, Cellarity
The 10th annual DPharm: Disruptive Innovations event is scheduled to take place on September 22-23, 2020. Learn more here.
In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Genentech's Aaron Mann discusses the use of historical data to transform clinical trials and how to rethink clinical development.
Speaker: Aaron Mann, Global Program Lead, Industry Collaborations Data Sharing Initiatives, Genentech, a member of the Roche Group
The 10th annual DPharm: Disruptive Innovation event is scheduled to take place on September 22-23, 2020. Learn more here.
In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Johnson & Johnson's Dr Martine Lewi discusses the evolution of their use of Real-World Data in their clinical programs. Including: What is the state of the art in real-world data and how is patient data being used today?Innovation initiatives at J&JAccelerating the drug development cycle Speaker: Martine Lewi, PhD, MBA, Janssen Clinical Innovation, Scientific Director, Johnson & Johnson
The 10th annual DPharm: Disruptive Innovations event is scheduled to take place on September 22-23, 2020. Learn more here.
In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Sanofi's Laura Kling discusses developing a digital endpoint for Parkinson's Disease using wearables.
Speaker: Laura Kling, Director, Digital Innovation, Sanofi
The 10th annual DPharm: Disruptive Innovations event is scheduled to take place on September 22-23, 2020. Learn more here.
This podcast presents a session on planning for and addressing missing data form the 2019 Mobile in Clinical Trials conference.
When a protocol dictates a set period of time for data collection, what happens when there's a gap in the data due to technical glitches or human error? What are the regulatory and operational implications? Discussion points include: How to prepare for missing dataHow do we handle missing data?How to rewrite protocols so that you avoid the trapForewarning and communicating with regulatorsRegulatory advice on how to address missing data Moderator:
Jennifer Goldsack, MBA, Executive Director, Digital Medicine Society (DiMe)
Panelists:
Ariel Dowling, PhD, Associate Director of Digital Clinical Devices, Data Sciences Institute, Takeda Pharmaceuticals
Marie McCarthy, MBA, Senior Director of Product Innovation, Information Technology, ICON plc
Carrie Northcott, PhD, Project Team Lead, Early Clinical Development, Digital Medicine, Pfizer
Shyamal Patel, PhD, Director of Data Science, Digital Medicine & Translational Imaging, Pfizer
The 2020 Mobile in Clinical Trials event will take place on September 21. Learn more here.
In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Merck's Mark Travers presents a cornerstone discussion on Balancing Innovation with Solid Common Sense to Deliver Innovative Medicines.
Merck is walking the walk in disrupting how to restore best practices for people, products, and productivity. With a clear vision on output, their remarkable team mapped a plan to an enterprise to change operational delivery. In this R&D Leadership session hear the story on how they are delivering what they promise: How to plan upfront once and do it properlyGetting the basics right and what do you need to disrupt to get thereSignificant changes on greatly improving monitoringThe use of iPad technology to monetize CRA visitsHow monitoring reports got reduced from 8 to 2Building a stable workforce with strong employee engagementBehavior, structure, systems and toolsScaling it Speaker:
Mark Travers, PhD, MBA, VP, Head of GCTO Regions, Monitoring Excellence, Global Operations, Merck & Co.
The 10th Annual DPharm: Disruptive Innovations conference is scheduled for September 22-23, 2020. Learn more here.
This podcast presents a panel discussion from the 2019 Mobile in Clinical Trials conference on what we are striving for and measurements of success in virtual trials. Discussion points include: How is it getting our of pilotville?What is the barrier to adoption?Factors that impact success: Risks and Patient Preferences Moderator:
Adama Ibrahim, EMBA, Associate Director, Performance Operational Capabilities, Global Clinical Operations, Biogen
Panelists:
Christopher Ceppi, Chief Product Officer, Science 37
Jamileh Jamison, MD, Head of Clinical Development, HealthMode
Hassan Kadhim, Director, Clinical Trial Business Capabilities, GCO, BMS
Casey Orvin, President, Society for Clinical Research Sites (SCRS)
John Reites, Chief Product Officer, THREAD Research
The 2020 Mobile in Clinical Trials event will take place on September 21. Learn more here.
This podcast presents a session from the 2019 Mobile in Clinical Trials conference on Escaping Pilotville: How to Scale Mobile/Digital Deployment in Clinical Trials. Discussion points include: What KPIs are used to evaluate success/failure of a pilot?What are the barriers to scale, even when a pilot is a success?What are the operational models used by innovation teams to support deployment?Which models are working?Are study teams equipped to take on deployment efforts?What resources must be made available?How to position for scaleHow can industry remove the fear and transition from addition to the replacement of traditional efforts?Show good evidence of what works at scaleWhat should this include? Moderator:
Michelle Shogren, Director of Innovation, Pharma R&D Clinical Operations, Bayer
Panelists:
Arthur Combs, MD, FCCP, FCCM, CMO, MC10
Ken Thoelke, EVP, Chief Scientific Officer, PRA Health Sciences
The 2020 Mobile in Clinical Trials event will take place on September 21. Learn more here.
This podcast presents a session from Merck on Mobilizing Mobile Efforts and Engineering for Scale at the 2019 Mobile in Clinical Trials conference.
Mobile tool/device implementation has been widely accepted, tested, and piloted in clinical research. With the bar set, Merck looks to challenge it and create an ecosystem that continues to set the bar higher with a scalable model. In this session, Kai Bode walks the audience through their approach to coordinating and prioritizing digital efforts, building a prototype to test devices, mobilizing their mobile devices, mobile patient screenings, finding a workaround to perceived barriers and/or premature acceptance of timelines/processes and lessons learned.
Speaker: Kai Bode, Director, Digital and Analytics Technologies, Merck
The 2020 Mobile in Clinical Trials Conference will take place on September 21. Learn more here.
This podcast presents a panel discussion on What a Successful Digital Trial Looks Like from the 2019 Mobile in Clinical Trials conference. Including: What is a digital trial?Is a common definition needed in order to scale for success?What does success look like? Fully remote, data sharing, device/tool implementation?How do we measure success? And when?What about accessibility?patient/investigator experience?tool/device effectiveness?data quality and usability?did digital help answer the necessary clinical question?did it ensure representative patients in the study? Moderator:
Craig Lipset, Former Head of Clinical Innovation, Pfizer
Panelists:
Jennifer Goldsack, MBA, Executive Director, Digital Medicine Society (DiMe)
Jacob LaPorte, PhD, Co-founder & VP, Global Head of Novartis Biome, Novartis
The 2020 Mobile in Clinical Trials event will take place on September 21. Learn more here.
In the third episode of our series highlighting rare diseases, Conference Forum reporter Danny McCarthy sits down with Fernando Albertorio, PhD, to discuss Hermansky-Pudlak Syndrome.
Dr Albertorio is co-founder of Sunu, Inc, which creates wearable, IoT and mobile technology that empowers independence for people who a blind and visually impaired. Dr Albertorio is also an advocate for increasing awareness and treatments for managing Hermansky-Pudlak Syndrome (HPS).
HPS is an extremely rare autosomal recessive disorder, characterized by albinism, visual impairment, and a platelet dysfunction that results in prolonged bleeding. There are currently 10 known types of HPS.
In the episode, Dr Albertorio mentions several websites for more information: HPSNetwork.org, GlobalGenes.org and Sunu.com.
The COVID-19 pandemic has meant that, more and more, clinical trials are being disrupted or interrupted completely. Without the continuous momentum and contact, trials will lose patients as gaps in studies lengthen.
To combat that, Be the Partner designed “Bridge,” a new solution on their Patient Portal specifically for continuing secure, ongoing connectivity with trial patients during any temporary pauses in trials as a result of COVID-19. The end goal of “Bridge” is to maintain patient engagement throughout the trial’s indefinite pause and aid in a successful relaunch at the appropriate time.
For more information go to or contact www.bethepartner.com.
PharmaTalk Radio's Valerie Bowling welcomes guest, Kent Thoelke, EVP and CSO at PRA Health Sciences on his experience in rapidly setting up both therapeutic and vaccine focused programs for COVID-19. More specifically, they discuss lessons learned, what the new normal will look like for clinical trials and serving the needs of thousands of people who are currently in clinical trials.
Guest Bio:
Kent Thoelke is Executive Vice President and Chief Scientific Officer at PRA Health Sciences. Mr. Thoelke provides corporate oversight and strategy for Scientific & Medical Affairs, Pharmacovigilance & Patient Safety, Therapeutic Centers of Excellence, Real World Data, Patient Access & Experience, Digital Health & Virtual Trials, and their integration into operational delivery.
Information about PRA Health Sciences, visit PRAH.com
Information about upcoming conferences and podcasts on medicine development, visit theconferenceforum.org
In the second episode of a three-part series dedicated to highlighting rare disease, Conference Forum reporter Danny McCarthy sits down with C Frank Bennett, PhD, of Ionis Pharmaceuticals, to discuss Spinal Muscular Atrophy.
Dr Bennett is Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals, and one of the founding members of the company. He is responsible for continuing to advance antisense technology and expanding Ionis drug discovery platform. Dr. Bennet is a co-recipient of the 2019 Breakthrough Prize in Life Sciences for his contributions to the discovery and development of SPINRAZA® (nusinersen).
Spinal muscular atrophy is a genetic, degenerative neuromuscular disorder characterized by weakness and wasting in muscles used for movement. It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement.
Dr Bennett includes two sources of information about Ionis and SMA: Ionispharma.com and Spinraza.com.
In this three-part series dedicated to the physician's perspective on living with a rare disease, Conference Forum reporter Danny McCarthy sits down with Tracy Frech, MD, to discuss Systemic Sclerosis.
Tracy Frech, MD, is a rheumatologist at the University of Utah. At the university, she is the Director of the Systemic Sclerosis (SSc, scleroderma) Clinic at the University of Utah Hospital and the Director of Clinical Trials for the Division of Rheumatology.
In her work, Dr Frech treats patients with, and runs clinical trials on, systemic sclerosis, a complex autoimmune disease characterized by pervasive inflammation and fibrosis, and can lead to progressive vascular and organ damage.
Dr Frech talks about the disease, current treatment and taking a more holistic approach to treating SSc.
In the interview, Dr Frech references the education resource TotalSSc.com., a new disease education campaign website for healthcare providers focused on the “totality in systemic sclerosis”.
In this podcast moderated by Dr Michael Kalos, Janssen Oncology, you will hear a panel discussion from the 2019 IO Combinations 360° conference. Topic points include: What are the new opportunities in cell therapy for combinations?What the challenges are going to be with the microenvironment?What is being done to engineer cell therapy?How do you develop CARs and TCRs that deliver payloads?How do you manufacture all of this beyond mouse models to
figure out how to effectively do this in patients?How do you actually go about designing trials and testing
hypothesis?How do you create the regulatory framework to do these types
of studies?How do you engage with regulatory agencies to get these things
moving? Panelists include: Sharon Benzeno, PhD, MBA, Adaptive BiotechnologiesChaohong Fan, MD, PhD, FDABruce Levine, PhD, University of PennsylvaniaMark Stewart, PhD, Friends of Cancer ResearchBahram Valamehr, PhD, Fate Therapeutics To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com
Anti-PD-1 therapy has transformed cancer care but most patients do not respond. It is increasingly clear that there will be no single biomarker of response to a PD-1, and that a multi-omic approach will be required. In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Danny Wells, Parker Institute for Cancer Immunotherapy will address: Orthogonality and correlation of response biomarkers across histologiesIntegration of multi-omic data sets for mechanistic insights into tumor immunobiologyThe translational approaches to PD1 resistance program at the Parker Institute To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com
In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Darren Hodgson, AstraZeneca presented updates on PARP inhibition. Topics include: Strategies to target homologous recombination repair deficiencyMonotherapy indications and current development landscapeScientific hypotheses being explored in olaparib combinations To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com
First recorded at the 4th annual IO Combinations 360° conference, this talk provided by Dr Kenneth Hance, GSK addresses agonistic strategies, T and NK cell redirection and the use of genetic/phenotypic assocations to identify novel target space in IO.
To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com
In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Laureen Ojalvo, EMD Serono provides an overview of the moleculte Bintrafusp alfa/M7824. This molecule is an innovative, first-in-class bifunctional fusion protein composed of an anti-PD-L1 mAb fused with 2 extracellular domains of TGF-βRII (a TGF-β “trap”). The mechanism of action, pre-clinical and phase 1 studies of this molecule is discussed as well as an overview of the next wave of clinical development.
To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com
In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Willem Overwijk, Nektar Therapeutics discusses Bempegaldesleukin (NKTR-214): harnessing the IL-2 pathway in combination immunotherapies. Topics include: Bempegaldesleukin: Structure and function of an engineered IL-2 cytokine prodrug providing sustained IL-2Rβγ-biased signalingPreclinical PK, PD, MOA and combination with PD-1 checkpoint inhibitionClinical PK, PD, clinical response data and biomarkers in patients with melanoma and bladder cancerCombinations under investigation To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com
First recorded at the fourth annual IO Combinations 360° conference, this panel moderated by Dr Daniel Chen, IGM Biosciences discusses advancing bispecifics for combination immunotherapy. This discussion covers the following topics: What are the types of bispecifics and what are the limitations?What are the toxicity related side effects?What are teh next steps/levels for bispecifics?What does the future hold for bispecifics? Panelists include: Julie Bailis, PhD, AmgenRajkumar Ganesan, PhD, Janssen Research & DevelopmentDavid Schaer, PhD, Pfizer To learn more about the 5th annual IO Combinations 360° conference please visit www.iocombinations360.com
In this podcast, you will hear a panel discussion from the 2019 IO Combinations 360° conference regarding how AI, machine learning and big data are used to inform combinations.
Moderated by Matthew Albert, MD, PhD, Insitro
Panelists:
Edward Bowen, GSK
Ryan Fukushima, Tempus
Renée Deehan-Kenney, PhD, QuartzBio, part of Precision for Medicine
To learn more about the 2020 IO Combinations 360° conference please visit www.iocombinations360.com
In this podcast, you will hear a panel discussion from the 2019 Clinical Research as a Care Option (CRAACO) conference with patients and advocates on weighing your care options and considering participation in a clinical trial. Some points include, Strategies and ideas to reduce the burden to patientsUnderstanding of clinical care with their physician?Communication, consent and data sharing Moderated by Cindy Geoghegan, Cancer Veteran, Patient Advocate
Panelists:
Allison Greiner Patient Advocate
Sarah Larson, Director of Global Clinical Operations, Biogen and Cancer Veteran
Kelly Piacsek, PhD, VP, Patient-Centered Research, Aurora Research Institute
The 2020 CRAACO conference will take place on April 27-28 in Raleigh, NC. Learn more here.
In this podcast, you will hear a panel discussion from the 2019 Clinical Research as a Care Option (CRAACO) conference on Understanding the Goals of Care Vs Research. The panelists explore points including, Goals for care vs goals for researchOversight and governanceIs there an ethical burden of breaking down the line between research and care?What is the hesitation behind embracing the blurring of this boundary?In areas like precision medicine, this is already blurring, how to manage?Hurdles stopping large companies from thinking about this– Is it practical? Ethical? Moderated by Jennifer Byrne, CEO and Founder, Javara
Panelists:
Greg Burke, MD, MSc, Chief Science Officer, Senior Associate Dean for Research, Wake Forest School of Medicine
Amy Nordo, Director eSource Implementation, Pfizer
The 2020 CRAACO conference will take place on April 27-28 in Raleigh, NC. Learn more here.
This 6 minute podcast summarizes what you can expect during the virtual Patients as Partners conference.
Key topic areas include: BioPharma Strategies on Applying Patient Engagement Initiatives and Demonstrating ImpactDirect-to-Patient Clinical Trials Next Milestones and Actions to Get ThereMeasuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and DevelopmentCurrent Efforts for Educating and Enrolling Diverse Populations in Clinical TrialsProgress on Patient Data OwnershipCollaborating with Site Partners & CROs to Increase Efficiencies, Provide Greater Value to Patients and Clinical TrialsProgress on the National Health Council’s Patient Engagement Fair Market Value InitiativeFDA Reports on the Latest Guidance Updates and New Agency Efforts on Patient Engagement Keynotes include: Dr Dara Richardson-Heron, PfizerDr Joanne Waldstreicher, Johnson & JohnsonDr Darryl Sleep, AmgenBarry Greene, Alnylam PharmaceuticalsRonnie Sharpe, Cystic Fibrosis AdvocateKen Getz, Tufts CSDDJeff Borghoff, Alzheimer's Patient and AdvocateChip Bell, Customer Service Guru Patients as Partners takes place virtually, August 19-21, 2020. For more information please visit www.patientsaspartners.org
In this podcast, you will hear a session from the 2019 Clinical Research as a Care Option (CRAACO) conference on How to Integrate Industry-Sponsored Clinical Trials Into Your Health System to Give Patients the Best Options. Points include, How to build your programsHow to become an integrated care & research organizationHow to integrate clinical research into your care systemRoswell Park and TrialScout’s strategic partnership Speakers:
Irfan Khan, MD, CEO and Founder, Circuit Clinical
Doug Plessinger, Chief Clinical & Scientific Development Officer, Roswell Park/GBCT
The 2020 CRAACO conference will take place on April 27-28 in Raleigh, NC. Learn more here.
In this podcast, you will hear a case study presentation from the 2019 Clinical Research as a Care Option (CRAACO) conference on how Sanford Health Systems has increased their clinical trial participation from 3% to 10% over the last 8 years by integrating clinical care and clinical research. Points include, Creating a system for all providers to work seamlesslyEducational programs and continual training across all areas of care and specialties for trial offeringsIdentifying gaps in trial availabilityAttracting providers who are interested in clinical research for their patientsNCORP site The 2020 CRAACO conference will take place on April 27-28 in Raleigh, NC. Learn more here.
In this podcast, you will hear a keynote presentation from the 2019 Clinical Research as a Care Option (CRAACO) conference. Dr Laura Esserman, the architect behind the I-SPY 2 TRIALTM has achieved remarkable progress with this clinical trial in improving the outcomes of early stage, breast cancer for patients who are at high risk for early recurrence. I-SPY 2 is also impacting far beyond breast cancer by increasing efficiencies that promise to accelerate the development and delivery of more effective therapies for other cancer types and a range of other diseases. This would not be possible without the integration of care and research. In this keynote session, hear this surgeon’s view on the future of integrating care and research.
Speaker:
Laura Esserman, MD, MBA, Director, UCSF Carol Franc Buck Breast Cancer Center; Alfred A. de Lorimier Endowed Chair in General Surgery; Professor of Surgery and Radiology, UCSF
The 2020 CRAACO conference will be taking place April 27-28 in Raleigh, NC. Learn more about it here.
In this podcast, you will hear a session from the 2019 Clinical Research as a Care Option (CRAACO) conference. Jeff James, CEO of Wilmington Health, presented a case study on how they are streamlining the processes behind integrating clinical care and clinical research, including: Going from a fragmented patient journey to a streamlined oneHow to take the patient experience to “just making it another visit type”How to take study protocols and make them more native to EMRGeneral best practices for streamlining the process for patients and investigatorsWhat it took to actively normalize the flows and processes of clinical research The 2020 CRAACO conference will take place on April 27-28 in Raleigh, NC. Learn more here.
At the 2019 Clinical Research as a Care Option (CRAACO) conference, a panel discussed Barriers Health Systems Face in Integrating Clinical Care & Research, including: Financial barriers – Speaking to administration’s bottom lineHistorical barriers – Who are the key stakeholders that need to be converted into believers of the CRAACO movement?Logistical issues – How can we make study startup a more streamlined process?Culture change – Onboarding an outside group nested into an existing infrastructureDoes adding the offering of clinical trials disrupt the ability of the physicians in the clinics to have appropriate patient flow?How do you offer patients the options of clinical research?Insight from the front line of physicians seeing patients Moderated by: Lora Black, Senior Director of Clinical Research, Sanford Health Systems
Panelists:
Greg Burke, MD, MSc, Chief Science Officer, Senior Associate Dean for Research, Wake Forest School of Medicine
Adrian Hernandez, MD, MHS, Vice Dean for Clinical Research, Duke University School of Medicine
The 2020 CRAACO conference will be taking place July 13-14, 2020 in Raleigh, NC. Learn more here.
In this podcast, you will hear a discussion from the 2019 Clinical Research as a Care Option (CRAACO) conference on Effectively Democratizing Access to Clinical Trials. This panel covers how making clinical research a care option is the ultimate opening of access to clinical trials. Including points on: Current state of affairs: Gross underrepresentation of minorities 5-6% are represented in trials, but it should be closer to 40%What are the barriers to opening access?How can we educate underserved communities about clinical research?What are we doing to overcome this?Does offering these care options enhance access in a broad sense? Moderated by:
Jennifer Sheller, MPH, Regional Head, North America, Merck
Panelists:
Jonathan Jackson, PhD, Director, CARE Research Center, Massachusetts General Hospital
Cynthia Verst, PharmD, President, Design and Delivery Innovation, IQVIA
The 2020 CRAACO conference will take place on July 13-14, 2020 in Raleigh, NC. Learn more here.
A new way of doing business was required to achieve the mission of serving patients suffering from rheumatoid arthritis. In this podcast, first recorded at the 2nd annual Drug Delivery West conference, William (Bill) Rich, Amgen and Daniele Fazio, Flex discuss how Amgen and Flex created an integrated, single team with co-executive sponsorship and overarching program management that enabled the successful development and launch of a novel combination product.
To learn more about the 3rd annual Drug Delivery West conference happening May 17-18, 2021 in San Francisco, CA please visit www.drugdeliverywest.org
In this podcast, first recorded at the 2nd annual Drug Delivery West conference, Dr James Cunningham, Allergan leads a panel on exploring other routes of administration for ophthalmology. Discussion points include: Barries/challenges associated with drug delivery to the back of the eyeProlonging delivery & reducing frequency of administrationAlternative/less invasive routes of administration for delivery to the back of the eyeDelivery for emerging modalitiesImpact of delivery system design choices on development/scalabilityHow to effectively assess novel delivery approaches Panelists include: Dr James E Chastain, Novartis Institutes for BioMedical Research, IncDr Susan Crowell, GenentechDr Viral Kansara, Clearside Bio To learn more about the 3rd annual Drug Delivery West conference happening May 17-18, 2021 in San Francisco, CA please visit www.drugdeliverywest.org
First recorded at the 2nd annual Drug Delivery West conference, Dr Carlos Schuler, InCarda Therapeutics discusses transforming cardiovascular treatment with pulmonary delivery. This podcast discusses: Pioneering a novel approach for treating cardiovascular conditions by the oral inhalation routeWill be the ONLY non-invasive, self administered product for acute management of Paroxysmal Atrial Fibrilation, providing rapid cardioversionIn Phase 2: Dose dependent conversion observedWorking on enhancements to greatly improve speed of delivery To learn more about the 3rd annual Drug Delivery West conference happening May 17-18, 2021 in San Francisco, CA please visit www.drugdeliverywest.org
In this podcast, first recorded at the 2nd annual Drug Delivery West conference, Dr Isabelle Aubert, University of Toronto, provides an introduction to MRI-guided focused ultrasound (MRIgFUS) and reviews applications in preclinical models of neurodegenerative disorders where therapeutic molecules, gene therapy vectors, and progenitor cells are injected intravenously and delivered from the blood to targeted areas of the brain with MRIgFUS. Dr Aubert will describe the seminal work of the Sunnybrook team on MRIgFUS-BBB modulation, without exogenous therapeutic, leading to glial plasticity, amyloid pathology reduction, hippocampal neurogenesis and improved cognitive functions in a preclinical model of Alzheimer's disease.
To learn more about the 3rd annual Drug Delivery West conference happening May 17-18, 2021 in San Francisco, CA please visit www.drugdeliverywest.org
Bringing clinical research as a care option to patients is arguably the greatest change we can collaborate on to give patients the best choices of care and to help make clinical trial options easier for providers to access. This panel, moderated by Dr Irfan Khan, TrialScout and recorded at the 6th annual Patients as Partners US conference, will explore how to collaborate to create better strategies to inform patients on clinical research and trial participation.
Key talking points include: Demystifying physician/research burdens. What are physicians really up against?How to better inform physicians of clinical research and trialsHow can more physicians get involved in research and communicate the offering of clinical trials?Patient perspectives on clinical research as a care option Panelists include: Dr Alistair Lindsay, GSKLinnea Olson, Patient AdvocateDr Sanjay Sethi, University of BuffaloDr Kelly Wade, Children's Hospital of Philadelphia & CHOP Newborn Care at Pennsylvania Hospital/ University of Pennsylvania Perelman School of Medicine To learn more about the 7th annual Patients as Partners US conference happening June 29-30, 2020 in Philadelphia, PA please visit www.patientsaspartners.org
In this fireside chat, moderated by Ken Getz, Tufts CSDD/CISCRP and recorded at the 6th annual Patients as Partners US conference discusses the following: How do you create a culture that enables new strategic, operating and organizational models to flourish?How do you drive a patient-centric organization while continuing to execute on business imperatives? How do you balance that?How do you drive a patient-centric agenda through the value chain?How do you engage your employees and empower them to implement patient involvement strategies? And, how do you enlarge the outlook of employees who are stuck in status quo? Guests include: Julie Gerberding, MD, MPH, MerckJayne Gershkowitz, Amicus Therapeutics To learn more about the 7th annual Patients as Partners US conference happening June 29-30, 2020 in Philadelphia, PA please visit www.patientsaspartners.org
This case study presented by Thérèse Johnsen, Novartis and first recorded at the 6th annual Patients as Partners US conference, discusses how the patient perspective was included from the earliest planning of a clinical trial and how it impacted the design, trial sites and the patient experience throughout the study.
To learn more about the 7th annual Patients as Partners US conference happening June 29-30, 2020 in Philadelphia, PA please visit www.patientsaspartners.org
This 5 minute podcast summary helps prepare listeners on what they can expect at the4th Annual Patients as Partners Europe event, taking place January 27th and 28th in London. The venue is the Millennium Gloucester Hotel.
In a nutshell, Patient as Partners is the first conference in Europe dedicated to understanding how working with patients can drive greater clinical trial efficiencies throughout the entire medicines development process. It is ultimately about how to reduce risk in the development of hugely, costly clinical trials through working with patients. It is a wonderful opportunity for pharma and biotech and patient disease advocacy groups to come together and learn from each other.
The 2020 Summit is chaired by Claire Nolan, of Charities Research Involvement Group, GSK’s Andrew Garvey and Parexel’s Rosamund Round.
Our patient keynote guest is Lesley Gosden. Lesley is a Parkinson’s patient and advocate who participated in the GDNF clinical trial, which was featured on the BBC. For more information, visit the conferenceforum.org.
Linda Kollmar, Executive Director, Scientific Medical Patient Perspective - Oncology, Merck, shares with the audience at the 6th annual Patients as Partners US conference, Merck's strategy for bringing on a patient, as an equal stakeholder of their clinical development team, to provide patient input in protocol development and trial design. Ms Kollmar walks the audience through how this was done, the role of the patient employee and the impact it has to date on the clinical development initiatives.
To learn more about the 7th annual Patients as Partners US conference taking place June 29-30, 2020 in Philadelphia, PA please visit theconferenceforum.org
This podcast moderated by Mary Murray, BMS and recorded at the 6th annual Patients as Partners US conference discusses Improving Clinical Research and Trials Though Effective Pharma/Advocacy Partnerships.
Topics include: What are the key elements that make for an effective partnership between Industry and Advocacy Groups?What is not getting done or being left on the table to increase partnership value?In relation to clinical trials what can we and what must we learn from existing experiences in patient engagement that will help provide patients with the enhanced active role they deserve?From an industry perspective there are generally three key decision-making points: research priority setting, design of clinical trials, and early dialogue that can benefit from vaiours levels of patient engagement - are there other valuable areas we are missing hereFrom a patient advocacy group perspective in which areas should industry be improving its clinical research, trial development and planning? Panelists include: Ellen Miller-Sonet, CancerCareKristin Smedley, Curing Retinal Blindness FoundationTiffany Westrich-Robertson, International Foundation for Autoimmune & Autoinflammatory Arthritis (IFAA)Keri Yale, Boehringer Ingelheim To learn more about the 7th annual Patients as Partners US conference taking place June 29-30, 2020 in Philadelphia, PA please visit theconferenceforum.org
This podcast, first recorded at the 6th annual Patients as Partners US conference and moderated by Jan Nissen, Merck discusses the complexities of diversity and waht actions we can take to raise clinical trial awareness and enrollment that is reflective of the demographics of the populations.
This panel discusses: What are some examples of how industry has approached diversity such as developing partnerships, education and awareness to identify and address the barriers of diversity?Is industry and advocacy engaging on the community level? If so, how?How has advocacy helped with outreach, awareness and recruitment of diverse populations for clinical trials?How do we engage with patients who are without technology access or those globally whereby the latest technological advances are not the norm? Panelists include: Caroline Donovan, Lupus TherapeuticsLisa Fitzpatrick, The Community Wellness CollectiveKelly Franchetti, ICON plcDr Tara Hiley, GenentechPatricia Roselle, Sanofi To learn more about the 7th annual Patients as Partners US conference taking place June 29-30, 2020 in Philadelphia, PA please visit theconferenceforum.org
If you truly want to bring patients in as stakeholders, we have to start at the beginning by understanding patients, their lifestyles and how the trial protocols are developed to reflect that. This session moderated by Dr Marilyn Metcalf, GSK and recorded at the 6th annual Patients as Partners US conference discusses understanding these dynamics and how they will help industry design appropriate initiatives that help meet its goals while aligning with patient's needs.
This session addresses: What can we learn and what resources can we use to develop a baseline understanding of patient lifestyles?What can sponsors do throughout trial protocols that can help support patients, help alleviate their worries/concerns?What is the decision making process a patient goes through when considering treatment options?What do patients consider when determining to participate/not participate in a clinical trial?How can pharma help support/provide tools that will help patients while deciding which treatment pathway they choose?How can advocacy groups support this and how do they help inform patients? Panelists include: Robert Long, Uplifting AthletesLilly Stairs, Patient and AdvocateMary Stober Murray, BMSHannah Watson Eccard, InspireRobert Weker, Three Time Cancer Survivor To learn more about the 7th annual Patients as Partners US conference happening June 29-30, 2020 in Philadelphia, PA please visit theconferenceforum.org
This multi-center FDA podcast moderated by Anindita Saha, (CDRH) FDA and first recorded at the 6th annual Patients as Partners US conference, focuses on patient engagement and regulatory decision making.
This podcast discusses: What is each center doing in terms of patient engagement?What initiatives are underway and what is the impact they will have?What are the synergistic efforts across the FDA centers?How are the patient involvement initiatives within the FDA moving the needle forward in order to create greater efficiencies and better outcomes for patients? Panelists include: Megan Moncur, (CBER) FDADr Michelle Tarver, (CDRH) FDAPujita Vaidya, (CDER) FDA To learn more about the 7th annual Patients as Partners US conference happening June 29-30, 2020 in Philadelphia, PA please visit theconferenceforum.org
In this series, first recorded at the 6th annual Patients as Partners US conference, is led by Craig Lipset, formerly with Pfizer discusses the ideas of patients 'donating' data, patient data ownership, data rights, and why this is a disruptive force in advancing clinical trials, we address the need to ensure we have the appropriate systems, security, and the ability to withstand a Facebook/Cambridge Analytica Scenario. Craig is joined by Mark Scrimshire, NewWave/CMS and Bray Patrick-Lake, Duke Clinical Research Institute.
To learn more about the 7th annual Patients as Partners US conference happening June 29-30, 2020 in Philadelphia, PA please visit theconferenceforum.org.
In this podcast, Kate Woda, Conference Director provides an overview of Cell & Gene Therapy Day in less than 4 minutes. Cell & Gene Therapy Day takes place on February 27, 2020 in New York City and convenes stakeholders spanning the science and business communities to report on the latest cell and gene therapy progress to fight a wider range of cancers beyond hematologic malignancies.
Key Topic Areas: Landscape and Evolution to Marketplace: ProgressNew Scientific Frontiers in Cell Therapies for Solid TumorsCell Therapy Pivotal Developments for Solid TumorsCurrent and Future Innovations Toward GMP Manufacturing of CAR and TCR Engineered T CellsFDA Led Session on the Evolution of Regulatory Policy for Cell & Gene Therapy Cell & Gene Therapy Day is available as an independent one day program with a luncheon and networking reception, to learn more please visit theconferenceforum.org
Alternatively, attendees can register for the three day IO360° program, which includes Cell & Gene Therapy Day. For more information on IO360°, please visit www.io360summit.com
In this 10 minute podcast, Kate Woda, Conference Director for IO360°, walks you through what to expect at 2020 IO360° Summit happening February 26-28, 2020 in New York City. IO360°convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.
The 6th annual IO360° Summit features the following plenaries: Discovery/Preclinical ScienceImaging AspectsClinical OperationsBispecificsBusiness DevelopmentsCell & Gene TherapyTranslational ScienceEmerging BiomarkersIO Novel TechnologiesAI & Machine LearningClinical Developments Keynotes: Dr Carl June, University of PennsylvaniaDr Arie Belldegrun, AllogeneDr Andrew Baum, CitiDr Crystal Mackall, Stanford University School of Medicine Learn more at www.io360summit.com
Dr Jeffrey Chodakewitz, former EVP, Clinical Medicine and External Innovation, CMO at Vertex Pharmaceuticals, joins the Chief Medical Officer Summit for the first time to discuss his incredible journey as a CMO. Recorded at the 7th annual Chief Medical Officer Summit, Dr Chodakewitz sits down with Dr Julie Krop, AMAG Pharmaceuticals to discuss the following: The journeyPrioritizing resourcesSuccesses and failuresOvercoming hurdlesCareer decisionsTransitioning from large pharma to small biotechConsiderations for building your team in large and small companies Learn more at theconferenceforum.org
This session, recorded at the 7th annual Chief Medical Officer Summit and moderated by Dr Martin Childers, Asklepios BioPharmaceutical, discusses designing clinical trials for gene therapy.
Topics covered include: How to utilize adaptive trial design within the specific context of a gene therapy - are there any unique aspects of development conducive to this approach?How to ensure flexibility when pushing for an accelerated pathway?Communicating pros and cons of development options and your recommendation to your CEODe-risk identifying the primary efficacy endpoint without a proof of concept phaseHow to interpret the current FDA guidanceFactors to consider around in-vivo and ex-vivo regulatory guidanceHow to use the guidance to direct the path of your programGlobal regulatory considerations and how to overcome them Panelists include: Edward Conner, MD, Sangamo TherapeuticsKathleen Reape, MD, Spark Therapeutics Learn more at theconferenceforum.org
In this talk, first recorded at the 7th annual Chief Medical Officer Summit, Dr Tal Zaks, Chief Medical Officer, Moderna Therapeutics shares his experience and lessons learned through one of the biggest transitions a Chief Medical Officer can make in biotech: Expanding the role of the CMO to meet the requirements of a public companyInsights into the experienceManaging growthWhat role does the CMO have in articulating the data of clinical trials What role does the CMO have in business development opportunitiesWhat are the personal implications of being a CMO in a publicly traded companyLessons learned Learn more at theconferenceforum.org
In this session recorded at the 7th annual Chief Medical Officer Summit, Dr Steve Kanes, Chief Medical Officer, Sage Therapeutics, discusses how a company considered as an "up and comer" in the Cambridge biotech sector navigated the development and approval of the first treatment specifically designed for postpartum depression.
Learn more at theconferenceforum.org
In an increasingly competitive market, there is a growing need for efficiency in attracting and retaining top talent.
This session, recorded at the 7th annual Chief Medical Officer Summit, and moderated by Dr Julie Krop, AMAG Pharmaceuticals, addresses the following: How to source talent; pros and cons of recruiters versus word-of-mouthHow to make the work environment optimal to keep employees satisfiedHow to compete with the competition banging on the doorHow to ease or address relocation concerns of potential hiresWhen is a good time to have consultants or contractors filling the gapsHow to access the untapped talent in academia, do they know we exist?Benefit/risk of having non-MDs fill the gaps and guided by a physicianDoes the industry need to evolve to attract and retain talentHow do you decide whom to recruit firstHow to identify the right hire Panelists include: Kara Coluccio Bern, Perspective GroupJames Lewis, Barrington JamesChris Poshka, Govig Learn more at theconferenceforum.org
First recorded at the 7th annual Chief Medical Officer Summit, this session provides insight in what it takes and how to navigate and what to expect in the CEO role. Moderated by Dr Zain Kassam, Finch Therapeutics, this panel discusses: How can a CMO position themselves as a corporate leader?How to build a network of advisors and who should it include? Panelists include: Aoife Brennan, MB, BCh, BAO, MRCPI, SynlogicGreg Fiore, MD, Sollis Therapeutics Learn more at theconferenceforum.org
In this podcast, hear a session from the 2019 Patients as Partners EU conference on How do Patients Become Partners in the Sharing of Data to Advance Science? How to encourage the sharing of suitably anonymized data to further medicines development for the benefit of patients?What are the barriers/issues? Public mistrust of pharma? Language, medical records versus coded data? Speakers:
Natalie Banner, PhD, Understanding Patient Data Lead, Wellcome Trust
Richard Stephens, Patient/Consumer Lead, Chair Consumer Forum, NCRI
The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020 in London, UK.
To learn more about the program and patient centricity in R&D, visit theconferenceforum.org.
In this podcast, hear a panel discussion presented at the 2019 Patients as Partners EU conference on Best Practices for Pharma - Patient Advocacy Partnerships. Pharma and advocacy representatives discuss:
• Advocacy point of view on is what pharma is doing in clinical trials and medicines development truly patient-centric?
• How can advocacy groups work with the pharmaceutical industry to improve the clinical trial process?
• How can advocacy get their foot in the door at pharma? Pharma’s advice.
• How can pharma and advocacy better work together?
• Explore the value of pharma reps spending time at an advocacy office to better understand what they do
• How can this partnership impact patients and medicines development?
Moderator:
Chris Macdonald, Head of Research, Pancreatic Cancer UK
Panelists:
Vanessa Pott, Director, Patient Advocacy & Strategic Partnerships, Merck KGaA
Natasha Ratcliffe, PhD, Research Involvement Manager, Parkinson’s UK
The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020 in London, UK.
To learn more about the conference and patient centricity in R&D, visit theconferenceforum.org.
In this podcast, hear a session from the 2019 Patients as Partners EU meeting where Merck's Vanessa Pott presented a case study on Innovative Medicines Development and Merck KGaA's next phase of Patient Centricity in R&D.
The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020 in London, UK.
To learn more about the program and patient centricity in R&D, visit theconferenceforum.org.
In this talk, recorded at the 5th annual IO360° Summit, Dr Alex Minella, Amgen, provides a clinical update on AMG 420, an anti-BCMA BiTE®
This talk addresses the: Summary of IND enabling preclinical studiesFirst-in-human trial designFirst-in-human trial data (safety, efficacy) Save the date for the 6th annual Immuno-Oncology 360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com
At the 2019 Patients as Partners EU meeting, Servier's Lode Dewulf presented a discussion on connecting employee-centric culture to patient-centric culture. This presentation covered the following points:
• What impact can engaged employees have on positioning the company as the preferred partner for patients and other collaborators?
• How can this be done? And for what purpose?
• How do you engage your employees and empower them to implement patient involvement strategies?
• Inspiring employees to make change?
The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020.
To learn more about patient centricity in drug development and R&D and the Patients as Partners EU program, visit theconferenceforum.org.
In this podcast, listen to a session from the 2019 Patients as Partners EU conference on Sanofi Eliciting Patient Experience Data During Clinical Trials to Better Understand Patient-Perceived Benefits and Disadvantages of their Drugs.
Dr Aude Roborel de Climens, PRO/COA Lead at Sanofi discusses how they capture patient experiences during clinical research and the benefit of collecting direct patient feedback. More specifically, she presents how they evaluate and analyse qualitatively and quantitatively individual patient experiences of benefits and risks of drugs during clinical trials to better understand and support clinical results and help future design of patient support programs.
The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020 in London, UK.
To learn more about patient centricity in R&D and the Patients as Partners EU program, visit theconferenceforum.org.
In this podcast, hear a session presented at the 2019 Patients as Partners EU conference on the Process to Understand the Language of Patients and the Value of Health Literacy. Who is responsible for delivering the why and how of getting involved in medicines development? Pharma, regulators or advocacy groups?What practical goals can the industry set to effect change?How are we communicating the trial information to patients and care partners to help them understand and make informed decisions?How can we address the communication challenges faced by patients and care partners while navigating the systemConsiderations for language used in adverse events reporting, informed consent and clinical trial summaries Speaker:
James (Jay) Duhig, PhD, Director, Patient Integration, Pharmacovigilance and Patient Safety (PPS), AbbVie
The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020 in London, UK.
To learn more about the Patients as Partners EU program and patient centricity in R&D, visit theconferenceforum.org.
In this podcast, hear a case study from the 2019 Patients as Partners EU conference on UCB and Parkinson's UK Working Together to Improve a Phase 2 Trial through Patient Involvement.
In 2018, UCB and Parkinson’s UK co-developed a workshop to enable the UCB research team to work together with people affected by Parkinson’s to discuss and develop a potential phase 2 clinical trial. The aim of the workshop was to better understand people’s thoughts on clinical trials and get feedback on key features of the potential trial to maximise appropriateness, acceptability and success. In this session, attendees hear a multi-stakeholder perspective on the collaboration, including:
• How the workshop was co-developed
• Benefits and impact of patient involvement
• Key challenges and solutions during the collaboration
• Practical tips for industry and patient organisation collaborations
Speakers:
Natasha Ratcliffe, PhD, Research Involvement Manager, Parkinson’s UK
Elaine Sutcliffe, Patient Advocate
Kate Trenam, UK Patient Advocacy and Policy Manager, UCB
The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020 in London, UK.
To learn more about patient centricity in R&D and the Patients as Partners EU program, visit theconferenceforum.org.
The pipeline of adoptive T-cell therapies and other cell based immuno-oncology programs continues to expand with a number of modifications and improvements to the first generation programs. These platforms include improved spcificty and delivery - including non-viral platforms, targeting of multiple antigens, editing constructs, and a variety of strategies to address toxicity and the tumor microenvironment. This panel of experts, moderated by Dr Gbola Amusa, Chardan and recorded at the 5th annual Immuno-Oncology 360° Summit, will consider the major technical and clinical improvements to cell based IO therapeutics that will lead to more durable therapies and the ability to treat both liquid and solid tumors.
Panelists include: Dr Robert Ang, Neon TherapeuticsDr Usman "Oz" Azam, TmunityMichael Dombeck, Precision BioSciencesDr Aiman Shalabi, GSK Save the date for the 6th annual IO360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com
This panel moderated by Dr Andrew Baum, Citi and recorded at the 5th annual IO360° Summit discusses the preparation of an IPO, straight licensing with the transition to a public company and decision making on prioritization within portfolios.
Panelists include: David Epstein, Flagship PioneeringDan Passeri, Cue Biopharma Save the date for the 6th annual Immuno-Oncology 360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com
In this talk recorded at the 5th annual IO360° Summit, Dr Charles Link Jr, Newlink Genetics, addresses how IDO changes the T-cell balance in the tumor microenvironment.
This talk addresses how: IDO creates local immunosuppression by increasing T regulatory cellsIDO often works in concert with PDL-1 mediated immunosuppressionIDO mediated T-cell immunosuppression leads to poor prognosis in melanoma Save the date for the 6th annual Immuno-Oncology 360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com
In this podcast from the 2019 Immuno-Oncology 360° conference, Cello Health BioConsulting's EVP, Oncology Practice Head, Dr Jeff Bockman discusses deal-making and investments in the I-O space to see what can be learned about the expanding and shifting landscape of BioPharma and investor interest by examining who is placing what kinds of bets on which targets and modalities, at what stage and with what terms.
Additional topics include: Where are the next big paradigm shifts going to be?Where is the next great target that will supersize foundational checkpoint therapy? Join us for the 6th annual IO360° conference on February 26-28, 2020 at the Crowne Plaza Times Square hotel in New York City.
To learn more about the event, please visit IO360 2020.
Pharma Talk Radio producer, Valerie Bowling recently spoke with a young Alzheimer's patient, Jeff Borghoff. Jeff was officially diagnosed with Alzheimers in 2016 and is an active and patiionate patient advocate. Jeff generously shares his experience from diagnosis, to the experience of a clinical trial to his work in advocacy.
Jeff will be speaking at the Patients as Partners conference on June 29-30, 2020 in Philadelphia. For more information, visit theconferenceforum.org
We look forward to bringing you more podcasts featuring patient advocates and more on the topic of dementia.
Resources that Jeff recommends: Alzherimer's AssociationAlzheimer's Congressional TeamAlzheimer's Association Early-Stage Advisory Group
In this podcast from the 2018 Mobile in Clinical Trials conference, Mohammad Ali, Global Head Digital Trials- Global Clinical Operations, Boehringer-Ingelhiem and Joe Dustin, Principal, Mobile Health, Medidata Solutions discussed the internal infrastructure that is required for the successful scaling of mobile/digital tools in clinical trials.
The discussion focuses on how to come to terms with the demand of data, understanding the skill set required to purposefully use the data and implementing an internal system to allow for efficient scaling of mobile trials.?
Mohammad Ali is returning to Mobile 2019 to lead an interactive group activity on creating a pathway for brainstorming the digital biomarker process.
Speakers: Mohammad Ali, Global Head Digital Trials- Global Clinical Operations, Boehringer-Ingelhiem
Joe Dustin, Principal, Mobile Health, Medidata Solutions
In this podcast from the 2018 Mobile in Clinical Trials conference, patient advocate, Cindy Geoghegan sat down with Dr Daniel Karlin, CEO, Healthmode and Deanna Lennon, Director of Business Development, Medable Inc for a discussion on aligning the promise of technology with the patient voice.
The panel explores patient perspective on being monitored continuously and pharma perceptions of what patients want versus what patients really want.
Speakers: Cindy Geoghegan, Patient Advocate
Daniel Karlin, MD, CEO, Healthmode
Deanna Lennon, Director of Business Development, Medable Inc
In this podcast from the 2018 PODD: Partnership Opportunities in Drug Delivery conference, Dr Christopher Kovalchick, Chief Engineer, Drug Delivery & Devices R&D Innovation at Eli Lilly and Company presented on incorporating of digital monitoring biomarkers into drug delivery.
More specifically a framework is presented which stratifies key components and advances the concept of contextualized biomarkers. The framework codifies how direct, indirect, composite and contextualized composite data can drive innovation for the application of digital biomarkers in healthcare. In addition, application in disease and wellness is highlighted and incorporation in clinical feedback loops and closed-loop systems is illustrated.
Dr Kovalchick is returning to PODD 2019 to present on Achieving the Ultimate Outcome for Patients- Utilizing Digital Health Data to Improve Disease Management, Prevention and Overall Wellness.
The 9th annual PODD conference with take place October 7-8, 2019 in Boston, MA. Learn more at theconferenceforum.org
In this podcast, Valerie Bowling, Director of PODD, walks you through what to expect at PODD 2019 in under 4 minutes. The 9th annual PODD conference features the following: Building a Company around a Transformative Drug Delivery Invention with MIT's Dr Robert Langer, Dr Sangeeta Bhati, Dr Giovanni Traverso and Harvard Medical School's Dr Jeffrey Karp.Modality Fluid Development: Tales of Evolving Pipelines and Drug Delivery Solutions with Merck's, VP, Pharmaceutical Sciences, Dr Allen TempletonGene Therapy Keynote with Spark Therapeutics, President and Head of R&D, Dr Katherine HighZeitgeist Presentation on Immune Targeting Nanomedicine by AstraZeneca’s, VP, External Innovation and Novel Product Technologies, Dr Anand SubramonyConference Chair opening remarks provided by AstraZeneca's, Dr Shawn Davis Additional Featured Speakers: Roche’s, Senior Portfolio Strategy Director, Dr Beate Bittner will moderate the Formulation & Device Lifecycle Management for Biotherapeutics – Clinical and Industry Perspectives on Subcutaneous Delivery panel.Drug Delivery Pipeline and Technologies, A Year in Review, with Pharmacircle’s, VP, Kurt SedoDelivering Flexible Dosage Forms with Pfizer's Dr Advait Badkar The 9th annual PODD conference will take place on October 7-8, 2019 in Boston, MA. Learn more at theconferenceforum.org
It is estimated that between 7-10 million people, globally have Parkinson's disease. Our guest on Pharma Talk Radio, Lesley Gosden is living with Parkinsons and she is an outstanding patient advocate, who experienced the GDNF clinical trial. In this podcast discussion, our guest will give us an insight into living with Parkinson's, about the GDNF clinical trial, lessons for all stakeholders and in particular how the success rate of clinical trials could be improved from the patient’s point of view.
Ms Gosden will be the Keynote patient advocate speaker at the Patients as Partners EU conference taking place in London on January 27th and 28th and for more information, visit theconferenceforum.org.
Guest: Lesley Gosden, Patient Advocate
Host: Valerie Bowling, Producer, Pharma Talk Radio
For more information about the GDNF Trial: Reflections on the GDNF Trial
In this podcast from the 2018 Mobile in Clinical Trials conference, Dr Paul Glimcher, Julius Silver Professor of Neural Science and Physiology at NYU alongside Dr Daniel Karlin, CEO at Healthmode presented on the future of mobile data in clinical trials.
Drs Glimcher and Karlin discussed this rapidly evolving space with an emphasis on the barriers and opportunities in the mobile health arena. More specifically:
• What are the Barriers to gathering an incorporating Mobile data into clinical trials?
• What are the most important new datatypes that are evolving in the Mobile Health space?
• How can we use Real World Measurements to identify new classes of clinically relevant endpoints to go beyond Billing Codes?
• Can we expect to see large-scale Mobile databases for synthetic use on the model of EMRs and ICD codes?
• How should we think of these new classes of data, are they just novel bioindicators or something else?
Dr Karlin is returning to Mobile 2019 as co-chair.
Speakers: Paul Glimcher, PhD, Julius Silver Professor of Neural Science and Physiology, NYU
Daniel Karlin, MD, CEO, Healthmode
In this podcast from the 2018 Mobile in Clinical Trials conference, Eli Lilly's Joseph Kim, Sr Advisor, Clinical Operations and Digital Registry, Digital Health Office | Translational Technology & Innovation, reported on incorporating a variety of mobile devices – including a smart phone, smart insulin pens, connected devices, mifi, and laptops, into a clinical trial.
Considerations and lessons learned for:
• Connecting all the devices
• Implementation differences between traditional vs siteless
• Coordinating the equipment; challenges and successes
• Lessons learned
• What’s next?
Speaker: Joseph Kim, Sr Advisor, Clinical Operations and Digital Registry, Digital Health Office | Translational Technology & Innovation, Eli Lilly & Co
In this podcast from Mobile in Clinical Trials 2018, Pfizer's Project Team Lead, Early Clinical Development, Digital Medicine, Dr Carrie Northcott speaks about considerations and lessons learned from the validation, verification and use of digital wearable technology in a Atopic Dermatitis Clinical Trial and some of Pfizer's forward-leaning work in decision making around novel digital endpoints.
Dr Northcott is coming back to Mobile 2019 to share results and next steps on this trial.
Speakers: Carrie Northcott, PhD, Project Team Lead, Early Clinical Development, Digital Medicine, Pfizer, Inc
In this session presented at the Mobile in Clinical Trials 2018 conference, Merck's Kai Bode and Jyoti Shah share an exciting update on the company's progress in implementing a digital health and AI strategy. Session takeaways include: What Merck is doing in digital health and AIExternal collaborations on AISmart trial initiative to enable patient-centric studies Kai Bode is returning to Mobile 2019 to share an update on Merck's digital strategy 2.0 and how they are engineering for scale.
Speakers: Jyoti Shah, Associate Director, Data Development MRL IT, Merck & Co, Inc
Kai Bode, Director, Digital and Analytics Technology, Merck & Co, Inc
In this session from DPharm 2018, Roche provides an update on the company's progress in how they are collecting data with sensor technology and turning it into a clinically meaningful endpoint with multiple indications, including Parkinson's disease and Multiple Sclerosis. Session takeaways include: Understand what Digital Biomarker innovation means for the future of clinical development and potentially personalized healthcare.Be inspired to use mobile sensors technology in the context of clinical trials and beyond.Develop a detailed understanding of the underlying complexity to run such efforts and be able to plan for it.Understand how regulators are looking at these novel approaches. Speaker:
Christian Gossens, PhD, MBA, Global Head Early Development Workflows, pRED, Informatics, Roche Pharmaceutical Research and Early Development (pRED)
The 9th annual DPharm conference with take place on September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.
This is a keynote session from DPharm 2018. Dr Atala, a renowned key opinion leader on the topic of regenerative medicine, brings the DPharm audience a fascinating presentation on how it's possible to reduce the number of patients needed in clinical trials with the advancement of regenerative medicine, and how regenerative medicine can improve accuracy and speed up the clinical trial process.
Speaker:
Anthony Atala, MD, Director, Wake Forest Institute for Regenerative Medicine
The 9th annual DPharm conference will take place on September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.
This 4 minute podcast summarizes what you can expect at the 6th annual Mobile in Clinical Trials conference. This event provides sessions on the latest progress in applying mobile applications and patient-facing technologies to connect and empower patients, while obtaining better outcomes in drug development.
The conference takes place September 16, 2019 at the Renaissance Boston Waterfront Hotel, Boston, MA. The program is co-chaired by Bayer’s Michelle Shogren, Director of Innovation, Pharma R&D Clinical Operations and Healthmode’s Dr. Dan Karlin, CEO. For more information please visit www.theconferenceforum.org or contact us at service@tcfllc.org
An Insight into Our Possible Future Faster than You Think
This keynote session was presented at the 2018 DPharm conference. Estonia is now a digital republic with a virtual government, blockchained and secure. Our keynote guest from Estonia tells us how Estonia became the fastest country in the world to go digital. Its 1.3 million citizens pay with their mobile phones, have their health records stored in the digital cloud, and filed their annual tax return online in five minutes. This session demonstrates how Estonian citizens have come to own their personal health records, how doctors have to get their permission to use these records, and how patients choose their own medications digitally. We also learn about their challenges, policies, and of course their vision for digital clinical trials.
Speakers:
Indrek Onnik, Program Manager, E-Estonia Showroom, a partner of the Estonian Government
The 9th annual DPharm conference will take place on September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.
In this session presented at the 2018 DPharm conference, Rob Goodwin and Amy Nordo share an exciting new collaboration - including industry and academia, as well as health authorities and leading technologists - positioned to break through the barriers to allow the power and the promise of eSource across companies and medical centers.
The potential for eSource has been discussed for years, but realizing its promise has been difficult. While most health data today can be captured within electronic health records, the diversity of systems across medical centers and around the world coupled with a lack of health data interoperability has limited our ability to source clinical trial data from existing electronic systems across thousands of investigator sites supporting trials globally.
Speakers:
Rob Goodwin, VP, Operations Center of Excellence, Global Product Development, Pfizer, Inc.
Amy Nordo, Program Director, Duke Center for Healthcare Informatics
The 9th annual DPharm conference will take place September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.
In this podcast from DPharm 2018, Pfizer's VP of Clinical Supply Chain, Michael Ku, speaks about some of Pfizer's earliest work making blockchain real as well as some of their forward-leaning work digitizing supply chain for clinical trials.
The 9th annual DPharm conference will take place on September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.
In this podcast from DPharm 2018, Bayer shares how they use virtual assistants and chatbots to support study teams, research sites, and patients. Learn how they are doing this and what you should consider.
Speaker: Michelle Shogren, Head of Innovation, Portfolio & Operations, Bayer
The 9th annual DPharm conference will take place on September 17-18 in Boston, MA. Learn more at theconferenceforum.org.
In this podcast, Valerie Bowling, Director of DPharm, walks you through what to expect at DPharm 2019 in under 5 minutes. This is the 9th annual DPharm conference featuring keynotes from: Dr Scott Gottlieb, 23rd Commissioner of the FDATakeda’s CMO, Dr Andy PlumpMerck’s VP of Global Operations, Dr Mark TraversCellarity's Chief Data Officer, Milind KamkolkarStarbucks' Design Director of Global Digital Products, Robert MercerFast Company's Deputy Editor, David LidskyHealthgrades' Founder, Kerry HicksRadio City Rockette and Patient Advocate, Alyssa Epstein All of this plus: pharma reporting from the trenches, multiple track choices, opportunities to meet patients, and more.
The 9th annual DPharm will take place on September 17-18 in Boston, MA. Learn more at theconferenceforum.org
Trialspark, CEO, Dr Ben Liu recently sat down with Valerie Bowling, Executive Director of DPharm in a podcast discussion. Valerie checked in with Ben on the progress of life as a data science entrepreneur. They also discussed how Ben and his team are solving big challenges in drug development, new evolving R&D models and more. On Sept 17th, Ben will be interviewing Pfizer's Rod Mackenzie, Chief Development Officer at DPharm: Disruptive Innovations to Advance Clinical Trials in Boston. For more information, please visit theconferenceforum.org
When developing technologies to solve medical problems, one often encounters significant hurdles, that at times seems insurmountable. In this discussion, recorded at the 8th annual Partnership Opportunities in Drug Delivery (PODD) conference, Dr Jeffrey Karp, Professor of Medicine, Harvard Medical School and Director of the Laboratory for Accelerated Medical Innovation, Brigham and Women's Hospital discusses overcoming these hurdles with the use of nature for inspiration.
This talk will explore medical technologies being developed that harness lessons from nature for inspiration. Some of the technologies that will be described are rapidly advancing to the clinic and some are already on the market helping patients.
Join us for the 9th annual PODD conference business development event on October 7-8, 2019 at the Renaissance Boston Waterfront Hotel in Boston. PODD covers the latest advances in drug delivery science, while also providing a meeting place to network and form new partnerships.
To learn more about the event, please visit PODD 2019.
In this industry keynote recorded at the 8th annual Partnership Opportunities in Drug Delivery (PODD) conference, Justin Wright, PhD, Global Head of Innovation, Novartis, discusses how the transformation from traditional drugs to next-generation product systems, where sometimes the drug is only a component of the overall product offering, is creating a opportunity for non-traditional competitors and start-ups to access the market and potentially redefine the value model associated with drug pricing.
To stay competitive, the pharmaceutical industry’s current business model needs to evolve rapidly from a reactive to a prevention model. At the core of this type of evolved model will be a dynamic patient interface with extraordinary patient engagement. And the delivery system will undoubtedly be a key enabler in the process.
Dr Wright reviews the current and future state with his perspective and cases studies to help shed light on the key areas where focus is needed focus and corresponding opportunities lie.
Join us for the 9th annual PODD conference business development event on October 7-8, 2019 at the Renaissance Boston Waterfront Hotel in Boston. PODD covers the latest advances in drug delivery science, while also providing a meeting place to network and form new partnerships.
To learn more about the event, please visit PODD 2019.
In this podcast from DPharm 2018, Chip Bell shows pragmatic ways to change our culture to support service-oriented thinking that benefits patients and investigators. The patient's expectations are being quickly changed today by disruptors far beyond the Pharma industry. How will the concept of service make us better at drug development and help us become more disruptive thinkers?
Speaker:
Chip Bell, PhD, Keynote Innovative Service Speaker, Author, Senior Partner, The Chip Bell Group
The 9th annual DPharm conference will take place on September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.
Moderated by Marian Gindy, PhD, Executive Director, Discovery Pharmaceutical Sciences, Merck, this panel discussion recorded at the 8th annual Partnership Opportunities in Drug Delivery (PODD) conference explores how mRNA vaccines represent a promising alternative to conventional vaccine approaches for infectious diseases as well as oncology indications, including an emerging application for personalized cancer vaccines.
The panelists for the session are: Örn Almarsson, PhD, Head of Formulations, Moderna TherapeuticsDanilo Casimiro, PhD, VP and Head, External R&D and Vaccine Platforms, SanofiChristian W Mandl, PhD, MD, Chair, Scientific Advisory Board and Co-Founder, Tiba BiotechJinJun Shi, PhD, Associate Professor, Harvard Medical School and Faculty Member, Center for Nanomedicine at Brigham and Women’s HospitalSybil Williams, PhD, Senior Principal Scientist, Personalized Cancer Biology Lead, Merck Save the date for the 9th annual PODD business development event on October 7-8, 2019 at the Renaissance Boston Waterfront Hotel in Boston. PODD covers the latest advances in drug delivery science, while also providing a meeting place to network and form new partnerships.
To learn more about the event, please visit PODD 2019.
This session was presented at the 8th annual DPharm conference in September 2018.
When Amazon announced that the creation of a new healthcare company with Berkshire Hathaway and JPMorgan Chase, the move signaled how the company is stepping into the healthcare industry. However, Amazon Web Services (AWS) has been working directly with the healthcare and life science industries for quite some time. Life Science Director, Mark Johnston, shares how AWS thinks about innovation, in particular for the life science industry, including clinical trials.
More specifically: How AWS looks at problems and transforms processes through new technologiesHow to think about going faster to be more effective in solving problems without the worries of infrastructureHow to imagine what to do next if you were un-trapped by historical baggage and preceived limitationsOpportunities to considerExamples Speaker: Mark Johnston, Director of Global Business Development for Health Care, Life Sciences, and Agricultural Technology, Amazon Web Services
The 9th annual DPharm will take place on September 17-18 in Boston, MA. Click here for more information.
Roughly, 5.7 million people in the U.S. are living with Alzheimer’s. Globally, an estimated 47 million individuals are living with dementia. There is no cure, and treatments can only relieve certain symptoms for some people. Research studies so far have a poor record. Patients can face incredible enrollment hurdles in clinical trials.
A Patient Registry can be very useful in identifying patients. A registry can also address the original problem statement about failed trials. A robust, living registry becomes a data pool from which we can improve both drug discovery, using probabilistic statistics and AI/ML to identify new drug candidates, and drug development, using simulators to predict likelihood of success in Phase 2 or 3.
In this podcast, we discuss major challenges facing developers of Alzheimer’s therapies and address patient registries and how they can improve enrollment and trial design. In this podcast, we will hear some details about the HealthyMindsRegistry, Synexushmr.com and the Protect Study Registry, Protectstudy.org.uk registry. For US and UK citizens over 50 who have not been diagnosed with dementia can participate in the registry on-line.
Guests:
Dr Clive Ballard, Pro-Vice Chancellor and Executive Dean, University of Exeter, External partner in the AES HealthyMinds Registry (HMR)
Dr Heather Bryson, Director, Operational and Strategic Solutions at Accelerated Enrollment Solutions, (AES)
Host: Dr Julie Adams, Psychiatrist and Regional Medical Officer, PPD Biotech
Producer: Valerie Bowling, Executive Director, the Conference Forum
This 8 minute podcast summarizes what you can expect at the 4th annual IO Combinations 360° conference. This conference provides the latest data impacting immuno-oncology combinations and patient treatment with perspectives from science, clinical and business.
The conference takes place June 20-21, 2019 at the Wyndham Philadelphia Historic District, Philadelphia, PA. For more information please visit www.theconferenceforum.org or contact us at service@tcfllc.org
Dr Marco Ruella, Assistant Professor and Scientific Director Lymphoma Program, Division of Hematology and Oncology, Department of Medicine and Center for Cellular Immunotherapies (CCI), Perelman School of Medicine, University of Pennsylvania focuses on the next steps for CAR-T therapy for cancer, discussing the novel approaches that are being developing in Dr Carl June’s lab including CAR-T combinations with small molecules and gene-editing.
Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City.
The hardest thing to figure out now is what interventions and combinations make the most sense in which patients and how to combine all these emerging modalities in a way that is cost effective, benefits patients and unfolds in our lifetime. There are hypothesis on what technologies should be explored together, however very few companies have all the relevant skills, reagents or product candidates in one setting, so it requires collaboration to generate the most powerful combinations and sequence of interventions. This overview talk, followed by a panel will delve into the following: What is the underlying pathobiology and how it is similar from patient to patient and how it is different in individuals?What interventions make the most sense and how to get the right patient into the studies to test your hypothesis?How can we build an integrated suite of tools to ask and answer all the relevant questions to appropriately characterize patients?How can we develop something cost effective that doesn’t necessarily require 100K worth of diagnostic tests in every patient? Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City.
In this panel, moderated by Dr Axel Hoos, GSK, individuals from large pharma and biotech business development leads discuss decision-making when it comes to partnering and collaborations in today’s IO environment. What is the current nature and types of partnerships being done in IO?Is dealmaking and partnerships evolving due to the need for IO combinations? How so?What is the balance between in house R&D and external innovation in IO?What is the decision making regarding exclusive licensing and “no strings attached” partnerships? Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City.
This panel, moderated by Dr Priti Hegde, Genentech, discusses the following: How can biomarkers act as a tool for understanding the biology at a level that is sufficient for making decisions around combinations?What are the potential biomarkers that can help predict if a patient will respond to combinations?Once a biomarker is identified in terms of biology, been measured and the technology platform identified to meet those measures, how is the biomarker developed to the level of clinical grade that meets approval?How do we validate diagnostics in IO/combinations?How do you satisfy regulators?Are there other biomarkers in development?What are the implications for intervention?Are biomarkers and companion diagnostics crucial for rational combination success? Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City.
In this podcast, Dr Gregory Goldmacher, Executive Director, Translational Biomarkers and Head of Clinical Imaging, Merck Research Labs along with Dr Matthew Silva, Executive Vice President, Scientific Applications, Invicro discuss innovations in IO imaging.
Together, Dr Goldmacher and Dr Silva address: The evolution of treatment response criteria in immuno-oncologyNovel Tracers: Monitoring tumor or immune cell populations with imagingRadiomics, AI and Digital Biomarkers Join us February 26-28, 2020 in NYC for the 6th annual Immuno-Oncology 360° Summit where we will continue to expand on imaging aspects for cancer immunotherapy. To learn more visit www.theconferenceforum.org
The 2nd annual Drug Delivery West (DDW) Summit provides a west coast venue for biotech, pharma and drug delivery companies to address scientific and business solutions for the best routes of delivery across different therapeutic areas with an emphasis on emerging technologies and to prepare for the future of R&D and clinical care. This podcast discusses who will be presenting and the topics covered at the summit taking place May 6-7, 2019 at the Marines' Memorial Club and Hotel in San Francisco, CA
Modernizing Clinical Trials with IQVIA's Dr Cynthia Verst
Host: Valerie Bowling, Executive Director, Pharma Talk Radio and DPharm:Disrupting Clinical Trials
Guest: Dr Cynthia Verst, President, Design and Delivery Innovation for the Research & Development Solutions organization at IQVIA
In this podcast, Valerie Bowling, Executive Director of the Conference Forum, interviews Dr Laura Esserman, breast cancer surgeon and researcher at the University of California, San Francisco. Dr Esserman shares her thoughts on how we can move towards uniting care and clinical research and the future of how medicine should be practiced.
This discussion was presented at the inaugural Drug Delivery West conference in 2018.
One of the key challenges in global health is ensuring safe and effective delivery of life saving interventions to remote and non-clinical settings. The Bill & Melinda Gates Foundation invests in technologies, which will help achieve this goal. Learn about an RFP they are launching to indentify new ideas for delivering lyophilized products and how you can participate.
Presented by David Robinson, PhD, Deputy Director, The Bill & Melinda Gates Foundation
To learn more about the 2019 Drug Delivery West conference taking place May 6-7, 2019 in San Francisco, CA, please click here.
This panel, presented at the inaugural Drug Delivery West conference in 2018, provides patient perspectives on what they want from drug delivery technologies. These case examples provide insight that every technology can benefit from and lessons learned through our patient representatives.
Co-Moderators:
Valerie Bowling, Patient Advocate and Executive Director, Drug Delivery West
Sudeshna Dutta Ray, Senior Engineer, Advanced Device Technology and Innovation, Amgen
Panelists:
Cynthia Goldstein, Patient & Communications Specialist
Mikaela Saugstad, Patient, Co-Founder, Director of Customer Relations & Marketing, Gigil Precision LLC
Lily Stairs, Patient and Head of Patient Advocacy, Clara Health
To learn more about the 2019 Drug Delivery West conference taking place May 6-7, 2019 in San Francisco, CA, please click here.
In this discussion, CRAACO co-chair, Katherine Vandebelt, Chief Ecosystem Officer, Reify Health, Inc, and Alison Bateman-House, PhD, MPH, MA, Assistant Professor Division of Medical Ethics, NYU Langone Health, consider what lines are being drawn in the integration of clinical care and clinical research. More specifically: Research and care or treatment are separate spheres in the regulatory and ethical worlds. What happens when they are brought together?Are there ethical barriers that need to be overcome to allow clinical research to be offered as an option as part of clinical care?What are the ethical issues that surround offering a patient the opportunity to consider enrolling in a clinical trial?What current efforts are underway to address these issues? This session was presented at the Clinical Research as a Care Option (CRAACO) meeting in April 2018 in Cambridge, MA.
The 2019 CRAACO conference will take place April 29-30, 2019 in Raleigh-Durham, NA. Learn more here.
In this discussion, stakeholders from medical practices, hospitals, service providers, and patient advocacy discuss how medical practices can offer clinical trials to patients. Including: Infrastructure and supportHow to establish physician championsHow to influence leadership supportContacting patients Moderated by: Jennifer Byrne, Founder, Greater Gift Initative
Panelists:
Judy Hung, MD, Director Trial Innovation Unit, Division of Clinical Research, Massachusetts General Hospital
Jeff James, CEO, Wilmington Health
Greg Sweatt, Senior EVP Value Based Crae, Co-Founder, ePatient Finder
Kurt Waldhuetter, VP Research Innovation & Business, Aurora Research Institute
This panel was presented at the Clinical Research as a Care Option (CRAACO) meeting on April 11, 2018 in Cambridge, MA.
The 2019 CRAACO conference will take place April 29-30, 2019 in Raleigh-Durham, NC. Find out more here.
Murray Abramson, MD, VP Clinical Operations, Biogen and Jeff James, CEO, Wilmington Health, discuss the blockers and enablers to making clinical research a care option. Discuss includes: What are the blockers or conflicts (laws, culture, behaviors, etc) that prevent clinical research from becoming a care option?What is the difference between a movement and an initiative - how should be think about clinical research as a care option? Benefits?What are the enablers or requirements to incorporate clinical research into care options for the patient?How to pave a path for possibilityUpdate on data to support how trials can be a care option This discussion was held at the Clinical Research as a Care Option (CRAACO) meeting held April 11, 2018 in Cambridge, MA.
The 2019 CRAACO meeting will take place April 29-30 in Raleigh-Durham, NC. Find out more here.
Jonathan Jackson, PhD, Director CARE Research Center, Massachusetts General Hospital, and Jim Kremidas, Executive Director, Association of Clinical Research Professionals (ACRP) sit down for a frank discussion on the benefits of offering clinical research in underserved communities. Many communities, whether affected by race, ethnicity, or socioeconomic lines, are underrepresented in clinical research. How can offering these care options enhance access to other resources in a broader sense and better educate these communities to the opportunities that clinical research provides?
This discussion was presented at the Clinical Research as a Care Option (CRAACO) meeting on April 11, 2018 in Cambridge, MA.
The 2019 CRAACO conference will take place April 29-30 in Raleigh-Durham, NC. Find out more here.
Chief Medical Officer Summit co-chair, Jim Roach, and prominent biotech investor, Elizabeth Stoner, sit down for a fireside chat to discuss what investors are seeking when investing in a biotech company, particularly traits of a Chief Medical Officer. Stoner shares her insights on longevity, key qualities of an effective CMO, and how her perspective as a biotech veteran and former director of clinical development across biopharma both large and small is affecting her investment decisions in the future of the biotech industry.
You can join us at the 7th annual Chief Medical Officer Summit happening April 4-5, 2019 in Boston. To learn more visit theconferenceforum.org
Mark Currie, President of R&D at Ironwood Pharmaceuticals, shares his amazing journey driving a product from establishing the foundation for the discovery of linaclotide by Ironwood scientists and leading every aspect of linaclotide's development and regulatory review. He shares his thought processes, pressure points, and lessons learned in leading the R&D team to get a product successfully to market.
For more information on the Chief Medical Officer Summit and details for the 7th annual program taking place April 4-5, 2019 in Boston, please visit theconferenceforum.org
In this podcast, Dr Alison Bateman-House, Assistant Professor, Division of Medical Ethics at NYU Langone Health, discusses the debate of compassionate use and the right to try. It dives into the implications, both positive and negative, of opening up that door.
In this podcast, Raju Joshi, Managing Partner at Clinical Partners Group and Dr Zain Kassam, CSO at Finch Therapeutics, discuss how CMO's can more effectively communicate with CEO's, CSO's, and Clinical Operations executives in order to prove a comprehensive summary of the science and business aspects of the company.
You can join us at the 7th annual Chief Medical Officer Summit happening April 4-5, 2019 in Boston. To learn more visit theconferenceforum.org.
Mary Stober Murray, Associate Director, Diversity and Patient Engagement for BMS, discusses applying quality systems framework (structure, processes, outcomes) to patient engagement initiatives to help create clinical development deliverables that meet industry goals while aligning with patients needs.
Mary Stober Murry will be joining the 6th annual Patients as Partners US program on March 11-12 at the Wyndham Philadelphia Historic District Hotel in Philadelphia to lead a roundtable discussion on Building Patient Engagement into Systematic Processes. Patients as Partners US is the only conference that demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. For more information visit www.theconferenceforum.org.
In this podcast, we were joined by Mr Charles Graeber, award-winning journalist and author who recently published The Breakthrough: Immunotherapy and the Race to Cure Cancer along with Dr James Gulley, Head of the Immunotherapy Section and Director of the Medical Oncology Service at the Center for Cancer Research within the National Cancer Institute.
Together Mr Graeber and Dr Gulley delved into the significance of this moment in science, what the progress has been and explore what is next on the horizon within immuno-oncology.
Both Dr Gulley and Mr Graeber will be presenting at the 5th annual IO360°, February 6-8 at The Crowne Plaza Times Square Hotel, NYC. For more information visit IO360°.
This podcast features a panel previously recorded at the 5th annual Patients as Partners US program on Engaging Patients By Giving Them their Data.
The panel, moderated by David Leventhal, Director of Clinical Innovation for Pfizer, discussed:
• What information and data do patients want during a clinical trial?
• What initiatives is pharma currently doing to support this?
• What impact will it have if patients have access to their data?
Additional panelists included:
Jenny Ahlstrom, Myeloma survivor and Co-founder, CrowdCare Foundation
Kristina Figueroa, MSPH, Patient and Advocate
Cindy Geoghegan, Cancer Survivor, Patient Advocate & Team Lead, CTTI’s Mobile Clinical Trials Stakeholder Perceptions Project
Thérèse Johnsen, Associate Director, Patient Engagement Management, Novartis
Join us for the 6th annual Patients as Partners US program on March 11-12 at the Wyndham Philadelphia Historic District Hotel in Philadelphia where we feature extended sessions on The Democratization of Patient Data & Returning Data to Patients.Patients as Partners US is the only conference that demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research.For more information visit www.theconferenceforum.org.
Les Jordan, Working Group Member and Cindy Geoghegan, Team Lead for CTTI, the Clinical Trials Transformation Initiative, share findings from a multi-stakeholder project undertaken by the Clinical Trials Transformation Initiative to better understand patient perspectives on mobile technologies in clinical trials.
The survey, conducted amongst 100 patients across multiple therapeutic areas, evaluated the ways patients would be willing to use mobile technologies and the impact on their participation in clinical trials. Additional focus areas included:
• Potential impacts of mobile on participant experiences in clinical trials
• Patient willingness to share personal health data
• Important attributes for designing trials that address patient preferences and expectations
• Implications for the research enterprise
CTTI will also be joining the 6th annual Patients as Partners US program on March 11-12 at the Wyndham Philadelphia Historic District Hotel in Philadelphia where they will share newly-released recommendations and actionable tools, understand unique considerations for participants in mobile trials, and opportunities to effectively engage patients during trial planning.
For more information on the 6th annual event, visit www.theconferenceforum.org.
Dr Marilyn Metcalf, Head of the Center of Innovation for GSK, at the 5th annual Patients as Partners 2018 program. Dr Metcalf shares how GSK implemented pivotal end-to-end engagement initiatives at different stages of development. Dr Metcalf walked the audience through some examples of the engagement initiatives supported by:
• Creation of a framework and toolkit that builds on existing infrastructure
• Networks of champions and project leads
• Project planning
• Emerging best practices being shared throughout the organization
Dr Metcalf will also be joining the 6th annual Patients as Partners US program on March 11-12 at the Wyndham Philadelphia Historic District Hotel in Philadelphia where she leads a panel with patients and advocacy on Mapping Out the Patient Decision Making Journey. Patients as Partners US is the only conference that demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. For more information visit www.theconferenceforum.org.
To prevent ticking off a box and to ensure that patient involvement is systemic and sustainable, we have to move into patient-centricity 2.0. What does this mean and how is this done so we can turn the patient voice into value, impact, and benefit?
This session presented at the 2nd annual Patients as Partners EU meeting, which took place January 2018 in London, demonstrates best practices from Hoffman La Roche, Melanoma Patient Network, Patient Focused Medicines Development, and European Patients Forum.
Moderated by: Bettina Ryll, PhD, Founder, Melanoma Patient Network Europe.
Panelists: Nicola Bedlington, Secretary General, European Patients ForumNicholas Brooke, Chief Executive Officer, Patient Focused Medicines Development (PFMD)Irmi Gallmeier, Senior International Health Policy Leader, Patient Relations, F. Hoffman La Roche The 3rd annual Patients as Partners EU meeting will take place January 28-29, 2019 in London, UK. Find more information here.
What would have to change to make a patient-centric healthcare system a reality? How can this be achieved, given the huge resistance to change built into current systems? In this session, Alastair Kent, Director of Genetic Alliance UK, addresses: New opportunities to interveneDemographic changeConstrained funding right across EuropeThe introduction of Expert Reference NetworksHow we can work through this collaboratively. This session was presented at the 2nd annual Patients as Partners Europe meeting in London in January 2018.
The 3rd Annual Patients as Partners Europe meeting will take place January 28-29, 2019 in London, UK. You can find more information here.
This 8 minute podcast summarizes what you can expect at the 6th annual Patients as Partners US conference. This is the only event that truly demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research.
The conference takes place March 11-12, 2019 at the Wyndham Philadelphia Historic District, Philadelphia, PA. The program is chaired by Merck's Jan Nissen, VP, Patient Innovation and Engagement, Arthritis Foundation's Suzanne Schrandt, Director of Patient Engagement, and IQVIA's Cynthia Verst, President, Design and Delivery Innovation. For more information please visit www.patientsaspartners.org or contact us at service@tcfllc.org.
Medical research charities in the UK have been successfully integrating patient insight into their activities for over 10 years. In this session presented at the 2nd annual Patients as Partners Europe in January 2018, Claire Nolan, Research Involvement Manager, Parkinson's UK, and Chris MacDonald, Research Involvement Manager, Arthritis Research UK, explore a shift in attitiude towards pharmaceutical and medical research charity collaboration. They share how charities have developed their processes to strike a balance of delivering effective research outcomes whilst ensuring principled and meaningful patient involvement and how these experiences, resources, and processes can be used practically to support industry to put the needs and voice of patients at the centre of medicines development.
The 3rd annual Patients as Partners Europe will be presented January 28-29, 2019 in London, UK. Find more information here.
This 5 minute podcast summarizes what you can expect at the 3rd annual Patients as Partners EU conference. It is the only event in Europe that demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research.
It takes place January 28-29 at the Millennium Gloucester Hotel in the Kensington area of London. The program is co-chaired by GSK's Andrew Garvey, Global Patient Advocacy Lead and Servier's Dr Lode Dewulf, Chief Patient Officer. The conference kicks off with former professional English footballer and patient advocate, Geoff Thomas, in a keynote presentation on his journey through professional sports and his fight against cancer. For more information please contact www.theconferenceforum.org or contact us at service@tcfllc.org.
In this talk from the 5th annual Patients as Partners US conference, Beth Zaharoff, Director, Patient-Focused Clinical Trial Engagement of Tesaro will walk the audience through how they integrated patient input throughout multiple stages of the development process.
Other discussion points include: How Tesaro is working to eliminate some of the burdens inherent in clinical trial participationWhat patient focus means to Tesaro and why/how they decided to jump in the deep endTesaro focus groups and what they learned from the experts Join us this year at the 6th annual Patients as Partners US conference, taking place March 11-12, 2019 in Philadelphia.
Originally recorded at the 4th annual Immuno-Oncology 360° 2018 event, Dr Corey Langer, Director, Thoracic Oncology and Professor of Medicine for the Perelman Center for Advanced Medicine at the University of Pennsylvania, discusses data on Keytruda in combination with chemotherapy in non-small cell lung cancer.
This year, the University of Pennsylvania will be represented by Dr Marco Ruella, Assistant Professor and Scientific Director Lymphoma Program, Division of Hematology and Oncology, Department of Medicine and Center for Cellular Immunotherapies. Dr Ruella will be discussing the next steps for CAR-T therapy for cancer on day three during the Next Generation Cell Therapy Plenary
To join in on the discussion at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY!
In this podcast, originally recorded at the 4th annual annual Immuno-Oncology 360° 2018 event, Dr Axel Hoos, SVP, Oncology R&D, GSK, led a panel on The Future Value Generation in IO. Dr Hoos was joined by expert analyst Dr Andrew Baum, Head of Global Healthcare and Managing Director of Equity Research for Citi along with Dr David Grayzel, Partner of Atlas Venture, Dr Simeon George, Partner of SR One and Mark Simon, Partner of Torreya Partners. Key discussion points included: What is the most important IO event or trend that will carry us forward and shape the IO space?With the ever expanding range of indications, what is next and how do we get there?What have we learned from precision medicine and how can that be applied to IO?Which biomarker is next that will follow PDL1 and that will help guide the field in patient selection?With the many opportunities now with modalities, what do you think is a valuable next modality that could be important?With the maturing and evolving IO landscape, has that changed investment sentiment? For the latest news in immunotherapy, join us at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY.
Greg Simon, President at the Biden Cancer Initiative and Former Executive Director of the White House Cancer Task Force will reflect on the work of the Cancer Moonshot. Which provided the leadership to harness the millions of scientists and patients, powerful new therapies, and cultural changes needed to double our rate of progress against cancer.
He will also provide a progress report on the Biden Cancer Initiative which is now continuing this movement to double our rate of progress in preventing, detecting, diagnosing and treating cancer.
This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018.
For the latest news in immunotherapy, join us at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY.
Jeffrey Weber, Deputy Director at Laura and Isaac Perlmutter Cancer Center and Co-director of Melanoma Program and Head of Experimental Therapeutics at NYU Langone Medical Center, discusses the day to day management of, and the science around, IO adverse events that may help us understand how these drugs work. Including: The need to educate physicians about management of immune related adverse events with increasing penetration of checkpoint inhibitors into the communityThe relationship of these adverse events to outcome with checkpoint inhibitionThe relation of adverse events to other autoimmune diseases that are similar in nature This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018.
For more information on the IO360 conference and details for the 5th annual program taking place February 6-8, 2019 in New York, NY, please visit io360summit.com.
The BioCentury Report on Industry Trends covers how companies and academic investigators are driving innovations within immuno-oncology, including new targets, modalities and technologies, to address some of the field's biggest challenges. Some topics include: The broadening trend to harness the innate and adaptive arms of the immune system for immunotherapiesNew cell types beyond CAR-T and traditional T-cellsCombination strategies for neoantigens and other targets from the earliest stages of drug development This presentation, presented by Simone Fishburn, PhD, Editor, BioCentury Innovations, was given at the 4th Annual Immuno-Oncology 360° Event on February 7-9, 2018 in New York City.
Find more information at io360summit.com
IO360° brings together science, clinical and business under one roof to accelerate treatments to fight a wider range of cancers. This brief podcast gives you an overview on what you can expect at IO360°.
The three-day summit features 10 plenary sessions with over 80 speakers and includes ten plus hours of networking. There will be over 450 attendees.
Key benefits: Access to KOLs driving the sciencePartnership opportunities with all stakeholders in Immuno-OncologyPresentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology IO360° is chaired by Dr Andrew Baum, Citi along with Dr Axel Hoos, GlaxoSmithKline and Dr James Gulley, National Cancer Institute.
Learn more information about IO360° at www.io360summit.com
Take 10% off the regitration fee with code RADIO
The 8th Annual Partnership Opportunities in Drug Delivery (PODD) event will take place on October 18-19, 2018. PODD is designed with 3 purposes: To present a strategic level program for pharma and biotech biz development professionals with a thorough overview of the latest drug delivery technologies available along with an update on deals and opportunities.To provide drug delivery with a platform to present their technologies and get the latest insights on what the delivery and formulation needs are.To offer ample networking time, facilities and services for one-on-one meetings to establish new business contacts and enhance existing ones. PODD is chaired by Dr Barbara Lueckel, Head of Research and Technologies Partnering at Roche. MIT's Dr Robert Langer and Polaris' Amy Schulman, two dynamic entrepreneurs in biotech are the opeining keynotes in a fireside chat. Justin Wright, PhD, Global Head of Innovation, Novartis will provide an industry keynote. Also, Jeffrey Karp, PhD keynotes with Stories from Bioinspiration to drug delivery. Choice of delivery tech tracks and includes partnering support. More info: theconferenceforum.org
Host: Valerie Bowling, PODD Director
Can you imagine coming from a family of 21 kids in a small remote village in Africa with no running water or electricity and one day a snake bite changes your entire future and you end up a PhD student in WInston-Salem, NC? In this remarkable story, our guest Goodwell Nzou, PhD candidate in molecular medicine at the Institute at Wake Translation Science tells Valerie Bowling, Executive Director, the Conference Forum how he went from a village kid to an amputee to a band member that led him to a contest, a role in an Oscar winning documentary to a PhD candidate in a field that he hopes one day will allow him to grow back his own leg through regenerative medicine.
Schools cited in the podcast include:
Jairos Jiri Association
King George VI Centre
Wake Forest School of Medicine
Guest: Goodwell Nzou, PhD candidate in molecular medicine at the Inst at Wake Translation Science
Host: Valerie Bowling, Executive Director, PharmaTalk Radio and the Conference Forum
Podcast guest, Elise Felicione, who is currently a Scientific Collaborator at the Scripps Translational Science Institute is playing an integral role under the direction of Dr Eric Topol on a nation-wide initiative from the NIH. The initiative is called All Of Us, a US Precision Medicine program that aims to enroll a million Americans and follow them for 10 years, during which time participants will contribute biological, environmental, and lifestyle data. One-third of participants will participate virtually (not via a research site). The cohort will mirror the projected 2040 census. Individual pharma companies are never going to create cohorts like this, so the importance of this open source frame work that drug developers can tap into will be highly beneficial in serving the patient of the future.
Discussion points include: What is the All Of Us Research Program?Why does this matter to biopharmaceutical companies?How far along is the program and how to get invovled?What are your biggest challenges?How can biopharmaceutical companies get involved? For more information on the All of Us program, visit: https://allofus.nih.gov/
Elise will be speaking at DPharm on September 26th and will also have an exhibit booth to answer any questions are All of Us. For information on DPharm taking place September 25-26, 2018 in Boston. For information, please visit, www.theconferenceforum.org
Producer: Valerie Bowling, Executive Director, Pharma Talk Radio and DPharm
During his graduate work, Dr Benjamine Liu observed the many bottlenecks that get in the way of clinical trials slowing the development of new treatments for patients. This challenge inspired him to launch Trialspark.
Trialspark partners with doctors to create FDA compliant trial sites within their existing practices (like Airbnb), unlocking the 98% of patients and doctors not involved in trials today and democratizing access to research treatments. In this podcast discussion with Ben, we discuss how to reimagine clinical trials, entrepreneurism, the rise of Trialspark and reducing the barriers for patients and investigators.
Ben will be speaking at DPharm on September 26th in Boston with Dr Ulo Palm, SVP Global Drug Development Operations, Allergan on a case study to scale more efficient clinical trials.
For more information about Trialspark, visit www.trialspark.com
For more information about DPharm visit www.theconferenceforum.org
Producer: Valerie Bowling, Executive Director, Pharma Talk Radio and DPharm
Patients are at the center of research and their data is the foundation for clinical innovation. However, significant barriers exist that inhibit the secure and efficient sharing of patient data. In this podcast, Craig Lipset, Head of Clinical Innovation, Pfizer, Munther Barra, Head of New Clinical Paradigm, Pfizer and Aditya Kudumala, Principal, Deloitte discuss blockchain as a catalyst to significantly change how we can access and use data to improve patient lives. Where is the patient data storm going?
Discussion points include, but not limited to: Who owns my data and where it’s going?What are the interoperability challenges and progress?How can data be shared?How you can pull in your own health data?Where does blockchain fit in and how can it secure patient data? How blockchain gives us authentication without identification?Next steps? For more information on this topic and to get access to the Blockchain Opportunities for Patient Data Donation & Cinical Research, click here.
Craig will be leading an entire section on the democratization of patient data at DPharm on September 25-26 in Boston.
This 8 minute podcast gives you an overview on what to expect from the 8th annual DPharm conference. DPharm is the annual event in the US to get the best access to innovative ideas, especially disruptive ones, to advance clinical trials with a view to reducing the burden to patients and investigators.
DPharm 2018 is dedicated to all things digital, data science, patient data ownership and new approaches to optimize clinical operation systems.
DPharm is September 25-26 at the Boston Marriott Copley Place.
Chaired by:
Sylke Poehling, PhD, SVP and Global Head, Strategy, Portfolio & Clinical Operations, Pharma Research & Early Development, Roche
Andreas Koester, MD, PhD, VP and Global Head, Janssen Clinical Innovation, Janssen
Craig Lipset, MBA, Head of Clinical Innovation, Pfizer
For more information visit www.theconferenceforum.org
Producer: Valerie Bowling, Executive Director, DPharm
Welcome to the 5th annual Mobile in Clinical Trials podcast. In this quick fire podcast, you will get a brief overview on what to expect. The conference takes place in Boston on Sept 24th, the day before DPharm. It is researched and produced by the Conference Forum and is chaired by:
Daniel Karlin, MD Assistant Professor of Psychiatry, Tufts University and Former Head of Clinical, Informatics, and Regulatory Strategy, Digital Medicine, Pfizer Inc
Mobile and digital tools are the future of clinical trials and as the industry continues to transition into a data science industry with a responsibility to reduce patient burden, it is really important that we bring this conference to you to get the latest examples on what tools are available and who has used them and what are the lessons to engage patients?
For more information, visit www.theconferenceforum.org
Producers: Valerie Bowling, Executive Director, the Conference Forum and Jennifer Moran, Producer, the Conference Forum
Rational Combinations 360° addresses business aspects, clinical advancements and scientific data in IO combination strategies. The rapid advancement in our understanding of human cancer immunity and immunotherapy combinations is nearly impossible for individual scientists to comprehend. Only together, as an engaged and interactive scientific community, can we hope to enable a patient’s immune system to eradicate cancer.
Rational Combinations 360° addresses the following plenary topics over the course of 2 days: Discovery and Preclinical ScienceTranslational Science and Emerging BiomarkersOperationalizing IO CombinationsEmerging Clinical CombinationsEmerging Data Combinations in Clinical TrialsBusiness Aspects Dr Patrick Hwu, MD Anderson, Dr Axel Hoos, GSK and Dr Ian McCaffery, Janssen, together led the design of the 3rd annual program that includes more than 45 speakers and over 30 talks.
For more information about Rational Combinations 360°, visit, www.theconferenceforum.org. Be sure to use code TEML for a 10% discount. Thanks for listening.
How to Innovate in the Drug Delivery Space What does the innovation process look likeThe barrier to the innovation process and how to overcomethemSummary of disease spaceGood design and engineering practicesHow to salvage something that goes wrong?How do you find the unknown unknowns?Does it feel right? Uri Baruch
Head of Drug Delivery, Cambridge Design Partnership
This talk was given at the 2018 Drug Delivery West Meeting.
Opening talk at Drug Delivery West, 2018
Key Trends in Drug Delivery: Expert Perspective
Randall Mrsny, PhD
Professor's Chair, Department of Pharmacy and Pharmacology,
University of Bath
Patients as Partners Day 2 Session
How FARA and Horizon Pharma Partnered to Improve Clinical Development and Trial Design-Case Study
This session will feature how the Friedreich’s Ataxia Research Foundation collaborated with Horizon Pharma on aspects of clinical development and trial design to better understand patients living with the disease and how to better develop medicine to help manage their disease. Key areas of discussion include how they collaborated on the following:
• Focus groups to better understand drug administration • Clinical trial design to ensure feasibility and efficiency • Recruiting patients for clinical trials
• Open discussion at FDA meetings
Kyle Bryant
Director of the Bicycle Ride Fundraiser, rideAtaxia for the Friedreich’s Ataxia Research Alliance (FARA)
Robert Metz
SVP, Global Business Operations and External Affairs, Horizon Pharma
This talk was given at the Patients as Partners 2018 Meeting
There are many frameworks and models that exist from various organizations on aspects of patient engagement and may be challenging to navigate through when applying to your own initiatives. In this session, Takeda will walk the audience through how they used multiple patient engagement frameworks to create an internal R&D Patient Engagement Guide tailored for their drug development teams from discovery through marketed products. The audience will learn how the guide has help build support and a cultural shift for Takeda’s internal patient engagement initiatives and how it has helped each team at various phases of development with the following:
• Identifying what the patient engagement activities are at the different phases of development • How does patient engagement apply to the work I am doing?
• Identifying who is relevant to talk to, how to go about it
• What is the impact?
• Mapping the patient advocacy landscape
• Identifying what all the ways are that teams can learn from patients
• What you need to understand about patient advocacy groups before engaging with them • How to initiate relationships with patient advocacy
• Understanding where patients fit in your development, where online communities fit in, etc
• Implementing change and streamlining patient engagement initiatives internally
• Identifying each team’s key patient engagement issues
• Training teams on creating and documenting patient engagement plans
• Demonstrating how to integrate patient engagement plans with overall development plans • Helping initiate activities
Carol Meyer, R&D Patient Engagement Lead, Takeda Pharmaceuticals
This talk was given at the Patients as Partners 2018 Meeting
How Patient Research Advocates are Driving R&D: A Patient Case Study
In this session, patient and research advocate, Geraldine Blavat will walk the audience through 10 steps on how patient input is integrated through the entire clinical development continuum including:
Developing the Study Concept
Secure Funding
Preparing the Study Protocol
Creating Study Procedure
Implementing the Study
Monitoring the Study
Analyzing the Data and Interpreting Results
Disseminating Study Information
FDA Review and Approval
Post Approval Studies
This talk was given by Geraldine Blavat, Parkinson’s Foundation Research Advocate and Karlin Schroeder, Director, Community Engagement, Parkinson’s Foundation
Join us this year at the 6th annual Patients as Partners US event, taking place March 11-12, 2019 in Philadelphia.
John Patton, PhD, Chief Executive Officer and Chairman with Dance Biopharma and Ann Daugherty, PhD, Senior Manager, Drug Delivery with Genentech present the closing talk at Drug Delivery West, held May 21-22, 2018 in San Francisco. In this talk they discuss the lessons learned from drug delivery, what to be aware of in the future, and how to improve drug delivery methods. The next conference in Drug Delivery is the 8th annual PODD: Partnership Opportunities in Drug Delivery on October 17-18, 2018 in Boston. For more information, visit www.theconferenceforum.org
Nanotechnology Keynote Address given by Omid Farokhzad, MD, Professor, Harvard Medical School and Director, Center for Nanomedicine, Brigham and Women's Hospital
Omid Farokhzad is an inventor of more than 145 issued / pending patents. These for the launch of four biotechnology companies: BIND Therapeutics (acquired by Pfizer) Selecta Biosciences, Tarveda Therapeutics (formerly Blend Therapeutics) and Placon Therapeutics (spin-out from Tarveda), which are translating the aforementioned academic innovations toward commercialization and societal impact. Dr Farokhzad has served in various capacities on the Board of Directors and the Scientific Advisory Board of these companies.
In his lecture, Dr Farokhzad will be focusing on the emerging understanding of the nano-bio interactions and its implications for developing safer and more effective therapeutic and diagnostic modalities. Nanotechnology enabled drug delivery approaches for predictive and personalized medicines will be discussed with emphasis on the lessons that been learned during their bench-to- bedside translation.
Omid Farokhzad, MD
Professor, Harvard Medical School and Director Center for Nanomedicine, Brigham and Women's Hospital
This talk was given at the 7rth annual Partnership Opportunities for Drug Delivery (PODD) Meeting in 2017.
Panel: Utilizing a Device Platform Technology across Multiple Therapeutic Categories
Most pharma and biotech companies realize the need and benefit of having a platform device technology. The challenge then becomes figuring out how to utilize the device to deliver different types of drugs for various indications such as rheumatoid arthritis, cancer, and rare diseases.
Moderator: Paul Jansen
Former Associate VP Sanofi and Board Member and Senior Advisor, Haselmeier
Panelists: Donna French, PhD
VP Drug Delivery and Device Development, MedImmune
Michael Graffeo, MBA
VP Business Development, Drug Delivery Insulet
Rajan Patel
CEO, io Life science
Srini Sridharan, PhD
Group Director, Materials Science and Engineering, BMS
The Keynote was given at Partnerships Opportunities in Drug Delivery 2017 by
Lars Rebein Sorensen
Former President and CEO, Novo Nordisk
with
Barbara Lueckel, PhD
Global Business Development Director Roche Partnering Innovation, Roche
The expert panel of scientific leaders from industry will discuss current formulation and delivery challenges for therapeutic areas (ophthalmology, immunology, oncology infectious disease, and neurodegenerative area disorders). Each panelist will address a specific disease area and discuss the role of drug delivery in the treatment of disease. The panel will also cover currently available delivery technologies and where improvement is needed.
Moderator: Ann Daugherty, PhD
Senior Manager, Drug Delivery, Genentech
Panelists: Marianne Ashford, PhD
Senior Principal Scientist, Pharmaceutical Sciences, AstraZeneca
Advait Badkar, PhD
Senior Director Novel Delivery Technologies, Bio Therapeutics, Pfizer
Marian Gindy, PhD
Executive Director Pharmaceutical Sciences, Merck
Kapil Gupta, PhD
Associate Director, Protein Pharmaceutical Development, Biogen
Evan Thackaberry, PhD, DABT
Headm Preclinical Development, Ra Pharmaceuticals
This talk was given on Day 2 of the Partnership Opportunities in Drug Delivery (PODD) 2017 Meeting.
The expert panel will address the scientific and business challenges and opportunities in this space. Panelists will discuss the difficult nature of providing therapies for diseases of the CNS, covering both device and chemistry-enabled technologies. They will also address questions such as: Can devices take us where chemistry has not?What advances being made in the field of chemis conjugation technologies?Why is intrathecal, intracerebroventricular and intraparenchymal delivery relevant for CNS and other therapeutic categories? Finally the panel will talk about lessons learned, particularly with regard to scientific vs. business rationale.
Introduction by:
PJ Anand
Founder President and CEO, Lifesciences
Moderator: Lisa Shafer, PhD
Senior Director New Devices and Bioelectronic Technologies Teva Pharmaceuticals
Panelists: Dan Abrams, MD
CEO, Cerebral Therapeutics, LLC
Krystof Bankiewicz, MD, PhD
Director, Interventional Neuro Center UCSF
Mikhail "Misha" Papisov, PhD
Associate Professor Harvard Medical School and Massachusetts General Hospital
Lamya Shihabuddin, PhD
R&D Cluster Head Neuro Rare Diseases, Sanofi R&D
This Discussion took place on Day 2 of the Partnership Opportunities in Drug Delivery (PODD) 2017 Meeting.
Drug Delivery Needs in Oncology
Due to the increasing number of parenteral biologic therapies that are administered intravenously, the already high pressure on infusion capacity and healthcare resources is expected further increase. A change from intravenous to subcutaneous dosing has been shown to reduce dosing complexity and overall drug administration related costs. There is keen interest in technologies that facilitate subcutaneous administration and potentially enable drug administration in the home setting. Led by: Beate Bittner, PhD Portfolio Strategy Director, Roche Panelists: Panel: H Janice Adkins, MBA Associate Director Marketing, BD Medical The exp Pharmaceutical Systems, North America EMEA Ulrich Bruggemann Head Academics and Innovation, Global Medical Devices of the Development, Sanofi US Shawn Davis, PhD Director, Technology Strategy and Innovation, Amgen Declan Reilly Section Head, Device Engineering, Device Development PTDE-D, Roche Andrew J Yee, MD Medical Oncologist, Massachusetts General Hospital Cancer Center This presentation took place at the 7th Annual Partnership Opportunities in Drug Delivery (PODD) 2017.
Track 2: Clinical Operations for IO Trials
This section is designed for clinical trial operation executives who want to learn what it takes to execute an IO clinical trial. This is an
excellent opportunity to walk through the building blocks of IO clinical trial operations and discuss pitfalls and lessons learned.
Plenary Chair:
Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck
This discussion was presented at the 2018 Immuno-Oncology 360° Meeting.
Building Blocks of IO Trials: This talk will consist of 7 perspectives that identify operational aspects of IO trials, including a patient
perspective, site management, 3rd party component, clinical supply chain, a PI perspective, data management and project
management. The collaborative talk concludes with a panel discussion and Q&A.
This Discussion was presented at the 2018 Immuno-Oncology 360° Meeting.
Endpoints News Industry Report on IO Collaborations and Trends
In this episode of Pharma Talk Radio, John Carroll, Editor-in-Chief of Endpoints News, reviewed the build up of the immuno-oncology space over the past few years at the IO360° conference that took place February 2018. Mr Carroll discussed the impact the large amount of money and the extraordinary numbers that have been invested in the space, have had on collaborations. He also shed light on the natural limitations and boundaries that are going to impact IO R&D, along with exploring China as an upcoming major player in the IO space.
About John Carroll:
John Carroll is a biotech analyst with 38 years of prize-winning experience in journalism. For more information visit: https://endpts.com/
This talk was given at Day 2 of Immuno-Oncology 360° meeting in 2018.
Save the Date: The 5th annual Immuno-Oncology 360° program will take place February 6-8, 2019 in NYC. For more information visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/
Mobile Podcast Series #2
CTTI Findings are in from their Mobile Clinical Trials Program: Recommendations on Novel Endpoints
CTTI's Mobile in Clinical Trials program was launched three years ago to propose recommendations that clarify the pathway for developing novel endpoints for use in clinical trials from data generated using mobile technology. Jennifer Goldsack shares recommendations and insights from their findings on: Developing an internal process for identifying endpointsStrategies for reducing friction throughout the processExecuting the processThe science required to validate an endpointA suite of tools developed in the process to help facilitate implementation The next Mobile in Clinical Trials conference is September 24 in Boston. Mobile is the annual update on not only the latest progress in applying mobile/digital tools to clinical trials, but how and when to do this and for what benefit.
Speaker: Jennifer Goldsack, MChem, MA, MBA, CPHQ, Clinical Project Manager, CTTI
Producer: Valerie Bowling, Executive Director, Mobile in Clinical Trials
Podcast on Mobile in Clinical Trials Series #1
How a Mobile App Can Offer Unique Value in Assessing Patient Reported Outcomes
Crescendo Biosciences's CIO, Alex Bangs, reports on how a human-centered design approach was used to create MyRA, an award-winning app for patients living with RA. This podcast comes from the 2017 Mobile in Clinical Trials US event.
The next Mobile in Clinical Trials conference is May 15-16 in London and then September 24 in Boston. Mobile is the annual update on not only the latest progress in applying mobile/digital tools to clinical trials, but how and when to do this and for what benefit.
Speaker: Alex Bangs, Chief Information Officer, Crescendo Biosciences
Producer: Kim Chin, Marketing Director, Mobile in Clinical Trials
The Chief Medical Officer Summit is delighted to present a podcast featuring the Keynote Fireside Chat with Michael Rosenblatt, MD, on Lessons Learned from the Journey of a CMO Leader
In this session, Dr Rosenblatt, former Merck CMO, will share his insights on career path decision-making and will compare the experiences and lessons learned from being the CMO on the drug development side versus the biotech investor side of the industry. Moderated by CEO of Evelo Biosciences, Simba Gill, MBA, PhD.
Join us at the 6th annual CMO Summit, the largest annual gathering for physicians to exchange best practices in clinical development within the confines of the emerging biotech space. We already have 50 CMOs confirmed to attend. You won't want to miss out on this event.
Producer: Valerie Bowling, Executive Director, Chief Medical Officer Summit
The Chief Medical Officer Summit is delighted to share a podcast featuring a presentation prepared by Drs Alison Bateman-House and Arthur Caplan of NYU's Division of Medical Ethics on the topic of:
Developing a Pathway for Compassionate Use Cases What should the CMO do when they receive a request?What's the role of the CMO, the FDA and the IRB?Lessons learned from Janssen Case StudyHow do you scale down for a biotech?Potential modelsCan the process be accelerated? Join us at the 6th annual Chief Medical Officer Summit, the largest annual gathering for physicians to exchange best practices in clinical development and R&D within in the confines of the emerging biotech space. We already have 50 CMOs confirmed to attend, and you will not want to miss out on this event.
Speaker: Alison Bateman-House, PhD, MPH,Assistant Professor, Division of Medical Ethics,NYU
Producer: Valerie Bowling, Executive Director, Chief Medical Officer Summit
This podcasts gives you an overview on what to expect for the 2018 Chief Medical Officer Summit in a nutshell. The concept of the CMO Summit came from MPM Capital’s Dr Elizabeth Stoner, who told us that there is a deep need for a Summit that is designed for CMOs and heads of R&D in the emerging biotech space, specifically, where we can cover all the key issues affecting R&D decisions together with business development issues. The program takes place on May 7th and 8th at the Omni Parker House in Boston and we already have over 50 CMOs committed to attending.
The program is co-chaired by Julie Krop, MD, CMO, EVP, Clinical Development & Regulatory Affairs, AMAG Pharmaceuticals, Inc, and Jim Roach, MD, FACP, FCCP, CMO, Pulmatrix.
The 6th Annual Chief Medical Officer Summit is produced by the Conference Forum. The Conference Forum is life science industry research firm that carefully and meticulously presents strategic level programming. As with all Conference Forum events, you can expect prominent networking. To learn more about the event, visit www.theconferenceforum.org. Be sure to use code TEML for a 10% discount. Thanks for listening.
In this three minute podcast, you get an overview of one of the hottest topics we are covering in a full day 2nd annual event on Clinical Research as a Care Option. (CRAACO). Making clinical trials a care option is arguably the greatest challenge we can collaborate on in bringing patients closer to clinical trials. CRAACO takes place on April 11th at the Boston Marriott Cambridge. We look at how to integrate clinical research into the overall continuum of patient care and ask, how do we make clinical research a care option?
The program is co-chaired by Jeff James CEO, Wilmington Health and Katherine Vandebelt, Chief Ecosystem Officer at Reify Health.
The 2nd annual CRAACO event is produced by the Conference Forum. The Conference Forum is life science industry research firm with veteran researchers, who carefully and meticulously present strategic level programming. As with all Conference Forum events, you can expect networking activities and prominent networking. To learn more about CRAACO, visit www.theconferenceforum.org. Be sure to use code TEML for a 10% discount. Thanks for listening.
This podcast gives you a five minute overview of the 3rd annual Clinical Trial Collaborations conference, otherwise known as CTC.
CTC is a strategic level event focused on arguably the most important change in transforming drug development: How and who we collaborate with to drive better clinical trial outcomes?
CTC is ideal for people working in clinical trial operations, who are involved with external relationships or need to be involved with external relationships and want to see examples of strategic and creative solutions to successful collaborations and who we need to be collaborating with next?
The program takes place on April 9th – 11th at the Boston Marriott Cambridge and is divided into three parts, one on each day of the event. Part I deals with new advancements in clinical trial collaborations, current examples to challenge us, and progress. Part II focuses on strategic collaborations, virtual trials and next generation monitoring. Part III addresses how do we bring clinical research closer to patients and vice versa.
CTC is co-chaired by Ken Getz, Director of Sponsored Research, Tufts CSDD, Murray Abramson, MD, VP, Clinical Operations, Biogen, Jeff James, CEO, Wilmington Health and Katherine Vandebelt, Chief Ecosystem Officer, Reify Health.
Use code TEML for 10% off and for more information visit, www.theconferenceforum.org.
The Mobile in Clinical Trials conference comes to Europe for the first time on May 15th and 16th at the Millennium Gloucester Hotel in London. If you work or want to work with mobile and digital technologies to make clinical trials more efficient and reduce patient burden, we highly recommend this conference for you. Using our past four years of experience in the US, we are able to combine the best examples of mobile and digital optimization in clinical trials from the US with examples from the UK and other parts of Europe.
Mobile in Clinical Trials Europe is chaired by Pfizer’sDr Daniel Karlin with a pharma speaking faculty of who’s who in leading mobile in clinical trials. VIP Guests include Verily Life Sciences’Dr Tushar Parlikar on how Verily’s studywatch is tackling scalability of wearables in clinical trials and Vodafone’s Dr Nuria Oliver, who gives a visionary keynote to address data-driven decision making.
Mobile in Clinical Trials Europe is produced by the Conference Forum. The Conference Forum is life science industry research firm with veteran researchers, who carefully and meticulously present high quality programming. As with all Conference Forum events, you can expect networking activities and prominent networking.
To learn more, visit www.theconferenceforum.org. Be sure to use code TEML for a 10% discount. Thanks for listening.
Dr Roslyn Schneider, Global Patient Affairs Lead at Pfizer, speaks with Valerie Bowling, Executive Director, Patients as Partners, in a podcast interview on patients at the center of clinical research. Dr Schneider, better known as Roz, helps drive patient centricity and the integration of the patiemt voice throughout the development of medicines at Pfizer. She gives us a brief history of the evolution of the involvement of patients in clinical research, next steps, and how patients and industry can collaborate.
Roz, together with Suzanne Schrandt, Director of Patient Engagement at the Arthritis Foundation, will co-chair the 5th annual Patients as Partners conference, March 15-16 at the Rittenhouse Hotel in Philadelphia. For more information, visit theconferenceforum.org.
DPharm Podcast Series #5
Reducing the Burden of Type 1 Diabetes through a Model of Democratized R&D
Patient advocate star, Dana Lewis, founder of OpenAPS delivers a powerful session at DPharm on an idea to reduce the burden of type 1 diabetes with a smart system she created through open soucre. Learn how she drive the idea and creation of the "Self driving car for diabetes".
The next DPharm conference is September 25-26 in Boston. DPharm reports on innovation and disruptive innovation to advance clinical trials and supports the community behind the movement.
Speaker: Dana Lewis, Creator, Do-It-Yourself Pancreas System and Founder, OpenAPS
Producer: Valerie Bowling, Executive Director, DPharm
5th Annual Patients as Partners What to Expect Overview Podcast
Officially approved by Patients Included, Patients as Partners is the only program in the US that truly demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. Taking place March 15-16 in Philadelphia, the focus of this year’s program is on turning discussion into action, and Kate Woda, the Conference Director has worked meticulously with the advisory board and members of the speaking faculty both in person and over the phone to make this happen. Valerie Bowling, Executive Director of the Conference Forum gives listeners an overview in a nutshell on what to expect.
Co Chairs:
Roslyn Schneider, MD Global Patient Affairs Lead, Pfizer Medical
Suzanne Schrandt, JD (Newly confirmed!) Director, Patient Engagement, Arthritis Foundation
Patient Keynote: Stefanie Joho, Cancer Survivor, Advocate and Consultant
For more information, visit www.theconferenceforum.org
DPharm podcast series # 2
MIT Professor, Dina Katabi, PhD gave one of the best talks on in home non-intrusive patient monitoring at DPharm 2017 and provided a demo of technology that uses ambient radio signals to monitor a patient’s gait, falls, breathing, heart rate and even sleep, all without putting any sensor on the patient’s body. Find out how they have used the technology to redefine clinical endpoints and pushed clinical trials to the home. The next DPharm conference is September 25-26 in Boston. DPharm reports on innovation and disruptive innovation to advance clinical trials and supports the community behind the movement.
Speaker: Dina Katabi, PhD MacArthur Fellow, Andrew & Erna Viterbi Professor, MIT, and Director of MIT Center for Wireless Networks and Mobile Computing
Producer: Valerie Bowling, Executive Director, DPharm
The Conference Forum presents a 1 day meeting on Immuno-Oncology Clinical Trial Operations, February 8th at the Roosevelt hotel in NYC. It’s part of the IO360 conference, which runs over three days from Feb 7th through the 9th. The OPERATIONS portion of this conference is offered as a stand alone program. This podcast gives a brief summary of what to expect.
The morning provides first hand reporting on new trends and emerging technologies. The afternoon goes through 7 components including: the patient perspective, site management, 3rd parties, clinical supply chain, a PI perspective, data management and project management.
Many thanks to Andy Lee, SVP, Head of Global Clinical Trial Operations at Merck for his guidance on the topic and for bringing his team to help us understand the building blocks, providing a really unique insight into obtaining the necessary precision IO trial operations require.
For information, go to www.theconferenceforum.org
The 2nd annual Patients as Partners EU is the only conference in Europe that demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. In this short podcast, Valerie Bowling, executive director at the Conference Forum gives a brief summary of what to expect at this conference and runs through the highlights.
Chairs:
Tony Hoos, MD, PhD, MBA Head of Medical, Amgen Europe
Andrew Garvey Global Patient Advocacy Lead, GlaxoSmithKline
The premier event was attended by roughly 150 people and the program brings back: Accreditation by Patients Included “Ask the Patient” program to give attendees the opportunity to meet a group of individuals who’ve experienced a clinical trial.Attendee “Tool-Box” and an assortment of specially designed materials to help capture ideas. Patients as Partners EU is co-produced with industry, patient advocacy and government to establish a well-rounded program that addresses the needs of all stakeholders seeking to implement and advance patient involvement across the entire clinical development continuum with the goal of driving greater efficienices. It is attended primarily by pharmaceutical operation and advocacy executives and patient advocacy trusts. There is a small exhibit room with tons of networking.
January 23-24, 2018 Radisson Blu Portman Hotel, London, UK
For more information visit www.theconferenceforum.org
Special rates for trusts and use code TEML for 10% off.
If you are interested in hearing the 2017 drug delivery landscape year in review in 2017, please email service@tcfllc.org
Chair of the Partnership Opportunities in Drug Delivery (PODD) event, Dr Barbara Lueckel, Head of Research and Technologies Partnering at Roche, presents an annual year-in-review of the drug delivery landscape from 2016. Dr Lueckel’s opening remarks are a highlight of PODD every year, and we’re excited to have her return as program chair for the 2018 event, coming up on October 17-18 in Boston. We will post Dr Lueckel's 2017 overview of the drug delivery market shortly.
About Dr Lueckel:
Since end of 2014, Barbara leads the Research & Technologies Partnering (RTP) team belonging to the Innovation Partnering group in Roche Partnering. RTP team members lead evaluations & negotiations with biotech companies in an effort to enhance the discovery efforts of Roche’s Research & Early Development organization (pRED) across all of its therapeutic areas – either applying technology platforms to targets or molecules of interest to pRED (including drug delivery), or collaborating on early stage molecules. RTP team members are also responsible for alliance management of the resulting license agreements. Barbara joined Roche in 2007 as a Global Drug Delivery Evaluator, and transitioned to the Research & Technologies Partnering team in 2012. She is trained as a pharmacist with a PhD from the University of Basel.
Pan American Games Champion, Olympian and World Championship silver medalist, Jennifer Goldsack, became a world-class athlete while working and studying at the University of Oxford. How did she do it? She recently shared her story with DPharm Director, Valerie Bowling, discussing the lessons she learned from her Olympic experience and how she uses them in her professional life at the Clinical Trials Transformation Initiative (CTTI).
Ms Goldsack manages the development and implementation of Clinical Trials Transformation Initiative (CTTI) projects. In collaboration with team leaders, she creates project plans and budgets, and manages the implementation of those plans. She earned her master’s degree in chemistry from the University of Oxford, England, her masters in the history and sociology of medicine from the University of Pennsylvania, and her MBA from the George Washington University. Additionally, she is a certified Lean Six Sigma Green Belt and a Certified Professional in Healthcare Quality.
Ms Goldsack spent five years working in research at the Hospital of the University of Pennsylvania, first in Outcomes Research in the Department of Surgery and later in the Department of Medicine. More recently, Ms Goldsack helped launch the Value Institute, a pragmatic research and innovation center embedded in a large academic medical center in Delaware.
Ms Goldsack recently presented at the Mobile in Clinical Trials conference organized by the Conference Forum. For more information, visit: www.theconferenceforum.org.
Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all facets of IO including: Discovery / Preclinical ScienceTranslational ScienceClinical DevelopmentBusiness AspectsInvestor RelationsEmerging TechnologiesBiomarkers / DiagnosticsTrends in the Field Dr Axel Hoos, GSK and Dr James Gulley, NCI, together led the design of the 4th annual Immuno-Oncology 360° program to include 45 speakers and over 30 talks. Save the date: February 7-9, 2018 in New York City.
The Conference Forum is pleased to share a podcast featuring keynote speaker and world renowned customer service expert, Dr Chip Bell who spoke at the 6th annual DPharm: Disruptive Innovations to Advance Clinical Trials on the topic of service in clinical trials.
To truly service our patients, we need to understand service together with science. Can service be a disrupter in clinical research? In this keynote, Dr Bell tells us how to think like a service industry, why it’s worth it for R&D and how to get started. Dr Bell gives the listener practical insights on how to give patients a great experience. Although this podcast is primarily focused on serving patients in clinical research, you will find that hospitals and physician offices/medical groups will also benefit.
The 8th annual DPharm conference will continue to cover service, but through a patient perspective. DPharm 2018 takes place September 25-26 in Boston. For more information, www.theconferenceforum.org
About Dr Chip Bell:
Dr Bell is considered a world-renowned authority on customer loyalty and service innovation. He has authored eight national best-selling books. For more information visit, www.chipbell.com
Originally recorded during the 4th annual Patients as Partners US event held in Philadelphia, March 2017, Bristol-Myers Squibb’s Mary Stober-Murray moderates this multi-stakeholder panel to discuss what patients truly want when it comes to clinical care and patient involvement. Patients John Creveling, a Parkinson’s Foundation Research Advocate, and Deb Maskens from the International Kidney Cancer Coalition, join her and representing the industry perspective are Paul Graves from Takeda Pharmaceuticals and Dr Michelle Vichnin from Merck.
Closing the gap between clinical care and patients wants/needs:
• Ask patients what’s going on in their lives.
• Ask patients what their goals are.
• Because no one asks patients these questions, the result is they get care that’s aligned with what the doctor thinks is clinically relevant, even though it may be completely out of context to what is important to the patient.
What patients want and how pharma can help:
• Identify what patients and industry want respectively in terms of patient involvement and why that is meaningful for each.
• What can we do to enhance this across the development pipeline?
• What is getting in the way? Identify hurdles.
• How can we work through this collaboratively?
Initially developed out of the first DPharm event, the Patients as Partners US program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 5th annual Patients as Partners US will be March 15-16, 2018, in Philadelphia.
Internationally recognized digital health expert, Donald Jones, MBA, Chief Digital Officer at Scripps Translational Science Institute, shares his insights on the digital clinical trial landscape and the urgent need to pair digitization with drug products for patients during his keynote address from the 2016 CMO Summit.
The Chief Medical Officer Summit is designed for CMOs and R&D Leadership from small to mid-size life science companies. The 6th Annual CMO Summit will be held May 7-8, 2018, in Boston.
In this multi-stakeholder session from the 4th annual Patients as Partners US meeting, patients, advocates, industry and nonprofit organizations come together to discuss how they partnered and the outcomes of those partnerships.
• What’s the roadmap?
• What are the ways you have partnered with industry?
• What are some best practices or rules of engagement?
• How can the pharma industry better serve patient advocacy organizations?
• How are we creating and ruthlessly maintaining transparency and trust?
• Addressing global models of patient engagement
• Big companies are working in global environment and the Patient Engagement issues are quite different culturally, whether it’s China, Japan, Asia. What are the unique challenges and opportunities in countries outside US and EU?
Moderated by Lori Abrams, Director, Diversity and Patient Engagement, Bristol-Myers Squibb, panelists included: Stephanie Christopher, Program Manager, Patient Centered Benefit-Risk, Medical Device Innovation Consortium; Lauren McLaughlin, Associate Director, Research Partnerships, The Michael J Fox Foundation for Parkinson’s Research; Suzanne Schrandt, JD, Director, Patient Engagement, Arthritis Foundation; Nirmala Singh Steering Committee, Patient Focused Medicines Development and Former Patient Engagement Director, National Kidney Foundation.
The 5th annual Patients as Partners US will be held March 15-16, 2018 at The Rittenhouse, Philadelphia, PA, USA.
Adapted from the 2016 Chief Medical Officer Summit keynote address, Dr Akshay Vaishnaw, who serves as EVP of R&D and CMO at Alnylam Pharmaceuticals, tackles the challenges and opportunities in pursuing a new therapeutic modality from its inception.
The Chief Medical Officer Summit is designed for CMOs and R&D Leadership from small to mid-size life science companies. The 6th Annual CMO Summit will be held May 7-8, 2018, in Boston.
At the 2017 Partners Europe event in London, Nicholas Brooke, Chief Executive, Patient Focused Medicines Development (PFMD) and Jan Geissler, Director, European Patients’ Academy on Therapeutic Innovation (EUPATI) call on industry to partner with patients in the development and lifecycle of medicines.
The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.
Dr Axel Hoos, GSK, leads a panel discussion on Trends and Collaborations in the Immuno-Oncology Space, featuring Dr Ramy Ibrahim, VP and Head of R&D, Parker Institute for Cancer Immunotherapy; Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs, Cancer Research Institute; Dr Daniel Chen, VP, Global Head of Cancer Immunotherapy Development, Genentech; and David Wholley, MPhil, Director, Research Partnerships Division, Foundation for the National Institutes of Health.
The 4th Annual IO360° conference will take place February 7-9, 2018 in New York City.
At the inaugural Patients as Partners Europe event, Duncan Arbour from inVentiv Health explores the ‘how’ and ‘when’ for involving patients within clinical and commercial to enhance the development and delivery of innovative therapies.
The patient voice as a strategic driver is being included much earlier in the development process than ever before. In this session, pharmaceutical, biotech and device companies will gain insight into the value of smarter patient integration. Key focus areas include:
• The critical shift from drug-centric to patient-relevant
• Pivotal patient touch points throughout clinical development and launch planning that will maximize both clinical and commercial outcomes
• Positive impact of integration on efficiency and commercialization
The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.
Alastair Kent, Director of the Genetic Alliance UK, talks about how patients can and are influencing policy within the EU.
The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.
Originally presented during the business aspects plenary session at Immuno-Oncology 360° 2017, Dr Axel Hoos of GSK discusses business models for complex science.
Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. Dr Hoos returns as lead advisor, as well as moderating a talk called, "Investor Roundtable: The Role of IO within Large Pharma - Where Does it Stand?" with panelists from Citi, Atlas Venture, New Enterprise Associates, and SR One Ltd.
Chief Medical Officer at nanoString Technologies, Dr Alessandra Cesano, brings to light the increasingly critical role of predictive biomarkers in cancer immunotherapy, originally presented during the translational science and new technologies session from 2017’s Immuno-Oncology 360° conference.
Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.
About Dr Cesano:
Alessandra Cesano, MD, PhD has served as CMO at nanoString since July 2015. Prior to joining the company, Dr Cesano was Chief Medical Officer at Cleave Biosciences, Inc. From 2008 to 2014, she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc, where she built and led the R&D groups, while providing the overall clinical vision for the organization. In addition, Dr Cesano has held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Dr Cesano spent 12 years researching tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center at the University of Pennsylvania. She also holds membership in several professional and scientific societies, and has been an author on over 100 research publications.
Originally recorded during a panel session at the 2017's Immuno-Oncology 360°, Mark Simon of Torreya Partners moderates the conversation around issues, controversies, and other important business aspects of IO. He's joined by IO360° lead advisor and SVP at GSK, Dr Axel Hoos, Dr Robert Ang of Neon Therapeutics, Dr Jeffrey Bockman from Defined Health, Dr Jeffrey Legos from Novartis Pharmaceuticals, and Dr Chandra Ramanathan at Bayer Healthcare.
Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.
Originally recorded at the inaugural Patients as Partners Europe event, held in London in February 2017. Patient, industry, and regulatory perspectives are provided by Alastair Kent of Genetic Alliance UK, Dr Anton Hoos of Amgen Europe, and Isabelle Moulon of the EMD as they discuss on innovative ways of to include patient involvement in medicines development.
The Patients as Partners Europe program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 2nd annual Patients as Partners EU event will be held January 23-24, 2018 at Radisson Blu Portman Hotel, London, UK.
Originally recorded during the 3rd annual Immuno-Oncology 360° in February 2017, this panel discussion addresses clinical challenges within immuno-oncology. One of the IO360° lead advisors, Dr James Gulley of the National Cancer Institute, moderates the session between Merck’s Dr Roy Baynes, nanoString Technologies’ Dr Alessandra Cesano, MD Anderson’s Dr Patrick Hwu, and inVentiv Health’s Robert Millham.
Dr Hwu and Dr Baynes are also speaking on the 2nd annual Rational Combinations 360° program in June 2017, which is an exciting meeting dedicated to combination therapy in IO.
Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.
During the preclinical science plenary session from 2017's Immuno-Oncology 360° conference, Dr Charles Drake's talks about "Sequencing of Combination Agents."
Dr Drake is Director, Genitourinary Oncology and Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center. Previously, he was an associate professor of oncology, urology and immunology at the Johns Hopkins School of Medicine. He also serves as Co-Director of the Prostate Cancer Multidisciplinary Clinic. His areas of expertise include immunotherapy and the diagnosis and treatment of cancers of the prostate, kidney, bladder and testes.
Dr Drake graduated with a BS in electrical engineering and MS in biomedical engineering from Rutgers University in Piscataway, NJ. He then received a PhD in immunology from the National Jewish Center for Immunology, and in 1997 completed an MD at the University of Colorado Health Sciences Center. He conducted an internal medicine residency on the Osler Service at Johns Hopkins, and in 2002 he completed a fellowship in medical oncology, also at Johns Hopkins. He joined the Johns Hopkins faculty as an assistant professor in 2002.
Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.
At 2016's Rational Combinations 360° meeting, Dr Patrick Hwu of MD Anderson Cancer Center delivered a keynote address on the future outlook behind combination immunotherapy. Dr Hwu addresses innovations behind combination therapy, specifically focusing on what’s next after checkpoint combinations and whether combination of adoptive T-cell therapy and anti-checkpoint inhibitor therapies are the next wave.
Dr Hwu serves as a lead advisor for the 2nd annual Rational Combinations 360° meeting, which takes place June 28-29, 2017, at the The New York Academy of Medicine. Preview the program agenda, including Dr Hwu's plenary session on "DE-RISKING OF COMBINATION IMMUNOTHERAPIES."
We are delighted to bring the Patients as Partners US event to Europe on February 6-7 in London. We would like to thank our European attendees at the US conference for challenging and encouraging us to bring the conference to Europe. The goal of creating patient centricity as the ecosystem within pharma can not be achieved without patient involvement.
Patients as Partners Europe is accredited by Patients Included and addresses what matters most to patients to enable them to engage in clinical research.
Patients as Partners EU is co-produced with patients, industry, academia, government and nonprofit organizations to establish a well-rounded program that addresses the needs of all stakeholders seeking to implement and advance patient involvement across the entire clinical development continuum.
Each session seeks to put ideas into action and must demonstrate the what, where, when and how behind the topic. This radio blog post provides a seven minute overview on what to expect at the conference. For more information about the conference, visit, www.theconferenceforum.org.
The 3rd annual DPharm Europe: Disruptive Innovations to Advance Clinical Trials event is led by Co-Chairs Dr Sue Collier (GSK) and Dr Jeff Kasher (Patients Can’t Wait). This radio blogcast gives a five minute overview of the event, which presents global case studies on: Real World Clinical Trial Strategies and ResultsNew Leadership in Driving Clinical Trial InnovationStrategies to Validate the Siteless TrialCommunity Outreach and Education in Clinical TrialsNew Financial ModelsPatient Involvement and EngagementBrexit Update and Potential Impact on R&DProtocol SimulationAdaptive Trial Model DPharm EU takes place at the Millennium Hotel in London on February 8-9, 2017. For more information, visit www.theconferenceforum.org
The 3rd annual Immuno-Oncology 360° event takes place February 1-3, 2017 in NYC. Lead advisors, Dr Axel Hoos (GSK) and Dr James Gulley (NCI) co-present a program that provides a 360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated. In this brief radio blog post, get a five minute overview on what to expect at IO360 2017! For more information on the entire event and speaking faculty, visit, www.theconferenceforum.org
Members of the DPharm team engage in an informal conversation to highlight what's happening in innovation and the latest thinking to disrupt clinical trials at the 6th annual event. Also discussed is a brief history of how this conference dedicated to applying disruptive thinking to clinical trials came to be. This conversation is well worth listening to if you plan to attend DPharm or want to get a sense of the quality and depth this program brings to clinical trial executives.
DPharm takes place September 20-21, 2016 at the Fairmont Copley Plaza Hotel in Boston. Also featured on September 19 is a full day on Mobile Applications to Enhancing Clinical Trials.
DPharm Link for More information or to Register:
http://theconferenceforum.org/conferences/disruptive-innovations-us/overview/
Host: Valerie Bowling, Executive Director, DPharm
Guests:
Meredith Sands, Executive Director, Business Development, DPharm
Elizabeth Bard, Business Development Director, DPharm
Pfizer’s “Blue Sky” approach to transforming clinical research in Parkinson’s disease is an inspiring example of patient-centric innovation. Conference Forum's, Valerie Bowling welcomes co-host, Ed Miseta, Clinical Leader.com in a discussion with members of Pfizer’s "Blue Sky" team. Together they discuss the vision, goals and journey in taking a new approach to advancing drug development. More specifically, the Blue Sky team talks about their partnership with IBM, (first of its kind) decisions on how to use a device in a trial, real time data collection, an 1800s house for a 21st Century research and more.
Co-Hosts:
Valerie Bowling, Executive Director, The Conference Forum
Ed Miseta, Chief Editor, Clinical Leader and Contributing Writer, Life Science Leader
Guests:
Stephen Amato, PhD, Project Manager, BlueSky, Pfizer
David Caouette, MBA, Senior Director, Strategy and Operations Lead, BlueSky and Quantitative Medicine, Pfizer
Daniel Karlin, MD, Senior Director, Quantitative Medicine, Clinical Lead, BlueSky, Pfizer
Both DrsDavid Caouette and Daniel Karlin are co-presenting at the DPharm conference on September 20th in Boston. For more information go to www.theconferenceforum.org.
This discussion provides helpful approaches for Chief Medical Officers (CMOs) and other R&D leadership in biotech on how to communicate effectively in times of good, bad or unexpected news. Also discussed in this program are factors to evaluate for the discontinuation of a program. Dr Mark Weinberg, Chief Medical Officer and Managing Director of Halloran Consulting Group will be joined by Dr Lee Allen, CMO, Argos Therapeutics to discuss strategic communication strategies CMOs/R&D leadership can utilize to effectively deliver unexpected or difficult news.
More specifically: How do you communicate successfully?How does a CMO manage an unexpected realization?Tips on being an advocate and skeptic for your programsFlexibility and decision making with dataScenario planningTips on communicating to the publicEvaluating factors for discontinuing a programRationalizing your portfolio? Who decides? Guests:
Lee Allen, MD, PhD, CMO, Argos Therapeutics
Mark Weinberg, MD, MBA, CMO and Managing Director, Halloran Consulting Group
Producer:
Valerie Bowling, Executive Director, PharmaTalk Radio & The Conference Forum
Recommended Conference: The CMO and R&D Biotech Leadership Summit, Nov 14-15 in San Francisco. For more info:
http://theconferenceforum.org/conferences/rdbiotechleadershipsummit/overview/
What is the quality, capacity and efficiency of running clinical trials in Puerto Rico? In this discussion we speak with Dr Myrto Lee, Director, PwC'sStrategy&, UK and Dr Kosmas Kretsos, Executive Director of the Puerto Rico Consortium for Clinical Investigation to learn about key initiatives and outcomes so far to make running clinical trials more attractive in Puerto Rico. For more information about conductingclinical trials in Puerto Rico, please visit www.PRCCI.org. Why consider Puerto Rico for clinical trials?Status of new sites to expand clinical trial networksStatus of a central coordinator with sites to reduce bureaucracy e.g. central IRB, central invoicingPatient access and costsPatient engagementAccess to new technologiesTraining Guest Host:
Dr Myrto Lee, Director, PwC's Strategy&, UK
Guest:
Dr Kosmas Kretsos, Executive Director, PRCCI (Puerto Rico Consortium for Clinical Investigation), Puerto Rico
Producer:
Valerie Bowling, Executive Director, the Conference Forum
Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised by a wealthy individual primarily, in return for being in the trial. At DPharm Europe, Pfizer's Craig Lipset interviewed on stage Alexander to share his story. We are delighted to present the journey and latest updates on PharmaTalk Radio. The story of the formation of iCancer.org.uk and the Oncolytic Virus FundAn alternative way to make clinical trials more accessibleEthical and moral issuesA possible disruptive and sustainable model for other neglected medicines The next DPharm: Disruptive Innovations to Advance Clinical Trials event takes place September 20-21 in Boston. DPharm Europe is scheduled for February 8-9, 2017 in London. For more information about these events or our Immuno-Oncology events, visit, www.theconferenceforum.org.
Producer:
Valerie Bowling Executive Director, Conference Forum & Pharma Talk Radio
Guest Host:
Craig Lipset, MBA Head of Clinical Innovation, R&D,Pfizer
Guest:
Alexander Masters Author, Medical Campaigner and Co-Founder,iCancer.org.uk
Generic drugs can be repurposed to create effective treatments in unsolved diseases. However, there is no economic incentive for industry to pay for a clinical validation and regulatory approval process for most generic drug repurposing because it will not achieve the necessary ROI. Cures Within Reach, FindaCure, Numbers For Good and the National Health Service in England are working together to the create a new economic solution to this problem by piloting the first ever Rare Disease Generic Drug Repurposing Social Impact Bond (SIB). This SIB would be a “pay for success” initiative, in which investors fund the proof of concept repurposing clinical trials and the government provides a payment to the SIB for any repurposed therapies that both improve patient outcomes and reduce healthcare costs. The government success payment would allow the SIB to repay the investors, and have additional funds for the next group of repurposing clinical trials, creating a sustainable funding source for generic drug repurposing.
Producer:
Valerie Bowling Executive Director, Conference Forum
Guest Host: Bruce Bloom, JD President & CSO,Cures Within Reach
Panelists: James Potter Investment Director,Numbers for Good
Flóra Raffai Executive Director,Findacure
Dr Rick Thompson Scientific Officer, Findacure
Helpful Websites:
findacure.org.uk
numbersforgood.com
www.theconferenceforum.org
Pharmatalk's Valerie Bowling welcomes Anton (Tony) Hoos, MD, PhD, Head of Medical, Amgen Europe and Marc Boutin, JD, Chief Executive Officer, National Health Council. We address how industry and patients can work together to incorporate the patient voice in drug development and to improve patient's experience in clinical trials. We examine the current challenges and barriers to patient involvement, progress and next steps.
Host:
Valerie Bowling, Executive Producer, PharmaTalk Radio
Guests:
Anton (Tony) Hoos, MD, PhD, Head of Medical, Amgen Europe
Marc Boutin, JD, Chief Executive Officer, National Health Council
Both Dr Hoos and Mr Boutin will be speaking at the Patients as Partners conference scheduled for March 14-15, 2016 in Philadelphia. For more information, visit www.theconferenceforum.org
PharmaTalk Radio's Valerie Bowling welcomes Immuno-Oncology 360° Co-Chair James Gulley, MD, PhD,National Cancer Institute as he leads a discussion with fellow Co-Chair, Axel Hoos, MD, PhD, GlaxoSmithKline. Together they discuss what's currently happening in Immuno-Oncology and its impact on how cancer is being treated. They cover the latest challenges and next steps. More specifically they also address: Ipilumumab/Nivo/Pembro challengesWhat can we learn from the development of sipuleucel-T that may be applicable for other therapeutic vaccines?Challenges with the following modalities: Checkpoints, Oncolytic Virus', Adoptive T-Cells, Cancer VaccinesBlinitumumabThe more interesting agents in late stage development now in immunotherapy and its promiseImmune related adverse eventsAdoptive cellular therapies, what is the most promising?Will IO become backbone therapies for cancer?What's the next set of assets that are going to come out?Promises in combination therapies?What can we expect next? Guests:
James Gulley, MD, PhD Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute
Axel Hoos, MD, PhD, VP, Oncology R&D,GlaxoSmithKline
The Immuno-Oncology360° conference is scheduled for February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, please visit www.theconferenceforum.org.
At Dpharm US 2015, Katherine Vandebelt, Global Head, Clinical Innovation, Eli Lilly hosted a talk show on MakingClinical Trials a Care Option for Patients to fantastic reviews. Valerie Bowling, producer welcomes Katherine as she hosts a similar session on Pharma Talk Radio.
About the Show:
This talk demonstrates how an organized multispecialty healthcare system, clinical research site network and pharma company uses clinical research as a tool and connector to help improve patient engagement in their overall healthcare management and compliance. More specifically: Healthcare System: improving health and service to patients and advocators of clinical research participationClinical Research Site Network: bringing the right patients to the right trials with increased quality of data and engagement of patientsPharma: expanding our reach to patients and getting trials done fasterShifting the paradigm: Applying a Value Based Health Care Delivery Framework to improve outcomes and reduce healthcare costs Hosted by: Katherine Vandebelt Global Head, Clinical Innovation, Eli Lilly and Company
Guests: Jeff James, MBA, CEO, Wilmington HealthJennifer Byrne, CEO, PMG ResearchAllen Buechler, MBA, Strategy and Operations, Eli Lilly and CompanyToyin Okanlawon, MD, MPH, Senior Health Care Researcher, Harvard Business School Health Care Team For more information on cutting edge topics in clinical research/trials visit:
Dpharm US, visit www.theconferenceforum.org
Dpharm Europe, visit www.theconferenceforum.org
In this episode of Pharma Talk Radio, we feature medical oncologist, Dr Anna Pavlick, Director of the Melanoma Program at the NYU Cancer Institute on Safety Elements of Cancer Immunotherapies. Dr Pavlick originally gave this presentation in June 2015 at the IO360 conference. Her talk focuses on immune related adverse affects of immuno therapy. More specifically, she covers:
• Identifying warning signs and low threshold for workup and treatment
• Understanding “pseudoprogression” before response, delayed toxicities
• Reporting and assessing adverse effects during clinical trial phases
• How to predict safety concerns when moving from animal models to human trials
We are pleased to bring this session to the public to help researchers, doctors, patients and care givers with some information on immune related adverse affects of immuno therapy. Please note that Dr Pavlick does occassionally refer to slides which are not included in the recording of this session.
Anna Pavlick, DO, MD is the Director of the NYU Cancer Institute Melanoma Research Program. After finishing her studies at University of Medicine & Dentistry of New Jersey, School of Osteopathic Medicine, Dr Pavlick completed her residency in internal medicine and her fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. In 1999, she went on to become the Director of Clinical Oncology at UMDNJ in New Jersey before coming to NYU.
The next IO360 conference will take place February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, visit www.theconferenceforum.org.
At the May 2015 Chief Medical Officer’s Summit in Boston, we featured a session on: How the Availability of Capital Impacts the Role of the CMO
In this session, the panelists cover:
Optimal use of the proceeds
Determining a development path, new molecules vs. new studies on the same molecules
Appropriate stewardship of the capital
Balancing short-term and long-term objectives; particularly when they may conflict
Concerns and/or benefits of early financing without having reached clinical goals
Examining the new threshold in moving development forward
How is the progress in the industry translating into new drug discovery?
Maintaining the same rigor for investment
Moderated by: Louis Brenner, MD Chief Operating Officer, Allena Pharmaceuticals Panelists: Raj Malik, MD CMO, G1 Therapeutics
Jim Roach, MD CMO and SVP, Development, Momenta Pharmaceuticals
Oliver Rosen, MD CMO, Deciphera Pharmaceuticals
Ian Walters, MD VP and CMO, Intensity Therapeutics
The next CMO Summit is November 9-10 in Burlingame, California. It is one of the best face-to-face opportunities for R&D leaders in emerging biotechs to:
-
Address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital, working and meeting with investors, and strategizing for appropriate exits.
-
To create a network of CMOs & other R&D leaders from small to midsize life science companies to share ideas, solutions and support.
For information, visit www.theconferenceforum.org
Partial and full scholarships available for start-ups.
At the May 2015 Chief Medical Officer's Summit in Boston, we featured a session on:
How Investors Assess R&D Biotech Management Take a look at the details below:
In this session, we begin with a presentation on a perspective on the method of evaluating a disease space, which includes a comprehensive understanding of 1) the science, 2) the competitive landscape and 3) the management teams for each company. How does this get mapped out?
Following will be more discussion on:
Understanding the context of value proposition
Strategic fit
Processes used to evaluate management and an understanding of competitive strategy
How best to convey your plans
How best to communicate with investors (before investment) and boards (afterwards) – via the CEO or directly?
Importance of clinical development plan expectations Moderated by: Peter Kolchinsky, PhD Managing Director, RA Capital Management, LLC Panelists: Jonathan Behr, PhD EIR and Market Sector Leader, Innovation, Partners Healthcare, David Berry, MD, PhD Partner, Flagship Ventures, Vikas Goyal, MBA Principal, SR One, and Jeffrey Moore, DPhil, MBA President, MPH Venture Management
The next CMO Summit is November 9-10 in Burlingame, California. It is one of the best face-to-face opportunities for R&D leaders in emerging biotechs to:
- Address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital, working and meeting with investors, and strategizing for appropriate exits. 2. To create a network of CMOs & other R&D leaders from small to midsize life science companies to share ideas, solutions and support.
For information, visit www.theconferenceforum.org
Partial and full scholarships available for start-ups.
At the Conference Forum's 2015 Chief Medical Officer's Summit in Boston, David Schenkein, MD, CEO, Agios provided a warm and personal keynote sharing his journey as a Physican CEO. In this recording of the session, gain an insight into Dr Schenkein's views on leadership in running a biotech company and more specifically: The journeyThe people and mentorshipsPrioritizing resourcesSuccesses and failuresOvercoming hurdlesStrategic partnershipsBusiness planningAudience Q&A This is a great session for leadership and aspiring leadership in life sciences and beyond.
The Chief Medical Officer West Summit is this November 9-10 in the San Francisco area. See www.theconferenceforum.org for speaker line up and agenda information. The CMO West conference is dedicated to addressing the unique challenges faced by CMOs and their staff in managing R&D in emerging biotechs.
PharmaTalkRadio is a non-profit program organized and supported by the Conference Forum to give easy and free access of helpful information to all industry professionals and students in the life sciences.
Clinical Air Episode #14 is pleased to present a discussion on Consumer Electronics in Clinical Research.Craig Lipset, Head of Clinical Innovation R&D at Pfizer welcomes guests from Rebar Interactive and Eli Lilly to address and explore an update on what's available, what's capable and what's working with consumer electronics in clinical research. We explore topics including, but not limited to: How to scale new toolsThe level of validation of different instrumentsThe impact of tools like the Apple Research KitWhat future apps will offer Hosted by Craig Lipset, Head of Clinical Innovation, R&D, Pfizer
Guests:
Rahlyn Gossen, Founder, Rebar Interactive
Michael Luker, Director, Clinical Innovation, Eli Lilly
Katherine Vandebelt, Senior Director, Clinical Development Innovation, Eli Lilly
*Please note this session has some background sound interference at the start of the program.
The last 30 years of Immuno-Oncology research have provided strong evidence that tumors do recognize the immune system and their development can be stopped or controlled long term.
Given the impressive survival data over the past five years, it is not surprising that Immuno-Oncology is arguably the most exciting area in the advancement of science and patient care today. However, with all research, there are plenty of challenges and to get a better understanding of this innovative approach to cancer research, we are pleased to welcome to the program, James Gulley, MD, PhD of the National CancerInstitute and Roy Baynes, MD, PhDat Merck Research Labs. Joining Drs Gulley and Baynes is Kate Woda, Director of theIO360 conference taking place at Columbia University Faculty House on June 29-30 in NYC.
Host:
Valerie Bowling, Producer, Pharma Talk Radio
Guests:
James Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute
Roy Baynes, MD, PhD, Senior Vice President, Global Clinical Development, Merck Research Labs
and Kate Woda, Director, IO 360
Design Thinking is a human centered approach to innovation that helps uncover the sweet spot of opportunity where the needs of people, the possibilities of technology and the requirements for business success all converge. The application of the Design Thinking methodology (originating out of Stanford’s d.School) as a new approach to looking at solutions can lead to disruptive innovation in clinical trials for drug development. It allows for designing new ways of working, including the needs, challenges and insights about the complex world we work in.
In this discussion, we introduce the basic principals of Design Thinking and an understanding of how the methodology teaches empathy for the end user (the patients). We explore its ability to reframe questions and unleash innovative thinking as well as the "downside" of creative tension. Most importantly, we address how Design Thinking can drive more successful trials.
Hosted by Valerie Bowling, Executive Director of the Conference Forum, guests include:
Kate Helber
President at Infidea Agency, Past Co-Founder, The Helber Group
Jen Reichuber
Co-Founder & Principal at Altani Associates, Past Co-Founder, The Helber Group
Komathi Stem Strategic Innovation Leader, Genentech/Roche
Kate, Jen and Komathi Presented a in-person program in May 2015 in Boston. For more information on the next program, plase contact us at service@tcfllc.org
In September 2012, TransCelerate Biopharma launched with the aim of simplifying and accelerating the delivery of innovative medicines to patients. What progress has really been made and what are the realistic goals for 2015? In our 2015 kick off radio show, Clinical Air Episode #13, host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer talks with Dalvir Gill, PhD, CEO of Transcelerate and Andy Lee, MD, SVP, Head of Global Clinical Trial Operations at Merck. In this frank discussion, we learn: What’s working well and changes for 2015?Is Tanscelerate performing better or differently from other collaborations?How have engagements with outside organizations advanced? Where do gaps remain?How are new areas selected and scope defined?Thoughts on implementing new ideasNew role for CROsWhat deliverables does Tanscelerate anticipate for 2015?
Since the FDA and EMA published their current thinking on clinical oversight and risk-based monitoring (RBM) strategies, the topic has received a magnitude of attention, commanding column inches, webinar discussions and industry conferences. With so much discussion going on, it is unsurprising that many sponsors are feeling out in the cold when it comes to identifying how to practically implement RBM strategies within study designs. As data quality matters most in determining study success and ensuring patient safety, the latest recommendations have created growing demand for solutions that simplify the transition to risk-based techniques.
In this program, our guests discuss how emerging technologies and Central Statistical Monitoring (CSM) now present more practical means of implementing successful RBM strategies. Both Sanofi and Novartis will provide a large pharma perspective on making the move to RBM.
Host: Valerie Bowling, Executive Director, The Conference Forum
Guests:
Marc Buyse, Founder, International Drug Development Institute & CluePoints
Eric Genevois-Marlin, VP, Biostatistics & Programming, Sanofi
Thomas Haag, Data Integrity Process Expert, eClinical Quality Assurance, Novartis Pharmaceuticals
In Clinical Air Episode #12, Craig Lipset, Head of Clinical Innovation, R&D, Pfizer talks with Marc Sluijs, Director Life Science Business Development at Oracle Health Sciences.
Marc shares his thoughts on the digital health space and where technology is heading in clinical trials. In this informal discussion, Craig and Marc also cover how digital technologies can better serve patients as well as tips on keeping tabs on this rapidly moving space and what can disrupt pharma?
Host
Craig Lipset
Head of Clinical Innovation, R&D
Pfizer
Guest
Marc Sluijs
Director Life Science Business Development
Oracle Health Sciences
Producer
Valerie Bowling
Executive Director
The Conference Forum
Donald Jones, Chief Digital Officer, Scripps Translational Science Institute talks with host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer on what's happening with digital in drug development. Don discusses his thoughts on the evolution of new products with digital and the “digitazation” of tools for clinical trials. He also shares his thoughts on the biggest disruptors in pharma.
Don and Craig will be featured in an interview as well at DPharm: Disruptive Innovations to Advance Clinical Trials on September 11, 2014 in Boston.
Host
Craig Lipset
Head of Clinical Innovation, R&D
Pfizer
Guest
Donald Jones
Chief Digital Officer
Scripps Translational Science Institute
&
Founder & Chairman, Wireless Life Sciences Alliance
Producer
Valerie Bowling
Executive Director
The Conference Forum
Join host, Craig H. Lipset, Head of Clinical Innovation, R&D, Pfizer lead a discussion on what it really means to partner with patients in clinical trials.
Guests include:
Jeri Burtchell, Founder, Partners in Research
Regina Holliday, Artist and Medical Advocate
For more information on Jeri's new launch, visit: Healthivibe.com and for Regina walking gallary, google Regina Holliday, walking gallary.
For more information on the topic of Patients as Partners, visit www.theconferenceforum.org. The Conference Forum presented a program in March 2014 fully dedicated to understanding the journey a patient takes in clinical trials. Also take a look at Disruptive Innovations to Advance Clinical Trials scheduled for September 11-12, 2014 in Boston. This event addresses significant innovation to help improve a patients experience in a clinical trial.
Join host, Craig Lipset, Head of Clinical Innovation, R&D, Pfizer lead a discussion onInvesting in the future of clinical research.
Guests include:
Todd Pietri, Co-Founder, Milestone Ventures
Jeremy Sohn, Managing Director, MPM Capital
VC views on: Disruption in the clinical trial spaceEntrepreneursFinding opportunities (incubators and accelerators)Good sources of deal flowsInvesting in technology or people?MobileBig dataBeyond the pilland more.... Craig, Todd and Jeremy will also be speaking at Mobile@Dpharm on September 10th at the Farimont Copley Plaza hotel in Boston. This event helps drug developers get their arms around the mobile/digital clinical trial landscape and figure out: How mobile is innovating clinical trialsWhat parts of clinical trials mobile/digital technology is currently impactingHow mobile technology is making clinical trials cheaper, easier and more accurateHow mobile/digital is increasing the efficacy of drugsWhat the true value is to clinical trialsOpportunities There is an opportunity to participate in creating a clinical trial app. Mobile@Dpharm will also be of interest to investors and app developers. Following this one day event is DPharm:Disruptive Innovations to Advance Clinical Trials. For more information, visit www.theconferenceforum.org or call 646 350 2580.
In Clinical Air episode # 8, host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer hosts a show discussing investigators as partners in clinical research. Guests include:
Christine Pierre, President, Society of Clinical Research
Jacalyn Kent, Director, Clinical Development Information & Optimization, Eli Lilly
Key topics include: Misunderstandings around Remote Based Monitoring Training and communication challenges for remote site managersTranscelerate updateWhat are the real cost savings around RBM...are we just shifting costs?Real time data and how this should affect sites and paymentsReducing burdens to the sitesInvestigator turn over rate, making sites sustainable
In 2013 Pfizer launched the Pfizer Blue Button Project, a first-of-it’s-kind initiative enabling patients who have participated in clinical trials the opportunity to download their individual clinical data. Using the Blue Button standard launched by the White House, patients will be empowered to use the data to improve their overall health and wellness, from sharing with healthcare providers to powering clinical risk assessments. In this show, our host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer speaks to the leaders behind these initiatives to find out why they launched, initial learnings, and where the projects may go if successful. Also joining Craig is Thomas Krohn, Business Lead for the Lilly Clinical Open Innovation Team.
Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer
Guests:
Adam Dole, Presidential Innovation Fellow, The White House
Thomas Krohn, Business Lead for the Lilly Clinical Open Innovation Team
Jennifer Wulff, Director, Clinical Innovation, Pfizer
How a patient experiences a clinical trial is changing. Access, ease, efficiencey, safety and better quality data collection are the target goals. This episode features some of the emerging technologies together with a discussion on the opportunities and challenges to include patient access, recruitment and retention. Predictions for 2014 are shared by our guests.
Host:
Craig H. Lipset, MBA Head of Clinical Innovation, Worldwide Research and Development, Pfizer Inc.
Guests:
Tomasz Sablinski, MD, PhD Founder & CEO, Transparency Life Sciences
Komathi Stem Senior Director, Product Development, Innovation Lead, Genentech, A Member of the Roche Group, United States
Join guests Kerri Weingard, ANP, COO, Verified Clinical Trials and Susan Salgado, PhD, Founder, Hospitality Quotient as they identify the barriers and limitations in engaging patients in clinical trials. What we can do about it through communication and service? Hosted by Valerie Bowling, Executive Director, the Conference Forum, this episode addresses one of the hottest topics at the Patients as Partners event scheduled for March 3-4, 2014 in Philadelphia. For more information, visit www.theconferenceforum.org
About our Guests:
Susan Reilly Salgado, PhD founded Hospitality Quotient with Danny Meyer in 2010. Hospitality Quotient offers customized advice and training to inspire, build and sustain a company culture of service in organizations across industries. In addition to her PhD, Susan holds a BS and an MBA from Lehigh University. Susan has also served as an instructor in organizational behavior and business strategy at NYU and as a guest lecturer at Lehigh.
Kerri Weingard is the chief operating officer at Verified Clinical Trials (VCT), a New York-based firm specializing in ensuring the integrity of medical studies and clinical trials by creating a database of research study participants trials. Ms. Weingard, who is a nurse practitioner, holds a master’s degree in science from Stony Brook University. She has conducted over 500 clinical trials as a research coordinator and sub-investigator.
This episode provides a recap on what's happening with mobile/sensors in clinical trials especially as they affect patients.
Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer, Inc.
Guests:
Tim Davis, CEO & Co-Founder, Exco InTouch
Abbe Steel, Vice President of Patient & Physician Services, UBC
Eli Lilly and Quintiles entered into a co-investment partnership to develop a new solution using computer-assisted designs that emphasize the improvement of scientific and operational outcomes of clinical trials. The results were shared at the DPharm 2013 event and project leaders from both companies will talk to our host Craig Lipset on how this formation is doing a year later. Also joining Craig is Jeff Lee, CEO, Omniscience to discuss featured news and trends in clinical trial innovation and in particular mobile applications. Host: Craig Lipset, MBA, Head of Clinical Innovation, R&D, Pfizer, Inc. Guests: Jeffrey Kasher, PhD, VP & COO, Eli Lilly & Company Jeff Lee, CEO, Omniscience Mobile Rick Sax, MD, SVP Clinical Design & Reporting Services, Quintiles
A panel of executives from leading pharma and the venture capital community at the DPharm Disruptive Innovations conference recently awarded the 2013 Disruptive Innovator of the Year title to Medidata Solutions and Spaulding Clinical Research. They won for their collaboration on a novel study evaluating the impact of mobile and cloud-based technology on patient engagement for improved health outcomes in the diabetes community. Host Craig Lipset, Head of Clinical Innovation, R&D at Pfizer speaks with Dr. Andrew Lee of Sanofi on key takeaways from the 2013 DPharm conference along with the CEOs of the winning companies to learn more about their collaboration. Guests: Andrew Lee, MD, SVP, Deputy Head of Clinical Sciences & Operations, Sanofi Glen De Vries, President of Medidata Solutions Randy Spaulding, Founder and CEO of Spaulding Clinical Research
Join us in a discussion on serving patients in clinical trials. Making clinical trials more accessible for patients Emerging technologies / iPads and informed consent Disruption Headlines in the news Host: Craig Lipset, MBA Head of Clinical Innovation, R&D, Pfizer Inc. Guests: Andreas Koester, MD, PhD VP, Clinical Trial Innovation & External Alliances, Janssen Anthony Costello, CEO, Mytrus
The CMO of a biotech is like no other job in the world. The CMO is not only responsible for delivering on clinical trials, but also is a key player in the company's fundraising efforts. From the Chief Medical Officer Summit, please join co-chairs Dr. Greg Fiore, CMO of the The Medicines Company and Dr. Steven Zelenkofske, CMO of Regado together with opening presenter Dr. Tyler Martin, CMO & Founder of Great Plains Biotechnology, to discuss the role of the CMO and how to best manage it. Topics include: What should a CMO be focused on? Functioning with restrictive capital Supporting a CEO who does not have experience in the therapeutic area you are in charge of The great balancing act
Drs. Christopher Gallen, CEO at SK BioPharmaceuticals and Mitchell Katz, Executive Director, Medical Research Operations at Purdue Pharma, in a candid conversation on navigating the complexities of Global Clinical Trials and addressing topics including:
Why global trials? Why are global trials so expensive? How are companies re-thinking global trials? What's happening with global outsourcing? Thoughts on emerging markets and patient recruitment What can we do to help mitigate the risks of global trials?
Join host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer with guests Joe Kim, Clinical Operations Director, Shire and Dr. Hugo Stevenson, physician and serial entrepreneur, as they discuss innovation transforming the clinical trial space to include:
* Mobile technology and apps * Clinical trials and diversity * Google Glass for health * Investigator database sharing * Key motivations for innovators and more
The opinions shared by Craig and our guests are those of the speakers and do not necessarily reflect the opinions of their employers.